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ABSTRACT 
Dengue is an arboviral disease that exerts a significant public health burden on the tropical 
world. Currently there is no available vaccine or specific therapeutic. My reviews show that 
our understanding of dengue pathogenesis, transmission dynamics and optimal case 
management is incomplete. The work presented in this thesis is a compilation of expert 
reviews/perspectives and primary research that addresses some of these knowledge gaps. 
Understanding dengue pathogenesis and in particular, risk factors for progression to severe 
dengue, is an important priority to reduce morbidity and mortality, especially in young 
children. Genetic variants of the MICB and PLCE genes have been shown to be associated 
with severe dengue. I tested the hypothesis that these variants are also associated with less 
severe dengue infection and with higher early viraemia levels in two studies involving the 
genotyping of 3961 and 2742 dengue cases respectively. My studies showed that these 
genetic variants are associated with less severe but clinically apparent dengue infection but 
showed no evidence of an association with higher viraemia levels. The functional basis of 
these susceptibility mutations remains unclear. 
Dengue transmission dynamics are shaped by the prevalence of the permissive vectors, 
Aedes aegypti and Aedes albopictus. My research hypothesis was that susceptibility and 
transmission of dengue might differ between the two species. I conducted a clinical study that 
compared the susceptibility of Ae. aegypti and Ae. albopictus to both initial and disseminated 
dengue after direct blood feeding experiments on viraemic patients. This work showed that 
both mosquito types were equally susceptible to initial infection with dengue but that Ae. 
albopictus was less likely to develop salivary infection, and, thus, an infectious phenotype. 
These results have important implications for the development of dengue transmission 
models, especially in areas of dengue emergence where the influence of Ae. albopictus is 
thought to be greatest. In addition, the results confirm the central importance of patient 
plasma viraemia in causing successful DENV transmission, suggesting that reducing this 
through the use of antivirals could potentially reduce transmission. 
Clinical management of dengue patients remains an enormous challenge. Statins are rational 
candidate drugs for dengue because of their previously identified positive influence on 
vascular endothelial function. I conducted a clinical trial of lovastatin therapy in adult dengue 
patients. The trial showed that lovastatin was safe and well tolerated in dengue patients but it 
did not show any positive effects on the kinetics of viraemia or on any of the pre-specified 
clinical or laboratory features. I conducted a survey of platelet management in 20 countries 
and found a wide variety of approaches to the use of platelets in dengue underscoring the 
need for prospective clinical trials to inform evidence in this area.  To reduce the large sample 
size normally required for the development of dengue therapeutics, I considered the use of a 
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human dengue infection model in dengue drug development. This model has the potential to 
a game-changer in drug development and in the design of future trials.    
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PREFACE 
In accordance with LSHTM Research Degree Regulations much of this thesis is presented as 
a series of published or accepted review and research manuscripts. The papers are 
supplemented by additional material that explains how the research forms a coherent body of 
work. There is therefore some repetition of background information in the manuscripts. In 
addition, the differing editorial conventions used by various journals may have resulted in 
some inconsistencies with terminology and formatting. 
Research conducted in Vietnam by foreigners must be conducted in partnership with a local 
“competent authority” under the overall jurisdiction of the Vietnam Ministry of Health. All the 
work presented in this thesis was conducted under the umbrella of a project agreement 
between the Hospital of Tropical Diseases in Ho Chi Minh City and the Oxford University 
Clinical Research Unit.  
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1. INTRODUCTION AND AIMS OF THESIS 
Background 
Dengue represents a major global health challenge. It is the most important human arboviral 
infection with an estimated 390 million infections annually.1 Dengue causes considerable 
suffering to those affected but also exerts a significant economic cost to the communities and 
countries in which they live.2 Treatment is limited to supportive care and we currently have no 
way of predicting which patients are at most risk of progressing to severe disease with the 
result that health facilities are often overwhelmed by patients with dengue in endemic 
countries. Despite decades of research our understanding of disease pathogenesis is limited 
hindering both vaccine and therapeutic development.3 It was hoped that the Sanofi 
recombinant live attenuated vaccine candidate would be the answer to dengue control. 
However the vaccine trials showed mixed results with poor responses in those without pre-
existing immunity and against DENV-2.4,5 The phase 3 results suggest that the vaccine may 
reduce hospitalisation suggesting a possible disease modifying effect.5,6 These results imply 
that a vaccine might prove to have a role as part of a multifaceted approach to dengue control 
but is unlikely to be the sole answer that had been hoped for. Addressing the global problem 
of dengue requires a multidisciplinary approach encompassing therapeutics, vaccine 
research and vector control. The successful development of these areas requires clinically 
relevant basic science research as a foundation.  
Aims of thesis 
The work described in this thesis aims to improve our understanding of dengue with the hope 
of improving the clinical and public health management of the disease. To these ends the 
thesis has four major aims.  
Aim 1: To review the current state of understanding of dengue pathogenesis, transmission 
dynamics and clinical management of dengue patients 
Specific objectives: 
1. To conduct an overall review of dengue considering virology, epidemiology, 
pathogenesis, clinical features, and clinical management 
2. To conduct a in-depth review of dengue pathogenesis 
Aim 2:  To understand host factors associated with the outcome of dengue infection 
Specific objectives: 
1. To conduct a review of host factors in dengue pathogenesis  
2. To determine if genetic variants of the MICB and PLCE genes are associated with 
less severe dengue 
 16 
3. To determine if genetic variants of the MICB and PLCE are associated with higher 
early DENV viraemia levels 
Aim 3:  To improve our understanding of dengue transmission dynamics  
Specific objectives: 
1. To determine if Ae aegypti and Ae albopictus are equally susceptible to dengue 
infection 
2. To determine if the 2 species are equally capable of transmission to humans 
Aim 4:  To improve the management of dengue patients 
Specific objectives: 
1. To conduct a review of the current dengue therapeutics landscape  
2. To determine the safety and efficacy of lovastatin therapy in adult patients with 
dengue 
3. To survey the approach to platelet management in dengue infection in 20 countries 
4. To consider the potential role of a human dengue infection model in drug 
development 
 
Outline of peer-reviewed, published review papers in this 
thesis 
Dengue overview  
This manuscript provides an introduction to dengue. The article considers dengue virology, 
epidemiology, transmission, clinical features, pathogenesis, diagnosis, prevention and 
control. 
Dengue pathogenesis  
This monograph provides a detailed overview of dengue pathogenesis and considers the 
relevance of aspects of disease pathogenesis for vaccine and therapeutic development.  
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LITERATURE REVIEW 1: DENGUE FEVER VIRUSES 
  
  

Dengue Fever Viruses
JamesWhitehorn, London School of Hygiene and Tropical Medicine, London, UK andOxford
University Clinical Research Unit – Vietnam, Ho Chi Minh City, Vietnam
Based in part on the previous version of this eLS article ‘Dengue Fever
Viruses’ (2003) by Duane J Gubler.
Dengue viruses are the most important arboviruses caus-
ingdisease in humans. Approximately 3billionpeople live
in areas of risk, and there are an estimated 50–100million
cases occurring each year. These estimates reflect an
enormous burden of morbidity, predominantly affecting
urban centres of the developing world. There is currently
no specific treatment and disease control is limited to
tackling the vector. Despite considerable scientific
attention disease pathogenesis remains incompletely
understood. A better understanding of dengue virus
biology and disease pathogenesis has the potential to
pave theway to successful therapeutic interventions. This
article aims to review current understanding of virus and
vector biology, disease pathogenesis and clinical mani-
festations and management. Finally the article will
consider novel approaches to clinical management and
disease control.
Classification
Dengue viruses belong to the family Flaviviridae, genus
Flavivirus. There are four serotypes: DENV-1, DENV-2,
DENV-3 and DENV-4. They belong to a larger, hetero-
geneous group of viruses called arboviruses. This is an
ecological classification, which implies that transmission
between vertebrate hosts including humans is dependent
on haematophagous (blood-sucking) arthropod vectors.
See also: Human Pathogenic Viruses
There are over 70 antigenically related viruses in the
genus Flavivirus, including the type species, Yellow fever
virus. The genus includes several antigenic complexes,
including the dengue complex, the Japanese encephalitis
complex and the tick-borne encephalitis complex. The
Japanese encephalitis complex includes severalwell-known
disease pathogens of humans, including Japanese enceph-
alitis, Murray Valley encephalitis, St Louis encephalitis,
West Nile, Kunjin, Zika and other viruses, all of which are
transmitted by mosquitoes. The tick-borne flaviviruses
include Tick-borne encephalitis, Omsk haemorrhagic fever
andKyasanur Forest disease viruses. Some flaviviruses have
no arthropod vector, probably having lost the need for this
type of transmission during the process of developing
evolutionary relationships with their vertebrate hosts.
See also: Flaviviruses; Flavivirus Infections in Humans;
Yellow Fever Virus
The four dengue viruses make up a unique complex
within the genus Flavivirus (Holmes and Twiddy, 2003).
Although the four serotypes are antigenically distinct,
there is evidence that serological subcomplexes may exist
within the group. For example, a close genetic relationship
has been demonstrated betweenDENV-1 andDENV-3 by
using sequence homology and complementary deoxyribo-
nucleic acid (cDNA) hybridisation probes. In addition,
DENV-2 shows a high-sequence homology (71%) with
Edge Hill virus, an ecologically distinct flavivirus from
Australia. See also: Flaviviruses; Flavivirus Infections in
Humans
Structure
The dengue viruses have a structure similar to other flavi-
viruses; they are spherical, about 40–50 nm in diameter
(Figure1), with a lipid envelope, which is apparently derived
from the host cell membrane from which the viruses bud
(Perera and Kuhn, 2008). The envelope encloses an iso-
metric nucleocapsid core of 30–35 nm in diameter, which
consists of a capsid protein and single-stranded, positive-
sense ribonucleic acid (RNA) genome. The virion envelope
is fringed with fine surface projections, the envelope and
Advanced article
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membrane structural proteins. The envelope protein
facilitates virus maturation and membrane fusion. Non-
structural protein 1 (NS1) is found on the outer membrane
of infected cells, however its function remains unclear. NS5
acts as an RNA-dependent RNA-polymerase. NS3 is a
helicase and aids successful viral replication (Paranjape
and Harris, 2010). Both NS3 and NS5 have potential as
therapeutic drug targets. See also: RNA Virus Genomes
The dengue (Flavivirus) genome is approximately 11 000
bases in length, and consists of short untranslated regions
at the 3’ and 5’ ends with an uninterrupted open reading
frame in between (Figure 2; Kuhn et al., 2002). The genome
has a cap at the 5’ endbut nopolyA tail at the 3’ end. The 3’-
untranslated region appears to regulateRNAreplication in
place of the poly A tail (Alvarez et al., 2005). The complete
genome sequences are known for several strains of all
four dengue virus serotypes. There are three structural
proteins (capsid, premembrane and envelope), encoded by
sequences near the 5’ end of the genome, and seven
non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B and NS5) encoded by the remainder of the genome
(Figure 2). See also: Viral Capsids and Envelopes: Structure
and Function
Viral Replication
It is thought that dengue and other flaviviruses infect cells
by attaching to cellular receptors through the envelope
protein, although specific receptor proteins have not been
identified (Kuhn et al., 2002; Bartenschlager and Miller,
2008). The viruses are internalised by endocytosis, after
which the nucleocapsid is released into the cytoplasmof the
cell by membrane fusion, a process that is initiated by a
low-pH-dependent conformational change in the envelope
protein. See also: Virus Host Cell Receptors
The dengue gene order (Figure 2) is encoded in open
reading frames as follows 5’-C-prM-E-NS1-NS2A-NS2B-
NS3-NS4A-NS4B-NS5-3’ (Chiu et al., 2005). Translation
of the viral messenger RNA (mRNA) is initiated at the 5’
end, and the resulting polyprotein goes through extensive
cotranslational and post-translational proteolytic pro-
cessing and cleavage to form at least 10 mature viral pro-
teins (Kuhn et al., 2002; Chiu et al., 2005). Both viral and
host proteases appear to be involved in processing the
dengue polyprotein. AC-terminal hydrophobicmembrane
anchor domain in the capsid, premembrane and envelope
proteins function both as internal signal sequences
involved in the transfer of the polypeptide into the lumen
of the rough endoplasmic reticulum, and as membrane
anchor domains (Markoﬀ et al., 1994). Charged amino
acid sequences that follow this anchor act to stop the
peptide transfer through the endoplasmic reticulum
membrane aswell as a signalase cleavage recognition site of
the host cell signalase in the lumen of the endoplasmic
reticulum. The initial processing events that separate the
structural protein precursors and the N-terminus of the
NS1 are mediated by this signalase. Cell-associated virions
are constructed from the structural proteins, and mature
virions are released from infected cells through a process
involving cleavage of the pre-M protein in the Golgi
vesicles (Barth, 1999). See also: RNA Plant and Animal
Virus Replication
Dengue viruses have three natural hosts: Aedes mos-
quitoes, lower primates and humans (Weaver, 2005).
Dengue viruses are known to cause clinical illness and
disease only in humans. After introduction by a mosquito
bite the initial site of DENV replication is the cutaneous
Langerhans dendritic cell (Limon-Flores et al., 2005). The
migration of these infected cells around the lymphatic
system triggers the production of cytokines and the
recruitment of other immune cells. These include mono-
cytes and macrophages, which are the primary target of
infection and the main site of DENV replication (Durbin
et al., 2008). Other tissues fromwhich the viruses have been
isolated include the liver, lungs, kidneys, lymph nodes,
E
RNA
Nucleocapsid
Lipid
bilayer
M
Figure 1 The Flavivirus virion structure. Structural proteins: E, envelope
glycoprotein and M, membrane glycoprotein.
5’ 3’
EC prM
pr M
Structural Nonstructural
NS2A NS2B NS4A NS4B
NS1 NS3 NS5
PolymeraseMembrane-   Protease/polymerase
soluble HA
Figure 2 Genome of the Flavivirus genus within the family Flaviviridae,
showing gene order. Structural proteins: C, capsid; E, envelope and prM,
premembrane. NS, nonstructural proteins and HA, haemagglutinin.
Dengue Fever Viruses
eLS & 2012, John Wiley & Sons, Ltd. www.els.net2
stomach, intestine and brain, but it is not known to what
extent virus replicates in these tissues (Jessie et al., 2004).
There is some evidence that the viruses also replicate
in endothelial cells and possibly in bone marrow cells.
Although encephalopathy and encephalitis has been
documented in dengue infection, there is limited evidence
to support viral replication within the CNS (Soares et al.,
2006).
Viraemia in humans may last 2–12 days (average, 4–5
days) with titres ranging from undetectable to over 108
mosquito infectious doses 50 (MID50) mL (Halstead,
2008). Experimental evidence shows that several species of
lower primates (chimpanzees, gibbons and macaques)
become infected anddevelop viraemia titres high enough to
infect mosquitoes, but do not develop illness (Vasilakis
et al., 2011). Viraemia levels in lower primates are more
transient, often lasting only 1–2 days if detectable, with
titres seldom reaching 106 MID50 mL.
Low-passage or unpassaged dengue viruses can only be
propagated with consistent results in laboratory-reared
mosquitoes and in mosquito cell lines (Tesh, 1979; Gubler
et al., 1984). Mosquito species most commonly used for
in vivo propagation includeAedes aegypti,Aedes albopictus
and Toxorhynchites spp., all of which can be reared
with ease in the laboratory. In the mosquito vectors, den-
gue viruses infect and replicate to high titre in nearly all
tissues, including midgut epithelial cells, ovaries, fat body,
brain and central nerve cord ganglia and salivary glands.
Only three mosquito cell lines show high susceptibility
to dengue viruses: C6/36 from A. albopictus, AP-61 from
Aedes pseudoscutellaris andTRA-284 fromT. amboinensis.
Dengue viruses can also be propagated in babymice and
in several vertebrate cell lines (Vorndam and Kuno, 1997).
These all have lower susceptibility to infection than mos-
quito cells however, and dengue virusesmust be adapted to
each system by serial passage before consistent results can
be obtained. Baby mice, which are used for the isolation
and assay of many other arboviruses, generally show no
signs of illness after intracerebral inoculation with most
unpassaged strains of dengue viruses. Mammalian cell
lines commonly used include LLC-MK2 andVero (monkey
kidney), BHK-21 (baby hamster kidney), FRhL (fetal
rhesus lung) andPDK(primarydogkidney).See also: Viral
Culture Methodologies
Vectors
Only species of the genus Aedes appear to be natural
mosquito hosts for dengue viruses (Halstead, 2008). Spe-
cies of the subgenus Stegomyia are the most important
vectors in terms of human transmission, and include
A. aegypti, the principal urban vector worldwide, A. albo-
pictus (Asia–Americas), Aedes scutellaris spp. (Pacific),
Aedes africanus and Aedes luteocephalus (Africa). Species
of the subgenus Finlaya (Asia) and Diceromyia (Africa)
appear to be important mosquito hosts involved in
dengue forest maintenance cycles. Two other species,
Aedes (Gymnometopa) mediovittatus (Caribbean) and
Aedes (Protomacleaya) triseriatus (North America) have
been shown to be excellent experimental hosts for dengue
viruses (Fuentes et al., 1992).
Transmission Cycles
Dengue viruses exist in nature in three basic maintenance
cycles (Figure 3; Vasilakis et al., 2011). The primitive forest
cycle involves canopy-dwelling mosquitoes and lower pri-
mates. A rural cycle, primarily in Asia and the Pacific,
involves peridomestic mosquitoes (A. albopictus and
A. scutellaris spp.) and humans (Vasilakis et al., 2010). The
urban cycle, which is themost important epidemiologically
and in terms of public health impact, involves the highly
domesticated A. aegyptimosquito and humans (Halstead,
2008). Multiple virus serotypes are maintained in an
endemic cycle in most large urban centres of the tropics,
with epidemics occurring at periodic intervals.
Vertical
transmissionPrimates
Aedes
mosquitoes
Primates
Aedes
mosquitoes
Vertical
transmissionHumans
Aedes
mosquitoes
Humans
Aedes
mosquitoes
Vertical
transmissionHumans
Aedes
aegypti
Humans
Aedes
aegypti
Forest/Enzootic Rural/Epidemic Urban/Endemic/Epidemic
Africa = Aedes (Diceromyia)
Asia = Aedes (Finlaya)
?Americas = Aedes spp.?
Aedes (Stegomyia)
Aedes (Stegomyia)
?
Ae. aegypti
Ae. albopictus
Ae. polynesiensis
Ae. mediovittatus
Ae. aegypti
?
Figure 3 Transmission cycles of dengue viruses.
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Dengue viruses are only transmitted to humans and
lower primates by the bite of an infective mosquito vector
(Halstead, 2008).When a competentmosquito vector takes
a blood meal from a person during the viraemic phase
(see earlier discussion), virus is ingested with the blood and
infects the cells of the mosquito mesenteron. After 8–12
days, depending on ambient temperatures, the mosquito
vector and the virus strain, the virus will disseminate and
infect other tissues, including the mosquito salivary glands
(Halstead, 2008). When the mosquito takes a subsequent
blood meal, virus is injected into the person with the
salivary fluids. The mosquito is infected for life.
A. aegypti is a highly competent epidemic vector of
dengue viruses. It lives in close association with humans
because of its preference for laying eggs in artificial water-
holding containers in the domestic environment resting
inside houses and feeding on humans rather than other
animals. It has a nearly undetectable bite and is very rest-
less, in the sense that the slightest movement will make
it interrupt feeding and fly away. It is not uncommon,
therefore, for a single mosquito to bite several persons
in the same room or general vicinity over a short period
of time.
In addition to transmitting the virus to humans or lower
primates, the female mosquito may also transmit the virus
vertically through the eggs to her oﬀspring (Arunachalam
et al., 2008). Although the implications of vertical trans-
mission are not fully understood, it is thought to be
an importantmechanism in the naturalmaintenance cycles
of dengue viruses, especially in rural and forest settings
(Vasilakis et al., 2011).
Epidemiology
Geographic and seasonal distribution
Dengue viruses have aworldwide distribution in the tropics
(Figure 4). The viruses are endemic in most urban centres
of the tropics, with transmission occurring throughout the
year (Scott and Morrison, 2010). Epidemic transmission
occurs periodically in most virus-endemic areas, usually at
3–5 year intervals (Halstead, 2008). As surveillance inmost
endemic countries is poor, cases are not usually reported
during interepidemic years, thus potentially downplaying
the risk of infection. It is well documented, however, that
dengue viruses are maintained during interepidemic peri-
ods in most tropical areas and, although risk of infection is
lower than during epidemic periods, it is still substantial to
unsuspecting visitors.
Peak transmission of dengue viruses is usually associated
with periods of higher rainfall in most dengue-endemic
countries (Halstead, 2008). Factors influencing seasonal
transmission patterns of dengue viruses are not well
understood, but obviously include mosquito density,
which may increase during the rainy season, especially
in those areas where the water level in larval habitats
is dependent on rainfall. In areas where water storage
containers are not influenced by rainfall, however, other
factors such as higher humidity and moderate ambient
temperatures associated with the rainy season increase
survival of infected mosquitoes, thus increasing the chan-
ces of secondary transmission to other persons (Halstead,
2008).
Countries or areas of risk
(As of 1 November 2008)
The contour lines of the January and July isotherms indicate the potential geographical limits of the
northern and southern hemispheres for year around survival of Adeas cegypt, the principal mosquito
vector of dengue viruses.
10.C
July isotherm
10.C
January isotherm
Figure 4 Countries and areas at risk of dengue transmission. The contour lines represent the potential geographic limits of A. aegypti (WHO, 2009).
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Changing epidemiology of dengue
A combination of increased and unplanned urbanisation,
changing life styles and lack of eﬀective mosquito control
has made most tropical cities highly permissive for eﬃcient
dengue transmission by A. aegypti. Increased air travel by
humans provides the ideal mechanism for the transport of
dengue viruses between population centres. Consequently,
in the past 20 years there has been a dramatic increase
in the movement of dengue viruses within and between
regions, resulting in increased epidemic activity, develop-
ment of hyperendemicity (the co-circulation of multiple
virus serotypes) and the increased incidence of severe
dengue, including dengue shock syndrome. Once princi-
pally observed in Southeast Asia, severe dengue has spread
in epidemic form to west Asia, the People’s Republic of
China, the Pacific Islands and the Americas in the past two
decades.
The factors responsible for the emergence and spread of
severe dengue as an epidemic phenomenon are not fully
understood. The changing disease pattern described
above provides support for both principal hypotheses on
the pathogenesis of severe dengue, secondary infection and
virus virulence (see later discussion). Increased transmis-
sion of multiple dengue serotypes (hyperendemicity)
increases incidence and thus the probability that severe
disease will occur, regardless of whether the underlying
cause is due to increased virulence, immune enhancement
or, more likely, a combination of both.
Dengue in humans is primarily an urban disease. Most
major epidemics of severe dengue occur in tropical urban
centres, where large and crowded human populations live
in intimate association with the principal mosquito vector,
A. aegypti.
Clinical Features of Infection and
Pathogenesis
Dengue infection causes a spectrum of illness in humans,
ranging from inapparent to severe disease characterised by
plasma leak resulting in shock and haemorrhage (WHO,
2009). The most severe disease is observed in infants
and young children. The previously used WHO disease
classification categorised dengue into either ‘dengue fever’
or ‘dengue haemorrhagic fever’ (WHO, 1999). Dengue
haemorrhagic fever (DHF) was further subdivided into
four severity grades, with the two most severe grades
referred to as ‘dengue shock syndrome’ (DSS). There were
problems with this classification system, and it had a low
sensitivity for diagnosing severe disease (Srikiatkhachorn
et al., 2010). The updated WHO guidelines recognise that
clinical dengue is a dynamic entity and categorise disease
into either ‘dengue’ or ‘severe dengue’. The new guidelines
place emphasis on the warning signs that may indicate
a patient is progressing to severe disease (WHO, 2009;
Figure 5). The diﬀerential of dengue is broad and varies
depending on the local epidemiology of other infectious
diseases. It includes other haemorrhagic fevers, hepatitis,
leptospirosis, typhoid, malaria, measles and influenza,
Dengue ± warning signs
With warning
signs
Without
1. Severe plasma leakage
Severe dengue
2. Severe hoemorrhage
3. Severe organ impairment
Probable dengue Warning signs•
Criteria for dengue ± warning signs Criteria for severe dengue
Severe plasma leakage
leading to:
• Shock (DSS)
• Fluid accumulation with respiratory
   distress
Severe bleeding
as evaluated by clinician
Severe organ involvement
• Liver: AST or ALT >=1000
• CNS: Impaired consciousness
• Heart and other organs
Live in /travel to dengue endemic area.
Fever and 2 of the following criteria:  
• Nausea, vomiting
• Rash
• Aches and pains
• Toumiquet test positive
• Leukopenia
• Any warning sign
• Abdominal pain or tenderness
• Persistent vomiting
• Clinical fluid accumulation
• Mucosal bleed
• Lethargy, restlessness
• Liver enlargment >2 cm
(Important when no sign of plasma leakage)
Laboratory-confirmed dengue
• Laboratory: increase in HCT
• (Requiring strict observation and medical
   intervention)
concurrent with rapid decrease
in platelet count
Figure 5 Dengue classification and levels of severity (WHO, 2009).
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among others. See also: Haemorrhagic Fever Viruses;
Hepatitis Viruses; Leptospirosis; Malaria; Measles Virus
In ‘classical’ dengue a sudden onset of fever follows
a 4–7 days incubation period. This is frequently accom-
panied by headache, myalgia and severe retro-orbital pain
(WHO, 2009). A range of other clinical features may be
observed, and include sore throat, diarrhoea, vomiting,
anorexia and conjunctival injection. Rashes are commonly
seen in dengue: early in the course of illness the skin often
appears flushed with petechiae developing in the ‘critical’
phase and a macular rash occurring in the convalescent
period. Severe arthralgia can be a feature of the illness and
explains the use of ‘break-bone fever’ as a descriptive term
for dengue (McBride, 2010). The clinical features diﬀer
between age groups with clinical features such as cough,
vomiting and abdominal pain being more frequently
observed in children. The early febrile phase lasts for
2–7 days. This is followed by defervescence and the start of
the 24–48 h ‘critical’ phase when an increase in capillary
permeability with an associated rise in haematocrit can be
observed. The degree of plasma leakage is variable. If a
critical volume of plasma is lost patients will develop clin-
ical shock. Thrombocytopenia is almost universally seen in
dengue infection and minor mucosal bleeding can be a
feature of uncomplicated infection. Severe haemorrhage
can occur – gastrointestinal bleeding is well described
in those with a history of peptic ulcer disease (Tsai et al.,
1991). Intracerebral and pulmonary haemorrhage can
occur (Kumar et al., 2009). Other organs can be aﬀected
in dengue, and it is possible that these atypical presen-
tations are under appreciated. These include encephalitis,
myocarditis, hepatitis, pancreatitis, retinitis and the acute
respiratory distress syndrome (Gulati and Maheshwari,
2007).
The management of dengue remains limited to sup-
portive treatment. Uncomplicated infections can usually
be managed in the outpatient setting. It is important that
patients managed in the outpatient setting are encouraged
to maintain a good oral intake. Paracetamol is the anti-
pyretic of choice as non-steroidal anti-inflammatory drugs
are associated with an increased risk of haemorrhage, and
aspirin has an association with the development of Reye’s
syndrome (WHO, 2009).
Patients who develop warning signs suggestive of severe
disease should be admitted. Patients who have warning
signs should have a baseline haematocrit measured as this
could be used as a guide to treatment response or disease
progression. Patients should be started on parenteral iso-
tonic fluids and the infusion rate should be adjusted
according to the clinical response. Parenteral fluids are
generally needed for only 24–48 h – the ‘critical’ phase
(WHO, 2009).Continuing fluids for longer than this carries
a risk of fluid overloading the patient. In severe cases the
administration of parenteral fluid is life saving. Patients
with shock require more intensive management. The use of
isotonic crystalloid fluids in the resuscitation of children
with shock is supported by clinical evidence, and starch-
based solutions are advocated for more severe cases
(Wills et al., 2005). In cases of haemorrhage the transfusion
of blood products is often indicated.
There are currently no licensed antivirals for use in
dengue. Owing to the immune system’s key role in disease
pathogenesis it is possible that drugs that modulate the
immune response may be future therapeutic options.
Pathology and histopathology
The pathology of dengue virus infection is not well
understood because systematic postmortem studies have
not been done on patients representing all types of clinical
expression. The major pathophysiological abnormality in
classic DHF/DSS is an increase in vascular permeability,
which leads to leakage of plasma. Twenty-four Patients
may have serous eﬀusion in the pleural and abdominal
cavities and a variable amount of haemorrhaging in
most major organs. Studies have not revealed destructive
inflammatory vascular lesions, but some swelling and
occasional necrosis have been observed in endothelial cells,
as well as some perivascular oedema (Bhamarapravati
et al., 1967).
Limited studies on patients with a fatal outcome have
demonstrated focal central necrosis of the hepatic cells,
presence of Councilman bodies and hyaline necrosis of
Kupﬀer cells in the liver (Huerre et al., 2001). Changes in
the kidney are suggestive of an immune-complex type of
glomerulonephritis. There is depression of bone marrow
elements, which improves when the patient becomes afeb-
rile. Biopsy studies of the skin rash have demonstrated
perivascular oedema with infiltration of lymphocytes and
monocytes (de Andino et al., 1985).
Pathogenesis
The pathogenesis of dengue involves a complex interaction
between virus and host factors, and remains incompletely
understood. The severe manifestations of DENV infection
are observed at the point the virus is being cleared from the
host by the immune response as opposed to when the viral
load is highest, suggesting that the immune system plays a
key role in disease pathogenesis (Green and Rothman,
2006).
Prospective cohort studies in Asia and Latin America
have demonstrated that secondary infections are associ-
ated with more severe disease (Kyle andHarris, 2008). The
accepted explanation for this observation is that non-
neutralising cross-reactive antibodies elicited in a primary
infection bind virus in a secondary infection and then have
a greater ability to infect Fc-receptor bearing cells. This
is called antibody-dependent enhancement (ADE), and
potentially leads to an increased viral biomass, and there-
fore more chance of developing severe disease (Halstead,
2003). ADE was supported by epidemiological obser-
vations in Cuba where DHF was seen more frequently in
patients with secondary DENV infections. In addition,
there is evidence that ADE immunologically modulates
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infected cells in such a way that the microenvironment
becomes more supportive of DENV replication. A recent
study has provided further support for the concept of
ADE (Dejnirattisai et al., 2010). This work has shown how
antibodies to dengue structural precursor membrane pro-
tein (prM), a component of the humoral immune response
to DENV, are highly cross-reactive between serotypes,
are non-neutralising and appear to mediate ADE in
Fc-receptor bearing cells. Despite epidemiological and
laboratory support for ADE, severe disease can occur in
primary infections and most secondary infections do not
result in severe disease. This implies that other factors
contribute to the dengue pathogenesis.
The cellular immune response is also involved with the
clearance of dengue virus from the host, and is thought to
play a role in the development of severe disease (Rothman,
1999). The proliferation of activated memory T cells and
the production of pro-inflammatory cytokines are thought
to contribute to the development of plasma leak observed
in dengue. In addition, the level of T cell activation is
proposed to correlate with disease severity. It has been
demonstrated that the T cells produced in severe disease
have a low aﬃnity for the current infecting serotype, but a
high aﬃnity for a diﬀerent serotype responsible for a
past infection (Mongkolsapaya et al., 2003). This obser-
vation is consistent with the concept known as ‘original
antigenic sin’.
There is increased evidence that the observed clinical
severity varies depending on the infecting serotype. For
example, higher viraemia and NS1 antigenaemia were
observed in Vietnamese infants infected with DENV-2 as
compared to DENV-1 (Chau et al., 2008). In addition, a
prospective cohort study in Thai children suggested infec-
tion with DENV-2 and DENV-3 was twice as likely to
result in DHF than infection with DENV-4 (Fried et al.,
2010). Within each serotype there are distinct phylogenetic
genotypes that vary in their geographical ranges, and
appear to have diﬀerences in fitness. There is evidence that
the Asian/American genotype of DENV-2 is associated
with more severe disease and has a fitness advantage in
mosquitoes as compared with the American genotype of
DENV-2, perhaps reflecting the higher viraemia observed
with this phenotype (Rico-Hesse et al., 1997).
Many host factors appear to contribute to the develop-
ment of severe disease. A retrospective study in Vietnam
demonstrated that children admitted to hospital with
dengue aged between 1 and 5 years were four times more
likely to die than children aged between 11 and 15 years
(Anders et al., 2011). Various single nucleotide poly-
morphisms (SNPs) appear to have an association with
both protection and vulnerability to severe disease. For
example, a polymorphism in the vitamin D receptor
appears to protect against severe disease, perhaps reflecting
the role of the vitamin D receptor in immune modulation
(Loke et al., 2002). There have been conflicting results from
studies looking at polymorphisms in the tumour necrosis
factor a (TNF-a) gene with some studies showing an
association and others not. Genome-wide association
studies (GWAS) allow a broad approach in understanding
genetic susceptibility to diseases, including dengue. SNPs
at two loci with a significant association with DSS have
been identified from a GWAS conducted on samples from
Vietnamese children (Khor et al., 2011). These SNPs were
in the major histocompatibility complex class I poly-
peptide-related sequence B gene (MICB) on chromosome
6, and in the phospholipase C epsilon 1 (PLCE 1) gene on
chromosome 10. TheMICB gene encodes a surface protein
that contributes to natural killer (NK) and CD8 T cell
activation. The observed association with an SNP in the
MICB gene and DSS may reflect dysfunctional NK and
CD8 cell activity in severe disease, suggesting a key role for
these cells in disease control and pathogenesis. GWAS
technology has the potential to advance understanding of
pathogenesis, and may have a future clinical application
within the context of dengue pharmacogenomics.
Diagnosis
In many areas dengue remains a clinical diagnosis.
Whereas certain clinical and laboratory features are sug-
gestive of the diagnosis, the non-specific nature of early
infection means relying on this strategy is unreliable
(WHO, 2009). Three major laboratory methods have been
developed for dengue diagnosis. A patient is said to have
laboratory-confirmed DENV infection if they have symp-
toms suggestive of dengue in the presence of one of the
following: (a) DENV IgM seroconversion or high and
rising levels of DENV-reactive IgM/IgG in paired plasma
samples, (b) DENV viraemia, (c) NS1 antigenaemia or (d)
DENV isolated in cell culture (WHO, 2009).
Prevention and Control
The development of a safe and eﬀective dengue vaccine
would be a major advance in the global control of the
infection. There have been barriers to the successful
development of a vaccine. For example a candidate vaccine
would need to oﬀer protection against all four serotypes
and there are concerns that incomplete protection may
actually result inmore severe disease, reflecting the immune
system’s role in pathogenesis (Webster et al., 2009). In
addition, there are no animal models of dengue that may
assist pre-clinical development. Despite these challenges
there are currently several vaccine candidates in clinical
trials. On the bases of the success in developing vaccines
against yellow fever and Japanese encephalitis, initial focus
was on developing a live attenuated vaccine. Whereas ini-
tial results with monovalent candidates were encouraging,
the development of a tetravalent formulation proved dif-
ficult and development eﬀorts were suspended. The most
promising candidate, a chimeric vaccine based on a yellow
fever backbone, is now inphase 3 trials (Chimerivax, Sanofi
Pasteur) (Coller and Clements, 2011). The on-going safety
concerns will need to be addressed by long-term follow-up
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of vaccine recipients. The economic justification for a
dengue vaccine and the identification of its place in the
current schedule of immunisation remain important areas
to address. See also: Vaccination of Humans
Vector control has previously been used to control
dengue with some success, most recently in Singapore and
Cuba, and previously in the Panama canal region (Ooi
et al., 2006). Unfortunately these successes have generally
been short-lived, and dengue is increasing in many parts of
the world. Improving our understanding of the virus–
vector interface would aid our understanding of trans-
mission of DENV in the community, help construct
transmission models and potentially allow us to assess the
impact of new disease control interventions.
Environmental management aims to modify the envir-
onment in such a way that viable larval habitats are min-
imised and human contact with the vector is reduced. This
would include strategies such as regular emptying of
water containers, proper disposal of used tires and other
waste, and constructionofmosquito screens in homes. This
approach has the potential to reduce the incidence of
dengue infection, however the success of such strategies is
dependent on active engagement with the local community
(WHO, 2009).
Insecticides are often eﬀective, but are expensive as they
require repeated application and may have been unwanted
environmental side eﬀects. In addition mosquitoes are
able to develop resistance to insecticides. However, due
to the domesticated habits of A. aegypti, larviciding has
traditionally been seen as an adjunct to environmental
management.
Imaginative new approaches to vector control are nee-
ded. Infection of mosquitoes with fruitfly strains of sym-
biontWolbachia bacteria appears to reduce adult lifespan,
aﬀect reproduction and interfere with pathogen repli-
cation, including dengue (Walker et al., 2011). This exciting
new approach to vector control has been commenced
by releasing Wolbachia-infected A. aegypti in parts of
Australia with a view to expanding the programme to
endemic countries in Asia.
Future
Dengue represents a major challenge to global health. Its
global expansion, reflecting huge demographic changes,
has resulted in approximately 40% of the world’s popu-
lation being at risk of infection. Despite this, diagnosis
remains largely clinical, case management is supportive,
and disease control is limited to tackling the vector. The
pathogenesis of dengue, despite its enormous interest
to scientists, remains incompletely understood.
Understanding disease pathogenesis has been hampered
by the lack of a suitable animal model of dengue infection.
It is possible that future insights into pathogenesis
may come from detailed observations within intervention
studies, such as vaccine trials.
Improving the clinical management of dengue remains
an important area of research focus. The new dengue
case classification needs to be validated. Appropriate fluid
management is critical in the management of dengue.
However, the fluid management of those with co-morbid-
ities or pregnancy is particularly challenging and is an area
that warrants further research. There remains a need for
an eﬀective antiviral agent. It is possible that developments
in the treatment of hepatitis C, another flavivirus, may
be transferable to dengue. However, the nature of dengue
pathogenesis suggests that immunomodulatory agents
such as steroids or statins may have more potential in the
treatment of dengue than an antiviral. Dengue can cause
outbreaks that can overwhelm health facilities. In the early
stages of illness it is diﬃcult to distinguish dengue from
other febrile conditions. Distinguishing dengue from other
febrile illnesses, and predicting which patients are at risk of
disease progression would be major advances in dengue
management.
The development of a vaccine would be amajor advance
in the control of disease. As discussed above, the most
promising candidate is in phase 3 trials. If the candidate
vaccine is successful there will still be hurdles to overcome
before it becomes integrated into immunisation pro-
grammes in endemic countries. Understanding community
transmission dynamics by researching the virus–vector
interface may inform mathematical models of disease
transmission. These could potentially aid prediction of the
impact of various interventions, for example the intro-
duction of Wolbachia-infected A. aegypti into endemic
areas. See also: Disease Eradication by Vaccination:
Prospects
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Dengue  is an  important  cause  of  childhood  and  adult  morbidity  in Asian  and  Latin  American  countries
and  its geographic  footprint  is  growing.  The  clinical  manifestations  of  dengue  are  the  expression  of  a  con-
stellation of  host  and  viral  factors,  some  acquired,  others  intrinsic  to  the  individual.  The virulence  of  the
virus plus  the  flavivirus  infection  history,  age,  gender  and  genotype  of  the  host  all  appear  to  help  shape
the  severity  of  infection.  Similarly,  the  characteristics  of  the  innate  and  acquired  host  immune  response
subsequent  to infection  are  also likely  determinants  of  outcome.  This  review  summarises  recent  develop-
ments  in  the  understanding  of dengue  pathogenesis  and  their  relevance  to  dengue  vaccine  development.
© 2011 Elsevier Ltd. All rights reserved.
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1. Introduction
Dengue is a globally important arboviral infection transmitted
by Aedes mosquitoes that endangers an estimated 2.5 billion peo-
ple and represents a rapidly growing public health problem [1].
There are between 50 and 100 million infections each year, with
approximately 500,000 cases admitted to hospital with severe and
potentially life-threatening disease [2–4]. Dengue is an icosahedral,
0264-410X/$ – see front matter ©  2011 Elsevier Ltd. All rights reserved.
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enveloped virus with a single-stranded positive sense genome; it is
a member of the flaviviridae family and has 4 antigenically distinct
serotypes (DENV1-4) [3,5,6].  After infection of a susceptible host,
an acute, self-limiting febrile systemic syndrome ensues. Resolu-
tion of infection occurs within 4–7 days and is associated with a
robust innate and adaptive immune response. At present diagno-
sis is largely clinical, treatment is supportive and disease control is
limited to tackling the vector [1].  Development of a vaccine would
be a major advance in disease control but efforts have been ham-
pered by the lack of an animal model of the disease and concerns
about the role of the immune system in disease pathogenesis [6].
The lack of an animal model further limits our understanding of
immunopathogenesis.
Dengue is a syndrome and its pathogenesis an interplay between
virus and host factors that remains incompletely understood [1,7].
Explaining the heterogeneity between clinical presentations within
a similar cross-section of the population remains a vital area of
research. A better understanding of disease pathogenesis would
greatly aid vaccine development by addressing specific concerns
about vaccine safety and efficacy in light of the immune system’s
role in the development of clinical disease [8]. This review will
examine the different components of our current understanding
of dengue pathogenesis and then consider their implications for
dengue vaccine development.
1.1. Clinical signs, symptoms and management
Clinically apparent dengue (DEN) virus infection is associated
with a range of syndromes. Classical dengue fever is observed more
frequently in adults and occurs after an incubation of 4–7 days
[9,10].  The clinical manifestations of children with DEN can dif-
fer from adults – cough, vomiting and abdominal pain appear to
be more common [11]. The mortality rate in young children with
DEN is significantly higher than in older children or adults [12]. The
incidence of severe disease is perhaps highest in infants, which may
reflect increased capillary fragility and lower compensatory reserve
in this age group [13]. In classical DEN fever there is an abrupt onset
of fever often associated with myalgia, headache and sometimes
severe retro-orbital pain. Early in the illness the skin is flushed
with petechiae appearing in the “critical” phase; a macular rash
is observed in convalescence. The critical phase occurs around the
time of defervescence, typically on days 3–7, and is associated with
an increased propensity for capillary leakage and haemorrhage.
In some individuals, capillary permeability manifests as a rise in
haematocrit, pleural effusions or ascites [14]. This is the stage when
life-threatening clinical complications such as circulatory shock are
typically observed [14]. Disabling fatigue and depression may com-
plicate recovery [15]. Thrombocytopenia is almost universal and
minor bleeding may  occur in mild infections – this can be severe
in those with peptic ulcer disease [16]. Atypical clinical features
of DEN are being more frequently reported but are probably still
underappreciated [17]. These include encephalitis, myocarditis,
hepatitis, pancreatitis, retinitis and the acute respiratory distress
syndrome (ARDS) [8,10,18,19]. These atypical presentations likely
reflect pathology at different endothelial surfaces [17]. Recognizing
the warning signs that may  indicate progression to severe disease
is essential for successful case management – these signs include
abdominal pain, hepatomegaly, evidence of fluid accumulation and
a rising haematocrit (or conversely a falling haematocrit sugges-
tive of haemorrhage) [3].  The current WHO  guidelines recognize
dengue as a clinical continuum from dengue to severe dengue [3].
Careful fluid resuscitation is life-saving in DEN [3].  Ringer’s lactate
has been shown to be efficacious in moderately severe DEN, and
starch or dextran have been suggested for more severe cases [20].
Platelets are often given as prophylaxis to prevent haemorrhage;
however this is a controversial area without a clear evidence base
[21,22].  In many settings DEN is diagnosed clinically; however the
features of early infection are non-specific and mimic  those of other
febrile illnesses [23–25].  An early diagnosis would assist in patient
triage and will have an increasingly important role as therapeutic
drugs, e.g. anti-virals, become available for DEN [26].
2. Immunopathogenesis of dengue
The severe phenotypes of dengue are observed not at the time
when the viral burden is at its highest in vivo, but paradoxically
when the virus is being rapidly cleared from host tissues by the
innate and adaptive immune response. This has led to the sugges-
tion that the pathogenesis of clinically important complications is
closely linked to the host immune reponse [27].
2.1. The humoral immune response and antibody-dependent
enhancement
Although no correlate of immunity to dengue has been defined,
it’s hypothesized that the humoral immune response is vital for
controlling DEN virus infection and for the expression of acquired
immunity. In part, the belief that immunity to dengue is antibody-
mediated stems from observations in other medically important
flavivirus infections, e.g. Japanese encephalitis virus and Yellow
Fever, where the accepted vaccine-elicited correlate of immunity is
virus-neutralizing antibody [28–31].  Confirmation that virus neu-
tralizing antibody is a correlate of dengue immunity is most likely
to come from expanded phase II and phase III trials of the Sanofi
Pasteur developed ChimeriVax vaccine that are currently under-
way in Asia and Latin America [32]. (See Guy et al. article in this
Special Issue).
Sabin demonstrated in the post-war era how infection with
one serotype gave long-lasting protection to that specific serotype
(homotypic immunity) and short-lived protection against the other
serotypes (heterotypic immunity) [33]. The basis for homotypic
immunity is believed to be virus-neutralizing antibodies. The tran-
sient nature of heterotypic immunity is likely due to cross-reactive
E-protein specific antibodies that when above a certain concentra-
tion threshold are protective. However, over time, these antibody
concentrations decline and the individual is then susceptible to
infection with other DEN virus serotypes.
Multiple prospective cohort studies in Asia and Latin Amer-
ica have identified secondary infection as an epidemiological risk
factor for severe dengue [34–38]. Third, or even fourth infections
also probably occur in endemic settings, but hospital data and
the age-related burden of dengue (children) suggests the vast
majority of these tertiary or quaternary infections are clinically
silent or very mild [39]. The leading explanation for increased risk
of disease in secondary infection is that non-neutralising, cross-
reactive antibodies elicited by a primary infection bind the virus
which then have greater potential to infect Fc-receptor bearing
cells. This phenomenon, called antibody-dependent enhancement
(ADE), potentially increases the risks of developing severe disease
by virtue of increasing the number of virus infected cells and there-
fore the viral biomass in vivo [40,41]. Some evidence also suggests
cells infected via an ADE process are immunologically modulated
such that the local environment becomes more permissive for virus
replication [42]. Cells of the monocyte–macrophage lineage in par-
ticular are believed to be a major site of dengue replication under
conditions of ADE [27,43]. The concept of ADE was  initially pro-
posed for dengue in 1977 and was  supported by epidemiological
observations in Cuba [44,45]. Data from Cuba demonstrated that
DHF was more frequently observed in those patients who  had evi-
dence of previous infection with a different serotype. Recent work
has provided further support for the concept of ADE. This research
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has demonstrated that antibodies to dengue structural precursor-
membrane protein (prM), a component of the humoral response to
infection, are highly cross-reactive between DEN virus serotypes
[46]. In vitro studies indicate that even when anti-prM antibodies
are at high concentrations, they are non-neutralising but potently
mediate ADE in Fc receptor bearing cells [46,47]. The proposed basis
for prM-mediated ADE is that on a proportion of virus particles prM
is only partially cleaved from the virus surface during the virus
maturation process. In this scenario, such “immature” virus parti-
cles that would otherwise be non- or less-infectious, are rendered
infectious in an environment where anti-prM antibodies can medi-
ate ADE [46]. These in vitro observations have led to the suggestion
that a vaccine candidate should be designed in a way that would
minimise the anti-prM response [46].
A second epidemiological setting that implicates a role for ADE is
primary infection of infants born to dengue-immune mothers. Pri-
mary infections in infants aged between 4 and 12 months of age can
result in severe dengue, an outcome that is epidemiologically less
common in younger infants and children aged between 1 and 2 yrs
of age. At the age of 3–4 months, maternally derived virus neutral-
izing antibodies have generally declined below measurable levels
in infants, however non-neutralising antibodies, which represent a
much greater fraction of the virion-binding antibody population,
remain present [48–50].  These virion-binding, non-neutralising
antibodies are thought to enhance the risk of clinically apparent
and severe dengue through a process of ADE [51–54].  In support of
this hypothesis, neat plasma from 6-month old healthy Vietnamese
infants enhances the infectivity of DENV-2 in Fc receptor bearing
cells significantly more than plasma collected at the time of birth
or at 1-yr of age [52].
Concerns about ADE have led to fears that a vaccine could con-
tribute to increased disease severity due to re-infection in the
presence of incomplete protection to one or more serotypes. This
hypothetical concern needs to addressed by careful, long-term
follow-up of vaccine recipients. It is difficult however to envisage a
scenario whereby vaccination actually increases the risk of dengue
or severe dengue to a level where it exceeds the “natural history”
of dengue epidemiology in endemic regions.
2.2. The cellular immune response
Cellular immune responses are also suggested to play a role
in clearing virus infection and potentially triggering the devel-
opment of severe disease. Activated memory T cells recognizing
both conserved and altered peptide ligand epitopes, are suggested
to be involved in the development of plasma leakage [55]. It is
proposed that the expression of viral epitopes on the surface of
infected cells trigger the proliferation of memory T cells and the
production of pro-inflammatory cytokines that have an indirect
effect on vascular endothelial cells resulting in plasma leak. The
level of T cell response is thought to correlate to disease severity
[56,57]. Mongkolsapaya and colleagues in Thailand showed that T
cells in severe infection have a relatively low affinity for the cur-
rent infecting serotype but a high affinity for a past infection with a
different serotype, i.e. they display characteristics of original anti-
genic sin [57]. Moreover, T cell responses in severe patients are
mainly mono-functional in that they produce IFN-! and/or TNF-"
only and rarely CD107a, a marker of cytotoxic degranulation. Con-
versely, in patients with uncomplicated dengue, relatively more
CD8+ T cells expressed CD107a and only a few expressed only IFN-!
and/or TNF-" [58]. This is suggested to delay viral clearance, and via
cytokine-mediated effects, potentially increase the risk of severe
manifestations of disease. However, it remains to be shown, in even
a temporal way, that T cells contribute to capillary leakage in vivo.
Recent data in Vietnamese children suggests the emergence of acti-
vated T cells in blood of children with dengue is not synchronous
with commencement of capillary permeability [62]. One possibil-
ity is that activated T cells are sequestered in tissues during acute
dengue and are therefore difficult to detect at the time capillary
permeability becomes apparent. The role of T regulatory cells is not
clear in dengue. Their role in chronic infectious diseases has been
studied but their role in acute viral infections is not well estab-
lished [63]. However Luhn and colleagues demonstrated that they
are functional and expand in acute dengue infection [64]. They may
have a role in suppression of the production of vasoactive cytokines
– perhaps the regulatory response is inadequate in severe disease?
The absence of good animal models of disease (as opposed to
infection) is a hurdle to understanding the role of memory T cells
in immunity and immunopathogenesis. For this reason, insights
into the role of T cells in immunity will derive from prospective
cohort studies, or vaccine trials [65]. A detailed commentary on
the challenges of using cellular immune parameters as correlates
of immunity to dengue has recently been published [66].
2.3. Cytokines
It is thought that in some individuals with secondary infec-
tion, high viral burdens trigger expression of a wave of cytokine
and other inflammatory molecules from innate and activated,
cross-reactive T cells. This inflammatory mileau is hypothesized to
mediate permeability in the vascular endothelium, allowing water
and small molecules to leak from the intravascular space and in
some cases leading to the severe manifestations of dengue [67].
Increased levels of many different cytokines have been observed
in dengue infection [68]. In particular, higher concentrations of
cytokines such as IFN-!, TNF-" and IL-10 have been observed
in the sera of patients with severe dengue in Vietnam, Cuba
and India [69–71]. Reduced levels of nitric oxide (NO) associated
with increased levels of IL-10 have been described in patients
with severe dengue [72]. NO contributes to immune regulation –
lower levels of NO may  result in the increased expression of pro-
inflammatory cytokines [73]. In addition it is known that increased
IL-10 levels correlate to reduced levels of platelets and reduced
platelet function [74]. This phenomenon could, in part, contribute
to the development of the bleeding complications observed in
severe disease. Elevated levels of IL-6 have been observed in
children with ascites [75]. TNF-" promotes increased endothelial
permeability and it is plausible that increased levels of this cytokine
could result in a more severe disease course [76]. It is likely that
cytokines play a mutually synergistic role at the endothelial surface
contributing to the development of the transient plasma leak, how-
ever the exact dynamic of this interaction has yet to be elucidated.
It is worth noting that other infectious diseases and inflamma-
tory disorders result in elevated cytokines without the attendant
increased vascular permeability seen in severe dengue. Indeed, one
of the challenges in dengue is to dissect those elements of the host
immune response that are causally linked to capillary permeability
from those that simply reflect the normal host immune response
to a pathogen. This challenge is made more difficult by the absence
of good animal models of disease.
2.4. Complement
Reduction in the levels of complement components have been
described in patients with severe dengue, suggesting that com-
plement activation may  have a role in the pathogenesis of severe
disease [77,78]. In particular it has been suggested that excessive
complement activation at endothelial surfaces contributes to the
vascular leak observed in severe disease [79]. NS1, a non-structural
viral protein that is secreted from infected cells and present in blood
in concentrations exceeding 1 #g/ml in some patients, could be
an important modulator of the complement pathway. DEN virus
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NS1 attenuates classical and lectin pathway activation of comple-
ment by directly interacting with C4 [80]. NS1 promotes efficient
degradation of C4 to C4b and by this mechanism, NS1 is suggested
to protect DENV from complement-dependent neutralization in
solution [80]. The significance of these observations with the inde-
pendent observation that early NS1 concentrations in blood are
positively associated with disease severity are not yet clear, but
are consistent with a role for NS1 and complement in pathogenesis
[81,82]. Finally, it is plausible that the low levels of complement
observed in severe dengue are merely a marker of a severe sys-
temic disease rather than an indicator of their role in capillary
permeability.
2.5. Moving beyond descriptive studies in immunopathogenesis
Much of the literature describing the immunopathogenesis of
dengue has been correlative in nature, e.g. temporal associations
between elevated cytokine concentrations in the febrile phase
of dengue is often interpreted as being causally linked to the
important clinical events of plasma leakage or bleeding manifes-
tations. The challenge in this area of research is to move beyond
descriptive studies and begin to identify causal immunopathogenic
mechanisms. Therapeutic randomized controlled intervention tri-
als, with either anti-viral drugs or immunomodulatory agents, e.g.
corticosteroids, perhaps will offer insights into pathogenesis in a
more direct fashion. Such trials are underway (ClinicalTrials.gov
identifier NCT01096576 and ISRCTN39575233). Alternatively,
improvements in animal models of dengue have occurred such that
a productive, sometimes fulminant, acute virus infection can be
established [83]. As yet however, no small animal model mimics
the virological and pathophysiological events that occur in a child
with severe dengue, in particular the relatively slowly evolving cap-
illary permeability that clinically manifests between day 3 and 6 of
illness coupled with a fast declining viral burden. Clearly then there
is scope for further research into animal models and strong justifi-
cation for studying the host response during randomized controlled
treatment trials in dengue patients.
3. Host determinants of disease severity
Only a small proportion of individuals with secondary DEN virus
infections (and an even smaller proportion with primary infec-
tion) develop severe disease [1].  Therefore it follows that other
variables, besides pre-existing immunity, shape the outcome of
infection. This section will consider the role of age, gender, genetic
susceptibility determinants and pre-existing medical conditions in
determining the clinical phenotype.
3.1. Age and gender
Age is a risk factor for severe dengue and death. For example, the
odds of a Vietnamese child 1–5 yrs of age dying as an inpatient in
a Ho Chi Minh City Hospital between 2001 and 2009 was  four-fold
higher than a child 11–15 yrs of age. The greater relative prevalence
of DSS in children relative to adults is likely tied to their having
an intrinsically more permeable vascular endothelium, as demon-
strated previously by Gamble et al. in healthy Vietnamese children
and adults [84]. The risk for more severe outcomes in young chil-
dren argues for vaccination implementation strategies to include
this most vulnerable population.
Gender is also a risk factor for severe dengue and death-females
are over-represented in several case series of children with DSS
[85–87]. Girls were also over-represented amongst severe (odd
ratio 1.19) and fatal cases (odd ratio 1.57) in the cohort of dengue
inpatients at three large hospitals in Ho Chi Minh City between
2001 and 2009 [85]. The basis for an over-representation of females
amongst severe and fatal cases has been suggested to be due to dif-
ferences in health-care seeking behavior on behalf of girls and boys
in Asian countries, i.e. girls may  be presenting later in the course
of their illness, leading to a higher likelihood of severe outcomes
[85]. An alternative hypothesis is that physiological or immunolog-
ical differences exist between males and females that explain these
gender differences. Clearly, more research is required to under-
stand the role of age and gender as determinants of outcome.
3.2. Genetic determinants of dengue susceptibility
Epidemiological studies suggest that people with African ances-
try are less susceptible to the severe manifestations of dengue
infection – the evidence for this is strongest in studies from Cuba
and Haiti [88,89].  Other evidence for a host genetic basis to suscep-
tibility stems from case-control association studies. In the immune
response to DEN virus infection, viral antigens are presented to
T cells in association with the major histocompatability complex
(HLA) class I and II system. Some HLA alleles are suggested to be
associated with different clinical phenotypes of dengue [90]. In
addition, there is a suggestion of an association between HLA allele
and susceptibility to specific dengue serotypes, for example DENV-
1 and HLA *0207 and DENV-2 and HLA *B52 [91]. In addition some
associations appear to be protective, for example HLA DR alleles in
Mexican and Vietnamese populations [92,93]. However, most stud-
ies of genetic association with dengue are undermined by issues of
sample size, multiple testing, unknown population stratification
and variable case definitions. Indeed, with the exception of DC-
SIGN, no association in an HLA allele or candidate gene has been
replicated in an independent study.
Despite these limitations in study design, various single
nucleotide polymorphisms (SNPs) have been associated with both
protection and vulnerability to dengue infection [90]. The vita-
min  D receptor modulates the immune response by stimulating
cell-mediated immunity and inhibiting lymphocyte proliferation;
a polymorphism in the receptor appears to protect against severe
dengue [94]. The Fc! receptor mediates entry of antibody-coated
DENV into target cells; the same study demonstrated that homozy-
gotes for the arginine variant at position 131 of the Fc!  receptor
gene may  also be protected from severe disease [94]. This is per-
haps because these homozygotes have less ability to opsonise IgG2
antibodies. There have been conflicting results from studies look-
ing at polymorphisms in the TNF-" gene – data from Vietnam
did not show an association, whereas investigators in Venezuela
reported a significantly increased prevalence of the TNF-308A
allele in patients with severe dengue [94,95].  Dengue infection
of dendritic cells is mediated by the attachment factor, dendritic
cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN1, encoded by
CD209). The G allele of the variant of the promoter region (DC-
SIGN-336) was associated with protection against dengue fever,
but not dengue haemorrhagic fever [96]. This finding suggests that
different disease phenotypes may  be partly related to the activity of
CD209 and the degree of DC-SIGN expression. Another area of focus
in determining susceptibility to dengue has been polymorphisms
in human platelet antigens (HPA). HPAs mediate the interaction
between platelets and endothelium. Data from an Indian cohort
showed that HPA-1a and HPA-2b alleles were expressed more fre-
quently in patients with severe disease [97]. In addition the study
demonstrated that clinical shock was seen more frequently in HPA-
1 heterozygotes. It is possible that cross-reactive antibodies formed
in the context of dengue infection may  bind to HPA leading to
platelet reduction.
In the era of genome-wide association studies (GWAS), a more
expansive approach to understanding genetic susceptibility to
severe dengue is now possible and desirable. Equally, this approach
could be used in a pharmacogenomics fashion to understand the
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genetic basis for adverse events, immunogenicity and durability
of immune responses in participants of large dengue vaccine tri-
als. This approach typically requires thousands of cases that fit a
well-defined clinical outcome and population-matched controls.
The strength of the approach is that it has power to detect rela-
tively small contributions to genetic risk whilst also discounting
any population stratification in cases or controls. The next major
advances in our understanding of host genetic susceptibility to
severe dengue, or the immune response to vaccination, are likely
to come from GWAS methods.
3.3. Pre-existing comorbidities and predisposition to severe
dengue
There have been few studies that have explored associations
between underlying chronic diseases and predisposition to severe
dengue. It was  observed during the Cuban epidemics that chronic
conditions, for example bronchial asthma, diabetes mellitus and
sickle cell disease, were over-represented in patients with severe
disease [98–101]. In addition it has been observed that a chronic
medical condition is present in up to 70% of fatal cases in some
case series of adults [102]. Data from Singapore suggests that co-
morbidities such as hypertension are common in older patients
with DEN, but infections in this age group are relatively benign
[103]. Case control studies are necessary to further determine the
role that chronic illness plays in predisposing the host to the severe
manifestations of disease. Chronic hepatitis B virus infection is a
common health problem in DEN-prevalent areas; co-infection does
not appear to affect the clinical course but is associated with higher
liver enzyme elevations [104]. DEN-HIV co-infection is an area of
interest. There has been a recent intriguing observation that DEN
NS5 protein inhibits HIV replication [105]. However a small case
series in Singapore does not suggest the clinical course of dengue
is any different in patients with HIV [106]. Pre-existing morbidi-
ties, more common in adults, could also be a determinant in the
safety profile of live attenuated dengue vaccines. For example, it
is unknown how HIV co-infection impacts the safety profile of live
attenuated dengue vaccines currently in development. Similarly,
it is unknown if secondary immunodeficiency (e.g. through long-
term corticosteroid use) is a factor in the safety and reactogenicity
of live attenuated dengue vaccines. Insights in these areas will accu-
mulate as clinical development of candidate vaccines progresses, or
alternatively, from post-marketing surveillance.
4. Thrombocytopenia and coagulopathy in dengue
pathogenesis
4.1. Thrombocytopenia
As discussed above thrombocytopenia is an almost universal
finding in dengue. This occurs as a result of both reduced pro-
duction and increased destruction of platelets [107–109]. It has
been suggested that the degree of thrombocytopenia correlates
with clinical severity and complement activation [110]. As a result
of reduced platelet counts and increased complement activation
there is increased vascular fragility and thus an increased risk of
haemorrhage.
4.2. Coagulopathy
Disordered coagulation, together with plasma leak and throm-
bocytopenia is likely to contribute to the haemorrhage observed
in some cases of severe dengue [111]. This coagulopathy is likely
to be mediated by cytokines. In a mouse model of the disease
elevated levels of TNF-! correlated with endothelial cell dysfunc-
tion and haemorrhage [112]. Elevations of IL-6 and IL-8 have been
associated with disordered coagulation and fibrinolysis in dengue
[109,111].  Data from children in Vietnam has shown that increased
APTT and reduced fibrinogen are consistently observed in patients
with dengue [113]. The same study showed minor elevations in
prothrombin time (PT). Infections normally result in increased fib-
rinogen, unless these conditions are complicated by disseminated
intravascular coagulation (DIC). However the minor changes in
PT together with the infrequent observation of fibrinogen degra-
dation products (FDPs) do not support DIC being the cause of
dengue-associated coagulopathy [113]. There are conflicting opin-
ions about whether fibrinolysis or impairment of the fibrinolytic
pathway occurs in dengue pathogenesis [114]. It is clear that the
exact mechanisms contributing to dengue coagulopathy are incom-
pletely understoodand that a better understanding is needed to
allow for improvements in supportive care.
5. Viral factors in pathogenesis
5.1. Virus epidemiology and virulence
There are 4 antigenically distinct serotypes of dengue virus
– DENV-1, DENV-2, DENV-3 and DENV-4. Each of the DEN virus
serotypes is capable of causing severe dengue and early viral bur-
dens in the course of illness are associated with severe disease
[74,82,115]. Oscillations in the prevalence of each serotype are
common in endemic settings. Typically, one serotype is dominant
for a period of 2–4 yrs, after which it declines in prevalence as a
different serotype(s) emerges to replace it [116,117].  The basis for
the decline in prevalence of a serotype is presumably the accu-
mulation of herd immunity such that the number of susceptible
humans available is diminished. This cycling may  also be due to
immune enhancement when a new serotype is encountered. Each
DENV serotype isas phylogenetically distinct from one other as the
DENV groupis from Japanese encephalitis virus, suggesting that
each serotype could be considered a separate virus with distinct
in vivo characteristics. This concept is now gaining wider recog-
nition. For example, the kinetics of viremia and NS1 antigenemia
in DENV-1 infections is distinctly different (higher) from DENV-
2 infections in Vietnamese children [52,60]. Similarly, Vietnamese
infants with primary DENV-1 infections have significantly lower
plasma NS1 concentrations than DENV-2 infected infants at the
time of hospital presentation. Furthermore, a prospective study of
hospitalized Thai children suggestedDENV-2 and -3 were twice as
likely to result in DHF as DENV-4 [118]. Collectively, these data
are examples that suggest each DEN virus serotype has its own
constellation of virological characteristics in human hosts. Further
research is needed to understand the breadth of these differences
in humans, but also to understand differences with the mosquito
host.
Adding to the complexity of DEN virus biology, within each
DEN virus serotype there are distinct phylogenetic genotypes that
appear to have differing geographical ranges. Increasingly, it is
becoming clear that fitness differences exist between genotypes
of the same serotype [119]. For example, there is evidence that
the Asian/American subtype of DENV-2 is associated with more
severe disease and has a fitness advantage in infected mosquitoes
compared to the American genotype of DENV-2 [120]. Conversely,
in Viet Nam, the introduction of the Asian 1 genotype of DENV-2
led to the complete replacement of the resident Asian/American
genotype of DENV-2 [117]. The transmission fitness advantage of
Asian 1 viruses was attributed to this virus attaining higher viremia
levels in humans [117]. Other examples of genotype replacement
events have occurred in Sri Lanka and Thailand. In Sri Lanka, the
introduction of a new genotype DENV-3 virus was  associated with
an increased incidence of severe dengue [121]. Recently, evidence
of antigenic differences between genotypes of the same serotype
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has emerged [122,123].  To date these differences have been elu-
cidated using mAbs specific to the E protein and it remains to
be seen whether such differences are present in the face of poly-
clonal immune sera. Prospective cohort studies that can follow the
introduction of different DEN virus genotypes into the same pop-
ulation are needed to understand the clinical and epidemiological
significance of antigenic variation between DEN virus genotypes. It
is worth remembering however that clinically apparent recurrent
infections caused by the same serotype of DENV virus have not been
documented, suggesting antigenic variation between genotypes
might not be clinically relevant. Nevertheless, this is an important
question since any evidence of “immune escape” within a serotype
would have implications for vaccine development.
5.2. Cellular and tissue targets of DEN virus infection
The very early events in DEN virus infection of the human host
are poorly understood. After the bite of an infected mosquito it
is thought that initially immature Langerhan’s cells in the dermis
are infected first [124]. These infected cells migrate to the lymph
nodes, resulting in infection of cells of the macrophage-monocyte
lineage. This amplifies the infection, which is then disseminated via
the lymphatic and vascular system. After this primary viremia cir-
culating monocytes within the blood and macrophages within the
liver, spleen and bone marrow are infected [125,126].  The range of
tissues and cell types infected with DEN viruses suggests that the
host receptor(s) are broadly distributed. To date, there is evidence
for several candidate host receptors, for example mannose bind-
ing protein, heparan sulphate, chondroitin sulphate and DC-SIGN
[127–129]. The factors that determine the number of cells infected
at specific sites may  also influence the level of immune activa-
tion, and thus have a role in determining the disease phenotype
[111,125].  The time between the bite of an infected mosquito and
the onset of clinical symptoms is believed to be 3–5 days [130,131].
Whether infected individuals in this pre-syndromic phase are capa-
ble of transmitting virus to a biting mosquito is unknown.
The study of viral tropism and in vivo pathology in dengue has
been hampered by the lack of an animal model of disease and
limited autopsy data from fatal cases. Nevertheless, post-mortem
studies have detected suggested DEN viral antigen in a range of
host cells and tissues [132]. There was also selective apoptosis of
endothelial cells in the pulmonary and intestinal vasculature in one
study, although this needs to qualified since differentiating true dis-
ease pathology from post-mortem tissue changes can be difficult
[133].
6. Conclusions
Dengue continues to be a growing public health threat in many
parts of the world. It is clear that vector control is an inadequate
public health tool in endemic areas. Whilst careful clinical man-
agement can reduce the case-fatality rate amongst hospitalized
patients to less then 1%, the disease burden places enormous pres-
sure on health services and has a substantial social and economic
impact [134]. The virulence of the virus plus the flavivirus infection
history, age, gender and genotype of the host all appear to be deter-
minants of outcome. The host immune response appears to play
a central role in pathogenesis and much new information on this
topic has been derived in the last 10 yrs. Nonetheless, much work is
still needed to identify the precise causal mechanisms of the dengue
capillary permeability syndrome, and in turn, how this can be mod-
ulated to improve patient management. A better understanding
of dengue immunopathogenesis will assist not only development
of therapeutic interventions but also the understanding of dengue
vaccine efficacy or vaccine adverse events.
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2. HOST SUSCEPTIBILITY 
 
Background 
A key question in dengue is understanding why some patients infected with DENV get severe 
disease whereas others do not. Understanding the factors that determine the outcome of 
DENV infection is important and has the potential to expand our understanding of 
pathogenesis and, in the long-term, improve the clinical management of the disease.  
Outline of papers 
Dengue pathogenesis: host factors 
This monograph considers the role of various host factors in dengue pathogenesis including 
host genetics. It provides an introduction to this section of the thesis and considers the 
relevance of these factors to clinical practice. 
MICB and PLCE1 and host susceptibility 
SNPs at two genomic loci are associated with DSS in Vietnamese children.7 These SNPs 
were in the major histocompatibility complex class I polypeptide-related sequence B gene 
(MICB) on chromosome 6, and in the phospholipase C epsilon 1 (PLCE 1) gene on 
chromosome 10. The MICB gene encodes a surface protein that contributes to natural killer 
(NK) and CD8 T cell activation. The observed association with a SNP in the MICB gene and 
DSS may reflect dysfunctional NK and CD8 cell activity in severe disease, suggesting a key 
role for these cells in disease control and pathogenesis. Mutations in PLCE1 are associated 
with nephrotic syndrome, a condition characterised by proteinuria, reduced vascular oncotic 
pressure and subsequent oedema.8 Severe dengue is characterised by plasma leak 
suggesting the possibility of some similarities with the pathophysiology of nephrotic 
syndrome. It is possible that mutations in PLCE1 result in a reduced ability to maintain normal 
endothelial integrity, and therefore an increased risk of a more severe disease phenotype.7 
However these identified associations were in the context of paediatric patients with DSS, 
leaving unanswered the question whether they are also associated with less severe clinical 
phenotypes of dengue. To this end, the aim of this component of the thesis was to define the 
extent to which these alleles are associated with milder clinical phenotypes of paediatric and 
adult dengue. This work represents a natural extension of the original GWAS and has the 
potential to improve our understanding of disease susceptibility and pathogenesis and, in the 
longer term, pave the way to improved clinical management. 
  
 40 
LITERATURE REVIEW 3: DENGUE PATHOGENESIS: HOST 
FACTORS 
 
  

© CAB International 2014. Dengue and Dengue Hemorrhagic Fever, 2nd Edition
214 (eds D.J. Gubler et al.)
their infection (Anders et al., 2011). This study, 
of over 100,000 clinically diagnosed dengue 
cases, showed the odds of a child aged between 
1 and 5 years dying of dengue as a hospital 
inpatient in Ho Chi Minh City was four times 
higher than for a child aged between 11 and 
15 years. These findings are consistent with 
physiological observations that suggest that 
younger children have an intrinsically more 
permeable vascular endothelium and are 
therefore more prone to significant plasma 
leak and are thus more vulnerable to the devel-
opment of shock and a poor clinical outcome 
(Gamble et al., 2000).
A number of case series and cohort studies 
have suggested that gender is an additional 
risk factor for both the development of severe 
dengue and death (Halstead et al., 1970; Kabra 
et al., 1999; Anders et al., 2011). In the retro-
spective cohort study in Vietnam, Anders and 
colleagues demonstrated that females were 
over-represented in both severe (odds ratio 
1.19) and fatal cases (odds ratio 1.57) (Anders 
et al., 2011). In this study the authors suggest 
that these observed differences between males 
and females might reflect different health- 
seeking behavior on behalf of different gen-
ders in Asian countries. This explanation seems 
plausible given the striking overall bias towards 
males among dengue cases in this same cohort, 
suggesting that the over-representation of 
Introduction
Fortunately, severe dengue is an uncommon 
outcome of both primary and secondary 
DENV infections. The syndromic nature of 
severe dengue (see Chapter 8, this volume) is 
a reminder that no single host or viral factor 
should be considered a sole mechanistic cause 
of this outcome. Instead, a constellation of viro-
logical and host variables contribute to the 
expression of the clinical phenotype. These 
host and virus variables need to be thought of 
as risk factors that are measurable on a popu-
lation-wide scale, but are not necessarily risk 
factors in individual patients. Here we will 
review some of the host risk factors associated 
with severe dengue and identify knowledge 
gaps where future research could be directed.
Age and Gender as Risk Factors 
for Severe Dengue
Age is a risk factor for the development of 
severe disease and death from DENV infection. 
A retrospective study in Vietnam showed 
that while the incidence of dengue shock 
syndrome (DSS) was highest in children aged 
between 6 and 10 years, younger children had 
a significantly higher chance of dying from 
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females among the severe and fatal cases may 
reflect later presentation of girls to health ser-
vices. It has been suggested that the over-
representation of females in other case series 
may reflect a stronger, and thus pathological, 
cellular immune response to DENV, or a capil-
lary endothelium more vulnerable to leak in 
females (Halstead et al., 1970; Halstead, 1997; 
Kabra et al., 1999). Further research is needed 
to assess the contribution gender makes on 
the eventual disease phenotype.
Dengue in the first year of life
Severe dengue is strongly associated with 
secondary DENV infections (Sangkawibha 
et al., 1984; Burke et al., 1988; Thein et al., 1997; 
Graham et al., 1999). Severe dengue also occurs 
during primary DENV infection of infants 
born to DENV-immune mothers (Halstead et al.,
1970; Hongsiriwon, 2002; Nguyen et al., 2004; 
Simmons et al., 2007). Clinically, severe dengue 
in infants is associated with all of the clinical 
features seen in older children, with the dis-
tinguishing feature being that infants with 
dengue have primary DENV infections and 
are born to dengue immune-mothers. Halstead 
has proposed that infants born to dengue-
immune mothers and previously infected 
children or adults have in common a single im-
mune risk factor – DENV-reactive IgG anti-
bodies (Halstead, 1988). The capacity of sub-
neutralizing concentrations of DENV-reactive 
IgG antibodies to enhance DENV infections in 
Fc-receptor bearing cells (Halstead, 1988; Morens 
and Halstead, 1990; Gagnon et al., 2002), the 
process called antibody-dependent enhance-
ment (ADE), provides a unifying basis to 
explain severe dengue in secondary infec-
tions and in infants with primary infections. 
Support for this hypothesis stems from the 
observation that infants with severe dengue 
are typically between 4 and 11 months of age, 
a time when maternally derived neutraliz-
ing antibody has usually waned but when 
non-neutralizing, virion-binding antibodies 
remain and experimentally can cause ADE 
(Kliks and Halstead, 1983; Kliks et al., 1988; 
Chau et al., 2008). Refinement of this hypoth-
esis as it relates to infants has implicated 
maternal IgG as a risk factor for symptomatic 
dengue as well as severe dengue (Libraty 
et al., 2009). Further, maternally derived anti-
prM IgG antibodies are a logical candidate for 
supporting ADE in infants (Chau et al., 2008; 
Dejnirattisai et al., 2010). Primary dengue in 
infants is not associated with an anamnestic 
cellular immune response and therefore this 
aspect of the host immune response cannot 
explain the clinical complications of capillary 
leakage, bleeding and coagulopathy that are 
often observed in infants with severe dengue. 
It is possible that severe dengue in infants 
reflects their intrinsically poor compensatory 
reserve in the face of a severe, systemic viral 
infection that has been exacerbated by ADE. 
Further research is needed to understand the 
similarities and differences in the pathogene-
sis of dengue in infants compared with older 
children. Future studies should utilize pro-
spective cohort studies, as described previ-
ously (Libraty et al., 2009), to gain insights into 
the role of maternal antibody and the clinical, 
virological and immunological phenotype of 
dengue in infants.
Host Genetics and Susceptibility 
to Severe Dengue
A genetic component to susceptibility to severe 
DENV infection was indirectly suggested in 
1906, when Agramonte observed, ‘Black peo-
ple seem to have remarkable degree of resist-
ance to dengue disease’ (Agramonte, 1906). 
Agramonte’s statement has been supported 
by epidemiological observations in Cuba 
and Haiti that suggest that people with an 
African ancestry have a reduced risk of de-
veloping severe disease as compared to those 
with European ancestry (Guzman et al., 1990; 
Halstead et al., 2001; Guzman and Kouri, 2002; 
Guzman, 2005). Whether this reflects intrinsic 
genetic or physiological differences, or reduced 
exposure because of A. aegypti biting prefer-
ences, requires further study.
Most studies exploring genetic associa-
tion in dengue have been case-control associ-
ation studies. Unfortunately many of these 
studies have been compromised by poor design 
and sometimes vague reporting. Inadequate 
sample sizes, unclear case definitions, multiple 
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testing and undetermined population stratifi-
cation are prominent potential confounders to 
the results of these studies. The vast majority 
of previous studies examined polymorphisms 
in candidate genes where there was pre-analysis 
justification for an association. However, fol-
lowing the completion of sequencing for the 
human genome project and the advent of 
genome-wide association studies (GWAS) 
there have been considerable advances in our 
understanding of the genetic susceptibility to 
diseases, including infectious diseases, as a 
more comprehensive and rigorous approach 
has become possible (Hill, 2006; Casanova 
and Abel, 2007; Manolio, 2010). Despite the 
limitations of many earlier case-control genetic 
association studies, a panel of single nucleo-
tide polymorphisms (SNPs) has been nomi-
nated as being associated with both protection 
and vulnerability to dengue. The validity of 
many of these associations has yet to be tested 
in independent cohorts from either the same 
population or a different population.
HLA genotype and 
susceptibility to dengue
As the immune system is strongly implicated 
in DENV pathogenesis, it is natural that the 
genes involved in regulation of the immune 
response have been among the most closely 
studied. In the course of DENV infection, 
viral antigens are presented to T cells in asso-
ciation with the major histocompatibility 
complex (HLA) class I and II systems. Some 
of the highly polymorphic HLA alleles have 
been proposed to have an association with 
either disease susceptibility or protection 
(Coffey et al., 2009). Studies have been con-
ducted in different geographic and ethnic set-
tings that have shown an association between 
certain HLA class I alleles and vulnerability 
to severe DENV infection (Chiewsilp et al.,
1981; Paradoa Perez et al., 1987; Loke et al., 2001). 
A case-control study conducted in Thailand 
showed a serotype-specific association between 
various HLA class I alleles and the clinical 
outcome of infection (Stephens et al., 2002). For 
example, HLA-A*0203 was associated with 
less severe disease irrespective of the infecting 
serotype, whereas HLA-A*0207 was associated 
with more severe disease only in patients 
with secondary DENV-1 and DENV-2. In con-
trast, HLA-A*B51 was associated with more 
severe disease irrespective of serotype, and 
HLA-A*B52 was associated with a less severe 
disease phenotype in secondary infections 
with DENV-1 and DENV-2. In addition, vari-
ous HLA-B alleles (B44, B62, B76 and B77) 
appeared to protect against the development 
of clinical disease from secondary DENV 
infection (Stephens et al., 2002). Work in Mexico 
and Vietnam has suggested that certain HLA 
DR alleles protect against severe infection 
(LaFleur et al., 2002; Nguyen et al., 2008). For 
example, in the Mexican case-control study 
there appeared to be a protective association 
between HLA-DR4 and the risk of developing 
severe disease (LaFleur et al., 2002). The 
Vietnamese case-control study showed HLA-
A*A24 was over-represented in patients with 
severe disease, whereas HLA-DRB1*0901 was 
under-represented, suggesting an association 
with susceptibility and protection respec-
tively (Nguyen et al., 2008). There have been 
additional studies assessing the association 
between polymorphisms in the TNF-a gene 
and susceptibility to DENV infection (Fernandez-
Mestre et al., 2004; Perez et al., 2010; Garcia-
Trejo et al., 2011). These studies suggested an 
association between the TNF-308A allele and 
increased susceptibility to severe manifes-
tations of DENV infection (Fernandez-Mestre 
et al., 2004; Perez et al., 2010), and a possible 
protective association between the TNF-238A 
allele and severe DENV infection (Garcia-
Trejo et al., 2011). Another case-control study 
showed an in creased frequency of the trans-
forming growth factor b-1 (TGFb-1)-509 CC 
genotype in cases of dengue hemorrhagic 
fever, as compared to the milder dengue fever 
(Chen et al., 2009). This same study showed 
that the presence of the TGFb-1-509 CC geno-
type together with the cytotoxic T-lymphocyte 
antigen 4 (CTLA-4) +49G allele was associ-
ated with a higher viral load in DENV-2 infec-
tions and a more severe disease phenotype 
(Chen et al., 2009). These findings support dis-
ordered regulation of T cell responses playing 
a key role in the development of severe disease.
The vitamin D receptor (VDR) appears 
to play an integral role in the modulation 
of the immune response (Baeke et al., 2010). 
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The VDR is present on virtually all cells of the 
immune system and activation of the receptor 
modulates the immune response by trigger-
ing cell-mediated immunity and inhibiting 
the proliferation of lymphocytes (Baeke et al.,
2010). The tt genotype of a SNP at position 
352 of the VDR gene was associated with pro-
tection from severe dengue (Loke et al., 2002). 
Interesting this same SNP has been observed 
more frequently in other infectious disease 
phenotypes. For example, it is over-represented 
in tuberculoid as opposed to lepromatous 
leprosy (Roy et al., 1999). As the tuberculoid 
phenotype of leprosy is associated with a 
robust cell-mediated immune response, these 
observations support the role of enhanced 
cell-mediated immunity in controlling DENV 
infection. Loke and colleagues (2002) also 
showed that homozygotes for the arginine 
variant at position 131 of the Fcg receptor II 
(FcgRII) gene appeared to be protected from 
the development of severe DENV infection. 
FcgRII is a widely distributed receptor for all 
IgG classes, and has been shown to mediate 
antibody-dependent enhancement of DENV 
in in vitro experiments (Littaua et al., 1990). 
The arginine variant of the FcgRII receptor 
appears to be associated with reduced opsoni-
zation of IgG2 antibodies (Clark et al., 1991). 
It is plausible that the association between 
the arginine variant of the FcgRII gene and 
a less severe clinical phenotype may reflect 
reduced antibody-mediated enhancement at 
this receptor. Loke and colleagues showed 
no association between polymorphisms in 
mannose-binding lectin (MBL), interleu-
kin-1 and interleukin-4 receptor antagonist 
genes and severe dengue (Loke et al., 2002). 
However a different study has shown a poten-
tial association between polymorphisms in the 
MBL gene and protection from severe throm-
bocytopenia associated with DENV infection 
(Acioli-Santos et al., 2008).
Glucose-6-phosphate dehydrogenase (G6PD) 
deficiency is a common inherited enzyme 
deficiency with a particularly high preva-
lence in Asian countries. An in vitro study 
with DENV-2 showed a higher infection in 
monocytes from patients with G6PD defi-
ciency as compared to those with normal 
G6PD levels (Chao et al., 2008). The authors 
suggest that this observation might, in part, 
explain the high DENV burdens seen in Asian 
countries, although these findings have not 
been validated by larger case-control studies. 
Dengue virus–antibody complexes have been 
detected on platelets in patients with severe 
DENV infection and it is thought that viral 
binding to platelets via human platelet 
antigens (HPA) may result in the thrombo-
cytopenia observed in severe infection. A case-
control study in India showed that HPA-1a
and HPA-2b alleles were observed more fre-
quently in patients with more severe disease 
(Soundravally and Hoti, 2007). The study also 
demonstrated that DSS was observed more 
frequently in HPA-1 heterozygotes. Interestingly, 
HPA-1 and HPA-2 homozygotes appeared to 
be relatively protected from severe primary 
DENV infection, whereas heterozygotes 
were vulnerable to severe primary infection 
(Soundravally and Hoti, 2008).
Dendritic cell infection by DENV is 
effected by the attachment factor, dendritic 
cell-specific ICAM-3 grabbing non-integrin 
(DC-SIGN1), encoded by CD209. The G allele 
of DC-SIGN1-336 appears to protect against 
milder DENV infection, dengue fever, but not 
against more serious disease (Sakuntabhai et al.,
2005). These findings suggest that the severity 
of disease may be related to CD209 activity and 
the extent of DC-SIGN expression.
The limited strength of case-control study 
design for demonstrating a genetic associa-
tion is illustrated by the fact that, with the 
exception of DC-SIGN, no associations have 
been replicated in an independent cohort or 
study. As the technology of GWAS becomes 
more accessible as a result of reduced costs of 
genotyping and the development of high-
throughput sequencing, a more comprehensive 
approach to understanding genetic suscepti-
bility to severe dengue is possible. GWAS 
typically requires thousands of cases with a 
well-defined clinical outcome and population-
matched controls. The advantage of GWAS 
is that it can robustly detect relatively small 
contributions to genetic risk as seen in previ-
ous studies in, for example, type 2 diabetes 
mellitus, obesity and systemic lupus erythe-
matosus (Frayling et al., 2007; Scott et al., 2007; 
Hom et al., 2008). A recent GWAS demon-
strated susceptibility loci for severe dengue 
at MHC class I polypeptide-related sequence 
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B (MICB) (rs3132468) on chromosome 6 and 
phospholipase C, epsilon 1 (PLCE1) (rs3765524) 
on chromosome 10 (Khor et al., 2011). The 
cases used in this study were children with 
DSS. The controls were from cord-blood
samples. MICB encodes an activating ligand 
for the NKG2D type II receptor present on 
natural killer (NK) cells and CD8+ T cells. 
Ligation of NKG2D by MICB results in a 
range of antiviral effector functions includ-
ing cytokine expression and the cytolytic 
response (Raulet, 2003). MICB and other 
genes associated with NK cell activation are 
highly expressed in acute dengue infection – 
the association described between a muta-
tion in MICB and severe dengue may reflect 
altered or dysfunctional NK or CD8+ T cell 
activation perhaps resulting in higher viral 
load (Hoang et al., 2010; Khor et al., 2011). 
Mutations in PLCE1 are associated with 
nephrotic syndrome, a condition character-
ized by proteinuria, reduced vascular oncotic 
pressure and subsequent edema (Hinkes et al.,
2006). Severe dengue is characterized by plasma 
leak, suggesting some similarities with the 
pathophysiology of nephrotic syndrome. It is 
possible that mutations in PLCE1 result in a 
reduced ability to maintain normal endothe-
lial integrity, and therefore an increased risk 
of a more severe disease phenotype (Khor 
et al., 2011).
The ‘Cytokine Storm’ in 
Immunopathogenesis
The host immune response is widely con-
sidered to contribute to many of the clinical 
complications associated with severe den-
gue. Support for a role of the host immune 
response in mediating capillary permea-
bility is based on the temporal mismatch 
between the highest virus burdens in vivo
and the observed clinical manifestations of 
capillary permeability (the first 48 hours of 
illness, followed by rapid clearance, com-
pared with day 3–6 of illness, respectively). 
Thus, capillary permeability develops at a 
time when the viral burden is in sharp decline, 
arguing against a direct virus-mediated 
effect on the vascular endothelium. Further, 
the most severe complication of capillary 
permeability, DSS, manifests when many 
patients have low or undetectable viremia 
levels and are already or very nearly afebrile 
(Simmons et al., 2012). Finally, the character-
istic capillary permeability of severe den-
gue manifests relatively slowly and in many 
patients it is sufficiently well compensated 
for by homeostatic mechanisms that intra-
venous fluid therapy is not required (see 
Chapter 10, this volume). This is quite unlike 
the direct cytopathic insult on the vascular 
endothelium that occurs in fulminant Ebola 
virus infection and that leads to hemor-
rhage, rapid hypovolemic shock and a high 
mortality, despite supportive care (Zampieri 
et al., 2007).
A second line of evidence in support of 
the immune pathogenesis model of severe 
dengue lies in the observation that the vast 
majority of severe dengue complications occur 
in patients with immunological evidence of 
a previous history of DENV exposure, or in 
the case of infants, those with maternally 
acquired anti-DENV antibody. These obser-
vations have provided support to the hypoth-
esis that ADE is an important risk factor 
for severe dengue. In this model, ADE sup-
ports virus infection of Fc receptor bearing 
cells such as tissue macrophages that in turn 
secrete vasodilatory cytokines. An alterna-
tive, but not mutually exclusive model, is 
that cross-reactive memory T cells secreting 
vasoactive cytokines have a role in the patho-
genesis of severe dengue during secondary 
infections (discussed in depth in Chapter 14, 
this volume), although memory T cells cannot 
explain severe dengue in infants with primary 
dengue. In all of these models of patho-
genesis, the production of pro-inflammatory 
cytokines by immune cells during the course 
of infection is nominated as being central to 
the mechanistic process of capillary permea-
bility. In short, it is believed that the vasodila-
tory potential of some cytokines that occur in 
elevated concentrations during acute dengue 
are causally linked to endothelial cell dysfunc-
tion and capillary permeability. This hypoth-
esis of a ‘cytokine storm’ mediating capillary 
permeability is attractive since it helps unify 
the ADE hypothesis (greater virus burden) with 
the concept of immune activation of memory, 
cross-reactive T cells in secondary infection. 
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There are however important knowledge 
gaps that undermine the strength of the 
‘cytokine storm’ hypothesis. In Table 11.1, a non-
exhaustive summary of publications since 
1995 that describe cytokine or chemokine 
concentrations in clinical specimens from 
dengue cases is shown. The number of these 
studies is large (n = 38). Of note, there is 
significant heterogeneity in study designs, 
patient sample size, quality of clinical descrip-
tions and data reporting. Collectively, some 
of the obstacles in this body of publications 
that limit the development of a well-evidenced 
viewpoint on the role of a ‘cytokine storm’ in 
immunopathogenesis include:
• Study designs: many studies were hospital-
based and therefore lacked useful control 
groups, such as uncomplicated, ambula-
tory dengue patients.
• Study reporting: inadequate descrip-
tions of the inclusion/exclusion criteria 
and the enrolment process were com-
mon in many of the publications. Thus, 
in most studies it was unclear how many 
participants were screened for eligibility 
but were not enrolled, how many patients 
were screened and identified as eligible 
for enrolment but were not consented 
and for those enrolled how many com-
pleted the study investigations and were 
followed-up.
• Variable sampling strategies: many studies 
were cross-sectional in nature, whereas 
others performed serial measurements. 
In general, few studies investigated very 
early time points in disease (e.g. within 
the first 48 hours of illness).
• Variable clinical descriptions and pheno-
types: frequently, data from dengue hem-
orrhagic fever patients have been compared 
to dengue fever patients. In some studies, 
it is unclear if some dengue fever patients 
would have been re-classified if more 
investigations had been performed.
• Control groups: some studies recruited 
patients with other febrile illnesses (not 
dengue), used healthy controls or den-
gue convalescent blood samples.
• Pediatric vs. adult dengue: well-recognized 
differences in the clinical phenotype of 
dengue between children and adults 
(more DSS in children; more bleeding 
and comorbidities in adults) make it 
challenging to compare between studies 
of different patient age-groups.
• Multiple testing: none of the published 
studies stated that they followed an a
priori analysis plan. Instead, there is a 
hint of post-hoc testing, possible bias 
towards reporting of ‘favorable com-
parisons’, and all without correction for 
multiple testing. This is a major point of 
weakness in the literature.
In spite of these challenges in interpret-
ing the existing literature, there are some 
important themes relevant to understanding 
pathogenesis that can be graded according 
to the strength of evidence supporting them. 
These themes, and their level of evidence, 
are summarized in Table 11.2.
Table 11.2 identifies important knowledge 
gaps in our understanding of the natural his-
tory of changes in soluble pro-inflammatory 
mediators and their association with capillary 
permeability during dengue. Addressing these 
knowledge gaps is important because it helps 
provide a rational basis to move towards spe-
cific therapeutic approaches, e.g. anti-cytokine 
therapy with mAbs or other inhibitors. In the 
future, observational studies of dengue could 
learn from the rigorous approach used in 
clinical trials, with detailed attention to data 
collection, sample handling, analysis and most 
of all, transparent reporting of patient enrol-
ment and an a priori analysis and reporting 
plan. Observational studies would also be 
enhanced by early enrolment of patients, inclu-
sion of ambulatory and hospitalized patients 
coupled with serial observations during the 
acute phase and again in convalescence. 
Inclusion of patients with other febrile ill-
nesses (not dengue) provides a valuable refer-
ence population.
Conclusions and Relevance 
to Clinical Practice
Multiple host risk factors for severe dengue 
have been identified. Age, gender and host 
genotype all contribute to the outcome of 
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Table 11.1. Publications that describe cytokine and chemokine levels in dengue.a
Article Country Sample year Inclusion criteria Inpatients/outpatients Molecules measured
Agarwal et al. (1999) India 1996 Patients 8 months–55 years presenting 
with dengue as per the 1993 WHO 
guidelines
Inpatients TGF-β1
Assuncao-Miranda 
et al. (2010)
Brazil 2002 Severe dengue cases Inpatients MIF, TNF-α, IL-6, IFN-γ
Avila-Aguero et al.
(2004)
Costa Rica 2000–2001 Patients 13–70 years presenting with 
dengue as per the 1996 WHO 
guidelines
Inpatients IL-6, IL-1β, IL-8, IL-10, TNF-α
Azeredo et al. (2006) Brazil 2005 Patients 18–50 years presenting with 
dengue as per the 1997 WHO 
guidelines
Outpatients IL-15
Azeredo et al. (2006) Brazil 2001–2002 Patients 15–73 years presenting with 
dengue as per the WHO guidelines, 
2002 (with modifications)
Both TGF-β, IL-18, sICAM-1
Bethell et al. (1998) Vietnam 1993 Patients 1.2–8 years with dengue as 
confirmed by elevated dengue virus 
specific IgM titers, and exclusion of 
other diagnoses
Inpatients TNF, IL-6, IL-8, sTNFR-55, 
sTNFR-75, sICAM-1, CRP
Bozza et al. (2008) Brazil Unspecified Patients 15–73 years presenting with 
dengue as per the WHO guidelines, 
1997 (with modifications)
Both IL-1β, TNF-α, IFN-γ, IL-12, IL-4, 
IL-5, IL-6, IL-10, IL-13, IL-2, 
IL-7, IL-17, GM-CSF, IL-8, 
MCP-1, MIP-1β
Braga et al. (2001) Brazil 1997, 1999 Patients presenting with dengue as per 
the 1994 WHO guidelines
Outpatients TNF-α, IFN-γ, TNF-Rp75, IL-1β,
IL-6, IL-12
Chakravarti and 
Kumaria (2006)
India 2003 Patients 8–52 years presenting with 
dengue as per the 1999 WHO 
guidelines
Outpatients TNF-α, IFN-γ
Chaturvedi et al.
(1999)
India 1996 Patients 7 months–55 years presenting 
with dengue as per the 1993 WHO 
guidelines
Inpatients TNF-α, IFN-γ, IL-2, IL-4, IL-6, 
IL-10
Lee et al. (2006) Taiwan 2002 Patients 7–79 years presenting with 
dengue as per the 1997 WHO 
guidelines
Both MIF, IL-6, TNF-α, IFN-γ, IL-10
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De Kruif et al.
(2008)
Indonesia 2002–2003 Patients 3–14 years presenting with 
dengue as per the 1997 WHO 
guidelines
Inpatients IFN-γ, IL-12, IL-1b, IL-8, MIF, 
NFR1, MCP1, MIP1α, MIP1β,
IL-1A, IL-2, IL-6, IL-10, IL-18, 
MCP2
De Oliveira-Pinto 
et al. (2012)
Brazil 2001–2008 Patients 1–77 years presenting with 
acute exanthematic manifestation
Outpatients IFN-γ, IP-10 (CXCL10/IP-10), 
MCP-1, MIP-1β, IL-1Ra
Djamiatun et al.
(2011)
Indonesia 2005–2006 Patients <15 years presenting with 
dengue as per the 1997 WHO 
guidelines
Inpatients TGF-β1
Gagnon et al.
(2002)
Thailand 1994 Patients 6 months–14 years presenting 
with dengue as per the 1997 WHO 
guidelines
Inpatients TNF-α, TNF-β, IFN-γ, IL-2, IL-4
Green et al.
(1999)
Thailand 1994–1998 Children presenting with dengue 
fever of <72 hours
Inpatients IL-10, IL-12p70, IL-12 (p40+p70)
Hober et al.
(1998)
Vietnam Unspecified Patients 3–15 years presenting with 
dengue grades 2–4 as per the 1994 
WHO guidelines
Inpatients TNF-α
Houghton-Trivino 
et al. (2010)
Colombia 2005–2006 Patients 3 months–55 years presenting 
with dengue as per the 2005 WHO 
guidelines
Unspecified IL-1β, TNF-α, IL-8, IL-4, IL-5, 
IL-10, IL-12, IFN-γ, IL-2
Iyngkaran et al.
(1995)
Malaysia 1995 10-year-old Chinese male with dengue 
fever <2 days
Inpatient TNF, IL-6, IL-1
Juffrie et al. (2001) Indonesia 1995–1996 Children presenting with dengue as per 
the 1997 WHO guidelines
Inpatients IL-6, CRP
Juffrie et al. (2000) Indonesia 1995–1996 Children presenting with dengue as per 
the 1997 WHO guidelines
Inpatients IL-8
Kadhiravan et al.
(2010)
India 2006 Patients >12 years presenting with 
dengue as per the 1997 WHO 
guidelines with no HIV or other illness
Inpatients IFN-γ, IL-4, TNF-α
Kittigul et al.
(2000)
Thailand 1997 Patients presenting with dengue as per 
the 1997 WHO guidelines
Inpatients TNF-α
Kubelka et al. (1995) Brazil 1995 Adults with dengue Inpatients TNF-α
Laur et al. (1998) French
Polynesia
1996–1997 Patients 1 month–15 years presenting 
with dengue as per the 1986 WHO 
guidelines
Inpatients TNF-α, TGF-β1
Lee et al. (2006) Taiwan Unspecified Vietnamese patients with 
dengue as per WHO guidelines
Unspecified MCP-1
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Table 11.1. Continued.
Article Country Sample year Inclusion criteria Inpatients/outpatients Molecules measured
Levy et al. (2010) Venezuela 2005–2006 Patients 3–53 years presenting with 
dengue as per the 1986 WHO 
guidelines
Outpatients IL-6, IL-1β, TBF-α
Mangada and 
Rothman (2005)
India 2001 Patients presenting with dengue as 
per the 1993 WHO guidelines
Inpatients IL-13, IL-18
Masaki et al. (2002) Japan 1997 A 37-year-old male with fever <1 day Inpatient TFN-α, IFN-γ, IL-12
Nguyen et al. (2004) Vietnam 1998–2002 Patients <1 year presenting with dengue 
as per the 1997 WHO guidelines
Inpatients IFN-γ, TNF-α, IL-10, IL-6, IL-4, 
IL-12
Pacsa et al. (2000) Northern 
India
1996 Patients presenting with dengue as 
per the 1993 WHO guidelines
Inpatients IL-12
Perez et al. (2004) Cuba 1997 Patients 16–59 years presenting with 
dengue as per the 1997 WHO 
guidelines
Inpatients IL-10, IL-12 (p70 + p40), 
RANTES
Pinto et al. (1999) Brazil 1995–1996 Patients diagnosed with dengue Inpatients TNF-α, IL-6, IL-1β, sTNFR-55 
and sTNFR-75, IL-1Ra
Priyadarshini et al.
(2010)
India 2005 Patients 1–64 years presenting with 
dengue as per the WHO guidelines
Both IL-6, IL-8, TNF-α, IFN-γ
Raghupathy et al.
(1998)
India 1996 Patients 8 months–55 years with 
dengue as per the 1993 WHO 
guidelines
Inpatients IL-8
Restrepo et al.
(2008a)
Colombia 2005–2007 Patients presenting with dengue as 
per the 1995 Pan-American Health 
Organization guidelines
Outpatients IL-6, TNF-α, IFN-γ
Restrepo et al.
(2008b)
Colombia 2000–2002 Patients <1 year presenting with dengue 
as per the 1995 Pan-American Health 
Organization guidelines
Both IL-6, TNF-α, IFN-γ
Tolfvenstam et al.
(2011)
Singapore Unspecified Patients 23–66 years presenting with 
dengue as per the 2009 WHO 
guidelines
Both MCP-1, MCP-2, IP-10, MIP-1α
aThe search terms used to capture these publications were: dengue, cytokine, IFN, interferon, IL, interleukin, CSF, TNF, LT, lymphotoxin, CD40 ligand, CD40L, Fas ligand, FasL, CD27L, 
CD27 ligand, CD30 ligand, CD30L, 4-1BBL, Trail, AP0-2L, OPG-L, RANK-L, APRIL, LIGHT, TWEAK, BAFF, CD257, BlyS, TGF, MIF, CXCL, CCL, MIP, chemokine, HCC, TARC, 
DC-CK1, PARC, ELC, ELR, LARC, SLC, MDC, MPIF, CK, Eotaxin, CTACK, MEC, SCM.
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infection. Passively acquired antibody might 
be a unique risk factor in infants. However, 
each of these risk factors is not at the level 
of impact where they can be integrated into 
routine clinical care. Pro-inflammatory medi-
ators probably contribute to the capillary 
permeability syndrome but there are gaps 
in the quality of indirect evidence around 
this link. More fundamentally, it will be 
extremely difficult to identify causal medi-
ators of capillary permeability in observational 
studies. ‘Drug probe’ randomized con-
trolled clinical trials are one way to interro-
gate this process, with a recent trial of early 
corticosteroid therapy being one example 
of how this can be done (Tam et al., 2012). 
That early therapy with oral corticosteroids 
did not improve clinical or laboratory fea-
tures of dengue should not necessarily be 
interpreted as indicating immunological 
drivers are not important in pathogenesis, 
but possibly that earlier, more potent or 
better targeted immunomodulatory therapy 
is required. The field should be encouraged 
to explore a range of options for similar 
drug probe studies that encompass careful 
evaluation of the host immune response and 
clinical outcome.
Table 11.2. The evidence base for associations between pro-inflammatory cytokines and dengue pathogenesis.
Observation on plasma/serum 
cytokine levels
Strength
of evidence Example references
Elevations in pro- and anti-inflammatory 
cytokines occur during the febrile phase 
of dengue (both primary and secondary)
Strong De Oliveira-Pinto et al. (2012); Green et al.
(1999); Juffrie et al. (2001); Kitigul et al.
(2000); Laur et al. (1998); Nguyen et al.
(2004); Perez et al. (2004); Raghupathy 
et al. (1998); Restrepo et al. (2008a,b); 
Tolfvenstam et al. (2011)
Cytokines with functional relevance to 
inhibition of virus infection, e.g. IFN-α/β,
IFN-γ, TNF-α, are elevated during the 
acute, viremic phase
Strong Bozza et al. (2008); Braga et al. (2001); 
Chen et al. (2006); De Kruif et al.
(2008); Houghton-Trivino et al. (2010); 
Masaki et al. (2002)
During the critical phase, cytokine 
concentrations are significantly elevated 
in severe dengue cases compared to 
non-severe dengue cases
Variable Bethell et al. (1998); Bozza et al. (2008); 
Green et al. (1999); Juffrie et al. (2001); 
Kittigul et al. (2000); Levy et al. (2010); 
Mangada et al. (2005); Perez et al. (2004)
Elevations in cytokine concentrations occur 
in parallel to hemoconcentration or other 
signs of capillary permeability
Weak Bethell et al. (1998); Djamiatun et al. (2011); 
Houghton-Trivino et al. (2010); Juffrie 
et al. (2001)
Elevations in cytokine concentrations during 
dengue are qualitatively or quantitatively 
different from those observed in other 
acute systemic virus infections that do not
involve a capillary permeability syndrome
Weak De Oliveira-Pinto et al. (2012); Kubelka et al.
(1995); Gagnon et al. (2002); Green et al.
(1999); Lee et al. (2006); Houghton-Trivino 
et al. (2010) respiratory infection; Juffrie 
et al. (2000, 2001) bacterial infections
Evidence for a causal association between 
one or more soluble factors and capillary 
permeability during dengue
None None
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Abstract
Background: A recent genome-wide association study (GWAS) identified susceptibility loci for dengue shock syndrome
(DSS) at MICB rs3132468 and PLCE1 rs3740360. The aim of this study was to define the extent to which MICB (rs3132468) and
PLCE1 (rs3740360) were associated with less severe clinical phenotypes of pediatric and adult dengue.
Methods: 3961 laboratory-confirmed dengue cases and 5968 controls were genotyped at MICB rs3132468 and PLCE1
rs3740360. Per-allele odds ratios (OR) with 95% confidence intervals (CI) were calculated for each patient cohort. Pooled
analyses were performed for adults and paediatrics respectively using a fixed effects model.
Results: Pooled analysis of the paediatric and adult cohorts indicated a significant association between MICB rs3132468 and
dengue cases without shock (OR = 1.15; 95%CI: 1.07 – 1.24; P = 0.0012). Similarly, pooled analysis of pediatric and adult
cohorts indicated a significant association between dengue cases without shock and PLCE1 rs3740360 (OR = 0.92; 95%CI:
0.85 – 0.99; P = 0.018). We also note significant association between both SNPs (OR = 1.48; P = 0.0075 for MICB rs3132468
and OR = 0.75, P = 0.041 for PLCE1 rs3740360) and dengue in infants.
Discussion: This study confirms that the MICB rs3132468 and PLCE1 rs3740360 risk genotypes are not only associated with
DSS, but are also associated with less severe clinical phenotypes of dengue, as well as with dengue in infants. These findings
have implications for our understanding of dengue pathogenesis.
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Introduction
Dengue is the most important arboviral disease of humans.[1]
Dengue viruses (DENV) cause a spectrum of clinical manifesta-
tions ranging from asymptomatic infection through to life-
threatening shock and haemorrhage.[1,2] The clinical outcome
of an individual infection is influenced by a variety of virus and
host-related factors. The host factors that influence the clinical
course of an individual infection include flavivirus infection
history, host genotype, sex, age, and the presence of underlying
medical conditions.[3–5] The first GWAS in dengue identified
susceptibility loci for dengue shock syndrome (DSS) at MHC class
I polypeptide-related sequence B (MICB) (C/T, rs3132468) on
chromosome 6 and phospholipase C, epsilon 1 (PLCE1) (C/A,
rs3740360) on chromosome 10.[6] The MICB gene encodes an
activating ligand of natural killer (NK) cells (and possibly CD8+ T
cells). We have previously speculated that mutations in MICB
might result in impaired induction of anti-viral effector functions
in NK cells with the consequence being a greater DENV-infected
cell mass in vivo [6], a recognised risk factor for severe dengue.[7]
The identification of variants of PLCE1 as being associated with
severe dengue is intriguing.[6] Rare mutations of high penetrance
within PLCE1 are associated with nephrotic syndrome, a condition
characterised by oedema secondary to proteinuria and reduced
vascular oncotic pressure.[8] Since plasma leak, proteinuria and
hypovolemia are also characteristic features of severe dengue, it’s
plausible that nephrotic syndrome and severe dengue share some
common underlying pathophysiological processes. Furthermore,
there are data implicating PLCE1 in the homeostatic regulation of
blood pressure.[9] These findings have the potential to help us
define more clearly the functional basis of PLCE1 variants in
severe dengue.
The SNP associations identified at MICB (rs3132468) and
PLCE1 (rs3740360) by the GWAS study were in the context of
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pediatric patients with DSS, leaving unanswered the question
whether they are also associated with less severe clinical
phenotypes of dengue. To this end, the aim of this study was to
define the extent to which these alleles were associated with milder
clinical phenotypes of pediatric and adult dengue. We analyzed a
total of 3961 laboratory-confirmed dengue cases, independent
from the initial GWAS study, and 5968 cord blood controls.[6]
Materials and Methods
Ethics statement
All participants gave written informed consent to participate in
the prospective studies summarised in Table 1 (details of the
inclusion and exclusion criteria are available in Supplementary
Table 1). Parents or guardians provided written informed consent
on behalf of the children involved in the studies. The protocols for
these studies were approved by the Institutional Review Boards of
each study site (Hospital for Tropical Diseases HCMC, Children’s
Hospital 1 and 2 HCMC, Hung Vuong Hospital HCMC, Dong
Thap Hospital, Sa Dec Hospital and Tien Giang Hospital) and by
the Oxford University Tropical Research Ethics Committee. Each
ethical committee approved of the consent procedure detailed
above.
Enrolment and diagnosis
Blood samples for genotyping were collected in one of several
prospective studies of dengue in Vietnamese patients detailed in
Table 1. Dengue cases were laboratory-confirmed by one of three
methods: IgM-seroconversion by ELISA assay on paired samples,
detection of DENV RNA by RT-PCR, or detection of non-
structural protein 1 (NS1) by ELISA (BioRad Platelia). The control
samples used in this study were from blood samples collected from
the umbilical cord of newborn infants enrolled into the birth
cohort study detailed in Table 1. Within each cohort, dengue cases
were classified in a binary fashion as being ‘‘DSS’’ or ‘‘not-
DSS’’.[6] Consistent with the original GWAS study, DSS cases
were defined as laboratory-confirmed dengue cases with cardio-
vascular decompensation secondary to plasma leakage and
requiring fluid resuscitation.[2]
Genotyping
DNA extractions were performed using a MagNA Pure 96
DNA and Viral NA Small Volume Kit (Roche, Germany)
according to the manufacturer’s instructions. Candidate SNPs
were genotyped using a TaqManH genotyping assay to amplify and
detect the specific alleles in the DNA samples as per manufacturer
instructions.
Statistical analysis
The data were analysed using PLINK version 1.07 and the R
statistical software package version 2.12.0 (2010 The R Founda-
tion for Statistical Computing). For each cohort study per-allele
odds ratios with 95% confidence intervals were calculated to assess
the relationship between SNP genotypes (rs3132468 at MICB and
rs3740360 at PLCE1) and susceptibility to dengue. For the analysis
we considered non-DSS cases in children separately from adults
and considered infants with dengue as a distinct group. Infants
were defined as less than 1 year in age, children were defined by
ages between 1 and 15 years, and adults were defined by being 16
years and older. Other variables known to be associated with
disease severity were not included in this analysis, consistent with
the GWAS primary analysis for DSS as well as other infectious
diseases.[6,10–12] Pooled odds ratios across the different sample
collections were calculated using the inverse-variance, fixed effects
model, as previously described.[13] This model used the weighted
average of each study’s odds ratio. The weights used were the
inverse of the variance of the study’s estimated odds ratio, ensuring
Table 1. Summary of the cohort studies used in the analysis.
Group Number (% male)
Median age (range 5th –
95th)
Control 1068 (52) At birth
Infants 165 (55) 7 months (3 – 12 months)
DC 59 (52) 6 (3 – 11)
DT 88 (57) 7 (4 – 11)
DZ 8 (50) 8 (7 – 11)
FB 9 (55) 8 (7 – 15)
Children/Young adults 2759 (56) 12 years (6 – 16 years)
FG 576 (56) 11 (4 – 22)
06DX 220 (71) 13 (11 – 14)
DR 582 (56) 11 (6 – 15)
MD 1381 (60) 12 (7 – 14)
Adults 741 (46) 22 (15 – 35)
09DX 159 (41) 23 (19 – 27)
D001 54 (43) 20 (14 – 25)
FL 528 (48) 22 (15 – 35)
doi:10.1371/journal.pone.0059067.t001
Figure 1. Genotyping and sample quality control process
flowchart.
doi:10.1371/journal.pone.0059067.g001
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that larger studies command greater weight. Forest plots
demonstrating these results were created in R.
Results
Case and control cohorts
The patient cohorts that provided the laboratory-confirmed
dengue cases that were genotyped in this study are summarised in
Table 1. Across the 7 cohorts (4 pediatric and 3 adult) there were
297 DSS cases (161 pediatric and 136 adult), 3500 non-DSS
dengue cases (2759 pediatric and 741 adult cases), and 164 cases of
infants with dengue that were successfully genotyped at MICB
rs3132468 and PLCE1 rs3740360. Umbilical cord blood DNA
samples (n = 1068) were similarly genotyped at MICB rs3132468
and PLCE1 rs3740360 and served as population controls. Data
from this was complemented with genotype data from 4900
controls studied previously.[6] In a priori analyses we considered
non-DSS cases in children separately from adults. Infants with
dengue (n = 164) were also treated as a distinct cohort because of
the unique context of dengue in this age group. The sample quality
control process is illustrated in Figure 1.
Association between MICB rs3132468 and dengue in
children and adults
Pooled analysis of genotype data from the pediatric patient
cohorts revealed that non-DSS dengue cases were significantly
more likely to carry the MICB risk allele rs3132468 than controls
(per-allele odds ratio (OR) = 1.16; 95%CI: 1.07 – 1.25). Pooled
analysis of cohorts of adult non-DSS dengue cases revealed a
similar pattern of effect with the MICB risk allele, but this did not
reach statistical significance (OR = 1.10, P = 0.11; Figure 2,
and Table 2). However, a pooled analysis of all pediatric and
adult patient cohorts indicated a significant association (OR =
1.15, P = 0.0014; Figure 2, and Table 2) compared to controls,
with no heterogeneity between children and adults (Phet = 0.19).
In the relatively small number of adult and pediatric DSS cases (N
= 297), we were able to confirm the association and effect size
reported in our previous GWAS (OR = 1.42, P = 0.0014;
Figure 2 and Table 2).
Association between PLCE1 rs3740360 and dengue in
children and adults
We observed significant association with non-DSS cases upon
pooled analysis of all adults and children (OR = 0.92, P = 0.018;
Figure 3 and Table 3). Amongst DSS cases, the association at
PLCE1 revealed by the previous GWAS was confirmed (OR =
0.77: P = 0.0094).
Figure 2. Forest plot illustrating the association between MICB rs3132468 and susceptibility to dengue. 06DX, DR, FG and MD were
cohort studies of children, and 09DX, D001 and FL were cohort studies of adults. The oblongs represent point estimates (referring to the per-allele
odds ratio, expressed on the horizontal axis), with the height of the oblongs inversely proportional to the standard error of the point estimates.
Horizontal lines indicate the 95% confidence interval for each point estimate. Meta-analysis of children, adults, as well as children and adults with
uncomplicated dengue are reflected by blue diamonds. Data from our previously reported GWAS on DSS is reflected by the purple diamond.[6] The
width of the diamonds indicates their 95% confidence intervals. Each meta-analysis is accompanied by a test of heterogeneity between the sample
collections summarized by it (expressed as Phet).
doi:10.1371/journal.pone.0059067.g002
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Association between MICB rs3132468 and dengue in
infants
Since each of the infant cohorts was relatively small in their own
right, a meta-analysis was performed. Consistent with the findings
in older children, this pooled analysis revealed a significant
association between dengue in infants and MICB rs3132468 (OR
= 1.48; P = 0.0075), as well as PLCE1 rs3740360. (OR = 0.75, P
= 0.041) (Figures 2 and 3; Tables 2 and 3). Although the infant
cohorts included 16 cases of DSS, removal of these samples did not
affect the associations demonstrated.
Discussion
MICB rs3132468 and PLCE1 rs3740360 genotypes are
associated with DSS in Vietnamese children.[6] Here, we have
extended this finding by follow-up genotyping in a large number of
Vietnamese adult and paediatric dengue cases, together with a
new cohort of population control samples. The data revealed
significant association between MICB rs3132468 and PLCE1
rs3740360 and clinical phenotypes of dengue less severe than DSS,
albeit with smaller effect sizes than observed between these alleles
and DSS.[6] In addition, we observed association between both
SNP genotypes and infants with dengue at effect sizes comparable
to that seen with DSS. Finally, amongst children and adults with
DSS in these cohorts, we were able to confirm association ofMICB
rs3132468 and PLCE1 rs3740360 that was first observed in the
previous GWAS.[6] Collectively, these findings provide further
validation of the importance of MICB rs3132468 and PLCE1
rs3740360 risk genotypes to shaping the clinical phenotype of
dengue and raises intriguing questions about their roles in disease
pathogenesis.
The association of the MICB rs3132468 genotype with clinical
phenotypes of dengue less severe than DSS indicates a role for this
variant in susceptibility to overall clinically apparent dengue and
not just severe disease. Given the role of MICB in activation of NK
and CD8+ cells these findings support a central role for these cell
types in shaping the outcome of DENV infection. For example, it
is plausible that the MICB rs3132468 genotype is associated with
an impaired NK cell response, potentially resulting in a higher in
vivo virus titre and an increased risk of developing both
symptomatic and severe dengue. Furthermore, inefficient induc-
tion of regulatory NK cells might result in dysregulated T cell
responses that may also shape the clinical phenotype.[14]
The effect size between the PLCE1 rs3740360 risk genotype and
milder clinical phenotypes of dengue was less pronounced than
that observed for DSS cases.[6] Whilst a degree of endothelial leak
is likely to occur in most clinically evident DENV infections,
patients with DSS experience the most severe vascular perme-
ability.[15,16] Our current data, together with the recently
demonstrated association between PLCE1 rs3740360 and DSS,
may indicate a central role for PLCE1 in the context of vascular
leakage.[6] Further genetic fine mapping studies will be required
to pinpoint functional mutations that could mechanistically
explain the association between PLCE1 and DSS. In doing so,
Table 2. Per-collection analysis for MICB rs3132468.
Children
Collection Number MAF cases MAF
controls
OR 95% CI Weight P
06DX 220 0.160 0.134 1.23 0.95 – 1.51 49.45393 0.14
DR 582 0.129 0.134 0.96 0.78 – 1.14 119.4422 0.66
FG 576 0.156 0.134 1.20 1.03 – 1.37 134.8943 0.035
MD 1381 0.159 0.134 1.23 1.12 – 1.35 289.2313 0.00047
All children 2759 0.152 0.134 1.16 1.07 – 1.25 - 0.0011
Adults
Collection Number MAF cases MAF
controls
OR 95% CI Weight P
09DX2 159 0.118 0.134 0.86 0.51 – 1.21 31.03638 0.42
D001 54 0.173 0.134 1.36 0.85 – 1.87 14.72486 0.24
FL 528 0.151 0.134 1.15 0.97 – 1.33 120.2293 0.12
All adults 741 0.145 0.134 1.10 0.94 – 1.26 – 0.22
All mild cases (Adults and children) 3500 0.151 0.134 1.15 1.07 – 1.24 – 0.0014
Collection MAF cases MAF
controls
OR 95% CI Weight P
All infants 164 0.186 0.134 1.48 1.19 – 1.77 – 0.0075
Collection MAF cases MAF
controls
OR 95% CI Weight P
All DSS 297 0.180 0.134 1.42 1.20 – 1.64 – 0.0014
Number: Number of cases
MAF cases: minor allele frequency in dengue cases
MAF controls: minor allele frequency in controls
OR: per-allele odds ratio.
SE: Standard error of the OR
Weight: study-specific weight when meta-analyzed, not calculated for infants and DSS collections, which were not meta-analyzed.
P: P-value for association with disease (unadjusted).
doi:10.1371/journal.pone.0059067.t002
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we expect to contribute to the wider understanding of the role of
PLCE1 in health and disease, particularly in light of its association
with nephrotic syndrome, regulation of blood pressure and
esophageal cancer.[8,9,17] In light of the observed association
with PLCE1 and nephrotic syndrome it is interesting that the
degree of proteinuria has been proposed as a potential predictor in
determining which dengue patients are at risk of developing more
severe disease.[18]
Infants with dengue were analysed independently of other patient
populations. Primary infection in the context of waning maternal
antibody levels, immunological immaturity and vulnerable physiol-
ogy make infants with dengue a distinct group.[19] Our data shows
association between MICB rs3132468 and dengue in infants, with
effect sizes in keeping with that observed in DSS patients.[6] We
speculate that this reflects a prominent role for innate immunity and
particularly NK cells in controlling early viral infection in infants;
impaired control of viral replication could be a risk factor for clinically
apparent dengue in this age group. The effect size observed at PLCE1
rs3740360 was also similar to that observed in DSS patients.[6] It has
been noted that hospitalised infants with dengue represent a group
with the highest risk of death, and it is thought that this is partly
related to an intrinsically more permeable vascular endothelium in
this age group.[4] In infants with dengue, carriage of either risk alleles
thus represent an additional risk variable alongside the presence of
maternally-derived non-neutralising antibodies and poor compensa-
tory reserve.[19–20]
Our study has limitations. Misclassified control samples will be
more common in this study than in the original GWAS of DSS
cases because dengue without shock is a more common clinical
outcome for a given cohort of children in an endemic area.
Reassuringly, the fact that consistent associations were observed
despite this limitation lends credence to our observations. In
addition, as the functional basis of these mutations as yet to be
clearly defined our conclusions are to an extent speculative. As
dengue without shock includes a diverse range of clinical
manifestations our ability to determine this functional basis is
more limited.
We have shown that the MICB rs3132468 and PLCE1 rs3740360
genotypes are associated with clinically apparent dengue in both adults
and children, which is a significant extension from the earlier GWAS
on DSS cases alone. As expected, the effect sizes of these variants is
small and underscores that susceptibility to symptomatic dengue is
multifactorial and includes demographic risk factors (e.g. age).[21]
However, we have not performed multivariate analysis in this study as
the majority of risk factors for symptomatic (non-severe) dengue are not
clearly defined.. The challenge now is to define the functional basis for
these observed genetic associations at MICB and PLCE1 and thus
increase our understanding of disease pathogenesis.
Figure 3. Forest plot illustrating the association between PLCE1 rs3740360 and susceptibility to dengue. 06DX, DR, FG and MD were
cohort studies of children. and 09DX, D001 and FL were cohort studies of adults. The oblongs represent point estimates (referring to the per-allele
odds ratio, expressed on the horizontal axis), with the height of the oblongs inversely proportional to the standard error of the point estimates.
Horizontal lines indicate the 95% confidence interval for each point estimate. Meta-analysis of children, adults, as well as children and adults with
uncomplicated dengue are reflected by blue diamonds. Data from our previously reported GWAS on DSS is reflected by the purple diamond.[6] The
width of the diamonds indicates their 95% confidence intervals. Each meta-analysis is accompanied by a test of heterogeneity between the sample
collections summarized by it (expressed as Phet).
doi:10.1371/journal.pone.0059067.g003
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Supplementary Table 1: Details of the cohort studies used in the analysis 
Patient 
cohort 
name 
(sample 
size) 
Inclusion criteria Exclusion 
criteria 
Study site and 
study period 
Age Median (IQR) Serotypes present 
BC (n=1068) Babies born to 
mothers living in 
areas served by 
recruiting district 
hospitals 
 
+HIV  
 
Mothers < 
15yrs 
Hung Vuong 
Hospital, HCMC 
Dong Thap 
Hospital, DT 
Province 
At birth Controls 
FG (n=622) Inpatients 
Febrile and clinical 
suspicion of dengue. 
Fever less than 
72hrs  
Age >18 months 
N/A Dong Thap 
Hospital, DT 
province 
Sa Dec Hospital, DT 
province 
Tien Giang Hospital, 
TG province 
2007-2009 
 
11 (7-14) DENV-1 (63.7%) 
DENV-2 (15%) 
DENV-3 (10.8%) 
DENV-4 (0.5%) 
Unknown (10.1%) 
 
06DX 
(n=220) 
Inpatients 
Febrile and clinical 
suspicion of dengue. 
Fever less than 
72hrs Age < 20 
years 
Pregnant 
woman 
 
Hospital for Tropical 
Diseases, HCMC 
2009-2010 
13 (11-14) DENV-1 (60.9%) 
DENV-2 (25%) 
DENV-3 (10.5%) 
DENV-4 (3.2%) 
Unknown (0.5%) 
 
09DX 
(n=159) 
Inpatients 
Febrile and clinical 
suspicion of dengue. 
Pregnant 
woman 
Hospital for Tropical 
Diseases, HCMC 
2011-2012 
23 (19-27) DENV-1 (37.1%) 
DENV-2 (45.3%) 
DENV-3 (9.4%) 
Fever less than 
72hrs 
Age > 15 years 
DENV-4 (7.5%) 
Unknown (0.6%) 
 
DR (n=597) Outpatients 
Febrile and clinical 
suspicion of dengue. 
Fever < 72 hours 
(flexible) 
Age 5 - 15 years 
N/A District 8 Hospital 
Outpatients, HCMC 
2005-2009  
11 (9-13) DENV-1 (62%) 
DENV-2 (15.2%) 
DENV-3 (17.8%) 
DENV-4 (1.2%) 
Unknown (3.9%) 
MD 
(n=1464) 
Inpatients 
Febrile and clinical 
suspicion of dengue. 
Fever < 72 hours 
(flexible) 
Age 5 - 15 years 
N/A Hospital for Tropical 
Diseases, HCMC 
2001-2009 
12 (10-13) DENV-1 (65%) 
DENV-2 (14.5%) 
DENV-3 (11.7%) 
DENV-4 (0.7%) 
Mixed DENV 
(0.1%) 
Unknown (8%) 
D001 (n=76) Clinical suspicion of 
dengue 
< 72 hours illness: 
infection wards; < 6 
days illness ICUs 
Age 12 – 25 years 
 
 N/A Hospital for Tropical 
Diseases, HCMC 
2010-2011 
18 (16-23) DENV-1 (27.6%) 
DENV-2  (30.2%) 
DENV-3 (5.3%) 
DENV-4 (5.3%) 
DENV mixed 
(5.3%) 
Unknown (26.3%) 
FL (n=627) Clinical suspicion of 
dengue 
Any day of illness 
Infection wards and 
ICUs 
Age > 15 years 
N/A Hospital for Tropical 
Diseases, HCMC 
2006-2008 
21 (18-26) DENV-1 (16.6%) 
DENV-2 (10.0%) 
DENV-3 (4.8%) 
DENV-4 (0.3%) 
Not done (68.3%) 
DC (n=68) Inpatients 
Febrile and clinical 
suspicion of dengue  
Any day of illness 
Age <18 months 
N/A Children’s Hospital 
1, HCMC 
2005-2007 
 
6 (4-8) months DENV-1 (23.5%) 
DENV-2 (42.6%) 
DENV-3 (11.8%) 
DENV-4 (1.5%) 
Unknown (20.6%) 
 
DT (n=93) Inpatients 
Febrile and clinical 
suspicion of dengue 
Any day of illness  
Age <18 months 
N/A Children’s Hospital 
2, HCMC 
2005-2007 
 
 
7 (6-9) months DENV-1 (34.4%) 
DENV-2 (33.3%) 
DENV-3 (12.9%) 
Unknown (19.4%) 
 
FB (n=11) Inpatients 
Febrile and clinical 
suspicion of dengue 
Any day of illness  
Age <18 months 
N/A Dong Thap 
Hospital, DT 
province 
2005-2007 
 
8 (7-11) months DENV-1 (63.6%) 
DENV-2 (18.2%) 
Unknown (18.2%) 
 
DZ (n=8) Outpatients 
Febrile and clinical 
suspicion of dengue 
Any day of illness  
Ae <18 months 
N/A Children’s Hospital 
1, HCMC 
2005-2007 
 
8 (7-11) months DENV-1 (12.5%) 
DENV-2 (37.5%) 
Unknown (50.0%) 
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Associations between MICB and PLCE1 and laboratory 
features of dengue 
The work described above suggests that mutations in the MICB and PLCE1 genes have 
important associations with dengue of milder severity than DSS. However the functional basis 
of these observed associations remains unclear. The aim of the analysis described in this 
section was to define the association between these specific mutations and various laboratory 
features of dengue that have been shown to have correlation with the clinical outcome of 
infection. For example, the level of viraemia in the first days of illness has also been shown to 
have an association with the outcome of DENV infection with higher viraemia being 
associated with a more severe clinical phenotype.9 In addition, the degrees of lymphopenia 
and thrombocytopenia have been shown to have an association with subsequent 
development of DSS.10,11 This analysis has the potential to expand our understanding of 
these associations and further clarify host susceptibility and dengue pathogenesis. 
Aims 
The specific aims of this analysis were to measure the association between individuals with 
different MICB rs3132468 and PLCE1 rs3740360 genotypes (wild-type, heterozygous 
carriers, and homozygous variant) and various laboratory features. Specifically the features 
that were compared between the groups were: 
o Early viraemia level 
o Platelet nadir 
o White cell count nadir 
o Maximum haematocrit 
o Proportions of patients that develop “severe dengue” as per WHO criteria12 
Methods 
All participants gave written informed consent to take part in the prospective studies detailed 
in Table 1. All these studies took place in southern Vietnam. The parents or guardians of the 
children involved in the studies gave written informed consent on their behalf. The protocols 
of these studies were reviewed and approved by the Institutional Review Boards of each 
study site (Hospital for Tropical Diseases HCMC, Children’s Hospital 1 and 2 HCMC, and 
Tien Giang Hospital) and by the Oxford University Tropical Research Ethics Committee. 
This was a case-only analysis of laboratory-confirmed dengue patients obtained from 2 
prospective cohort studies and 1 randomised clinical trial in Vietnam. The cohort studies were 
conducted in both adults and children and aimed to create diagnostic and prognostic 
algorithms to improve the clinical management of dengue in this setting. The randomised 
clinical trial was an investigation of lovastatin therapy in adult patients with dengue and is 
described elsewhere in this thesis. The studies are summarised in Table 1. The inclusion 
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criteria for 13DX were (1) fever or history of fever for less than 72 hours, (2) clinical suspicion 
of dengue, (3) 1 – 15 years of age, (4) written informed consent, and (5) accompanying family 
member has a mobile phone. The exclusion criteria were (1) deemed unlikely to attend follow-
up, and (2) in whom an alternative diagnosis was thought more likely. The inclusion criteria 
for 22DX were (1) fever or history of fever for less than 72 hours, (2) clinical suspicion of 
dengue, (3) aged 5 years or over, (4) written informed consent. The exclusion criteria were (1) 
localising features suggesting an alternative diagnosis, and (2) inability to attend daily follow-
up. The inclusion and exclusion criteria for 26DX (lovastatin in dengue trial) are detailed in the 
therapeutics section of this thesis but, in brief, patients aged 18 years or over with less than 
72 hours fever and a positive NS1 rapid test were eligible for recruitment 
The study methodology varied – 13DX only obtained laboratory samples on the enrolment 
day, whereas 22DX and 26DX had multiple laboratory sampling points. Therefore all the 
studies were included for the analysis of the viraemia and clinical outcome data, however to 
ensure appropriate comparisons 13DX data were excluded from the analysis of other 
laboratory variables. 
 
Study Setting Number (% 
male) 
Median age (range 5th-95th 
centile) 
13DX Outpatient 1951 (57) 9 (3 – 14) 
22DX Outpatient 749 (60) 18 (6 – 39) 
26DX Inpatient 42 (57) 24 (18 – 51) 
Table 1: Summary of the studies used in the analysis 
DNA extractions were performed using a MagNA Pure 96 DNA and Viral NA Small Volume 
Kit (Roche, Germany) according to the manufacturer’s instructions. Candidate SNPs were 
genotyped using a TaqMan genotyping assay to amplify and detect the specific alleles in the 
DNA samples as per the manufacturer instructions. Samples failing picogreen QC (<5ng/uL in 
concentration) were excluded from further analysis. Similarly, during the genotyping process, 
samples which fail to show adequate allelic discrimination on the Taqman RT-PCR melt-curve 
were also be excluded from analysis. Each SNP has been shown previously to show good 
call rate exceeding >95%. 
Statistical analysis was performed in Stata 13 (Stata Statistical Software: Release 13. College 
Station, TX. StataCorp LP). Laboratory variables were compared between genotypes and 
stratified by DENV serotype using the binary chi-squared test, the Kruskal-Wallis non-
parametric test and the analysis of variance test.  
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Results 
2742 dengue cases were successfully genotyped at MICB rs3132468 and PLCE1 rs3740360. 
573 cases were in adults (age > 15) and 2180 were in children. There were 109 cases of 
severe dengue across the cohorts (6 in adults and 103 in children). 
The baseline characteristics of the study participants are summarised in Table 2. 
Association between MICB rs3132468 and enrolment viraemia 
The mean viraemia was compared between the MICB genotypes. The mean viraemia in 
patients carrying the C/C allele was 7.16 (95%CI: 6.84-7.47) log10-copies/mL. In those with 
the C/T allele it was 7.05 (95%CI: 6.92-7.18) log10-copies/mL, and in those with the T/T allele 
it was 7.08 (95%CI: 7.01-7.15) log10-copies/mL. The difference between these values was not 
statistically significant. The comparison in viraemia levels between MICB genotypes was 
repeated with data stratified by DENV serotype. Again, no significant differences were 
demonstrated. These data are summarised in Table 3. Collectively, these data indicate some 
variation in the viraemia between the DENV serotypes but no significant difference between 
the MICB genotypes. 
Association between PLCE rs3740360 and enrolment viraemia 
The mean viraemia was compared between the PLCE genotypes. The mean viraemia is 
patients carrying the A/A allele was 7.08 (95%CI: 7.00-7.15) log10-copies/mL. In those 
carrying the A/C allele it was 7.09 (95%CI: 6.99-7.19) log10-copies/mL, and in those with the 
C/C allele it was 7.02 (95%CI: 6.78-7.26) log10-copies/mL. The difference between these 
values was not statistically significant.  
The comparison in viraemia levels between PLCE genotypes was repeated with data 
stratified by DENV serotype. Again, no significant differences were demonstrated. These data 
are summarised in Table 3. As above, these data indicate some variation in the viraemia 
level between the DENV serotypes but no significant difference between the PLCE 
genotypes. 
Association between MICB rs3132468 and PLCE rs3740360 and severe dengue 
The proportions of patients developing severe dengue were compared between the 
genotypes in an overall analysis and after stratification by serotype.  
When analysing MICB, 6 patients (7.7%) with the C/C allele developed severe dengue, 24 
(4.1%) with the C/T allele developed severe dengue, and 79 (3.8%) with the T/T allele 
developed severe dengue. These differences were not statistically significant in both an 
overall analysis and when stratified by serotype. 
When analysing PLCE, 68 patients (4.4%) with the A/A allele developed severe dengue, 32 
(3.2%) with the A/C allele developed severe dengue, and 9 (4.9%) with the C/C allele 
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developed severe dengue. These differences were not statistically significant in both an 
overall analysis and when stratified by serotype. 
Collectively, these data indicate that there is no clear association between MICB and PLCE 
genotype and the development of severe dengue. 
Association between MICB rs3132468 and other laboratory variables 
After excluding data from 13DX, which only included enrolment results, the platelet nadir, the 
maximum haematocrit and the minimum white cell count were compared between the MICB 
genotypes in both an overall analysis and then stratified by serotype. The median platelet 
nadir in patients with the C/C allele was 82.5 (IQR: 47-101) x 109/L, in those with the C/T 
allele was 80 (IQR: 48-115) x 109/L, and in those with the T/T allele was 70 (41-113) x 109/L. 
These differences were not statistically significant. The minimum white cell count in those with 
the C/C allele was 2.6 (IQR: 2.3-3.1) x 109/L, in those with the C/T allele was 2.9 (IQR: 2.3-
3.8) x 109/L and in those with the T/T allele was 2.7 (IQR: 2.1-3.4) x 109/L. These differences 
were not statistically significant. The median maximum haematocrit in patients with the C/C 
allele was 45.4% (IQR: 44-49.2%), in those with the C/T allele was 45% (IQR: 42-48.3%), and 
in those with the T/T allele was 44.7% (IQR: 41.8-48.4%). These differences were not 
statistically significant. When these data were stratified by DENV serotype again no 
significant differences were demonstrated. These data suggest no measurable association 
between MICB genotype and the laboratory variables explored in this analysis. 
These data are summarised in Tables 4, 5, 6, 7 and 8.  
Association between PLCE rs3740360 and other laboratory variables 
The platelet nadir, the maximum haematocrit and the minimum white cell count were 
compared between the PLCE genotypes in both an overall analysis and then stratified by 
serotype. The median platelet nadir in patients with the A/A allele was 71 (IQR: 41-109) x 
109/L, in those with the A/C allele was 76.5 (IQR: 45-118) x 109/L, and in those with the C/C 
allele was 66 (37-114) x 109/L. These differences were not statistically significant. The 
minimum white cell count in those with the A/A allele was 2.7 (IQR: 2.1-3.4) x 109/L, in those 
with the A/C allele was 2.8 (IQR: 2.2-3.6) x 109/L and in those with the C/C allele was 2.9 
(IQR: 2.2-3.6) x 109/L. These differences were not statistically significant. The median 
maximum haematocrit in patients with the A/A allele was 44.6% (IQR: 41.9-48.1%), in those 
with the A/C allele was 45.1% (IQR: 42-48.3%), and in those with the C/C allele was 45% 
(IQR: 42.4-50.3%). These differences were not statistically significant. When these data were 
stratified by DENV serotype again no significant differences were demonstrated. These data 
suggest no measurable association between PLCE genotype and the laboratory variables 
explored in this analysis. 
These data are summarised in Tables 4, 5, 6, 7 and 8.  
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Discussion 
This analysis showed no association between MICB and PLCE genotype and early viraemia 
level, platelet nadir, white cell count nadir, maximum haematocrit or the development of 
severe disease in both overall analysis and in analysis stratified by serotype.  
Given the possibility that MICB may have an important role in the establishment of antiviral 
effector function we proposed that mutations in this gene might be associated with higher 
dengue viraemia. Our analysis in 2742 adults and children with dengue showed no difference 
in the enrolment viraemia levels between the different MICB and PLCE1 genotypes in both an 
overall analysis and analysis stratified by DENV serotype. The enrolment viraemia was taken 
in the vast majority of patients in the first 72 hours of clinical illness (Table 2). While our 
understanding of DENV kinetics suggests that this is likely to correspond near to the peak 
viraemia level it only gives a snapshot of the in vivo viral dynamics. It is possible that the viral 
clearance patterns varied across genotypes. In addition, measuring plasma viraemia only 
provides a surrogate of what is happening in other tissues – obviously, however, invasive 
assessments of this would not be appropriate in large prospective studies. However, an 
interesting finding was the range of early viraemia levels across the DENV serotypes and 
between the different MICB and PLCE genotypes. While the observed variation was not 
statistically significant, it does suggest that there are factors that influence the early viraemia 
level. This may be a combination of intrinsic genetic susceptibility, host immune status and 
various viral factors. Determining the factors that influence the DENV “set point” would be 
intriguing and would advance our understanding of dengue pathogenesis. 
As no associations between viraemia and genotype were shown, it is perhaps not surprising 
that no associations were demonstrated between genotype and the pre-selected routine 
haematological laboratory variables both in overall analysis and in analysis stratified by DENV 
serotype. These variables were chosen because they have been previously shown to have 
some correlation with dengue severity.10,11 However, differences in the study designs, 
particularly the frequency of laboratory investigations, across the cohorts described meant 
that the largest study in patient numbers (13DX) was excluded from this component of the 
analysis.  
While previous work has demonstrated an association between genetic variants of MICB and 
PLCE1 and both severe and non-severe dengue, the functional basis of these associations is 
not clear.7,13 MICB encodes an activating ligand for natural killer cells, and possibly CD8+ T 
cells, raising the possibility that mutations in this gene may result in altered antiviral effector 
functions and an associated increased viral burden, a recognised risk factor for the 
development of severe dengue.9 It is possible that the associations reflect an aspect of 
dengue pathogenesis unrelated to control of early viral replication. The association of PLCE1 
and dengue is harder to explain. It is interesting to note that mutations in this gene have been 
associated with nephrotic syndrome, regulation of blood pressure and oesophageal 
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malignancy.8,14,15 While it is plausible that the relationship between mutations in PLCE1 and 
both severe dengue and nephrotic syndrome suggests some role in the maintenance of 
endothelial integrity, it is more difficult to relate this potential function to oesophageal 
malignancy. The role of PLCE in control of blood pressure warrants further exploration as it 
raises the possibility of some overlap in function in dengue. This relationship with diverse 
conditions suggests an important, but as yet unclear, role for PLCE1 in human health and 
disease.  
Our study has limitations. The number of patients with the “risk” alleles for MICB and PLCE 
was relatively small. This raises the possibility that the lack of a clear association 
demonstrated in this analysis is not a true finding. In addition, the study methodology varied 
between the studies included in the analysis meaning that it was only possible to explore the 
relationship between genotype and laboratory variable in a smaller group of patients. The 
functional basis of these observed associations remains unclear but it is possible that pooled 
data from prospective intervention studies may provide clearer insights. The potential offered 
by this study approach reflects the more frequent sampling that typically occurs in this type of 
study. Greater insights into dengue host susceptibility have the potential to expand our 
knowledge of disease pathogenesis and, in the longer term, assist the development of 
vaccines and therapeutics. 
 
 
 
  
Table 2. Collated study population characteristics (n=2730) 
!  DENV1 (n=1042) DENV2 (n=593) DENV3 (n=263) DENV4 (n=832) All (n=2730) 
Age (median, IQR), years 10(7-13) 10(7-14) 9(6-13) 11(8-15) 10(7-14) 
 
Sex (n,%) 
    !Male 596(57.2) 357(60.2) 147(55.9) 474(57.0) 1574(57.7) 
Female 446(42.8) 236(39.8) 116(44.1) 358(43.0) 1156(42.3) 
 
Days of illness at enrolment  (n,%) 
    !0 9(0.86) 1(0.17) 0(0) 3(0.36) 13(0.48) 
1 323(31.0) 174(29.3) 85(32.3) 195(23.4) 777(28.5) 
2 437(41.9) 271(45.7) 113(43.0) 354(42.5) 1175(43.0) 
3 269(25.8) 146(24.6) 64(24.3) 279(33.5) 758(27.8) 
4 2(0.19) 1(0.17) 1(0.4) 0(0) 4(0.15) 
Viremia (mean, 95%CI), log10 copies/mL 7.39(7.29-7.50) 6.89(6.77-7.01) 7.14(6.94-7.33) 6.80(6.71-6.88) 
7.08(7.02-
7.14) 
 
Clinical classification (n,%) 
! ! ! ! !Dengue 950(91.2)! 553(93.3) 257(97.7) 780(93.8) 2540(93.0) 
Severe dengue 39(3.74) 32(5.4) 6(2.3) 32(3.85) 109(3.99) 
       
Table&3:&Viremia&by&MICB%and%PLCE%genotype&by&dengue&serotype&and&overall&(mean&(IQR)&(N))&
! !MICB% !! !! !! !! !! !! !! !!
Serotype! C/C!! C/T!! T/T!! P-value!
!
!!
! ! ! ! ! ! ! !
DENV1! 7.32!(6.7-7.95)!(n=24)! 7.28!(7.03-7.53)!(n=211)! 7.43!(7.31-7.55)!(n=761)! 0.238!
!
!!
! ! ! ! ! ! ! !
DENV2! 7.04!(6.32-7.76)!(n=18)! 7.03!(6.77-7.29)!(n=125)! 6.84!(6.7-6.98)!(n=450)! 0.833!
!
!!
! ! ! ! ! ! ! !
DENV3! 6.99!(5.24-8.75)!(n=7)! 7.15!(6.7-7.6)!(n=50)! 7.14!(6.91-7.36)!(n=206)! 0.836!
!
!!
! ! ! ! ! ! ! !
DENV4! 7.13!(6.67-7.59)!(n=28)! 6.75!(6.56-6.93)!(n=184)! 6.8!(6.7-6.9)!(n=620)! 0.86!
!
!!
! ! ! ! ! ! ! !
Overall! 7.16!(6.84-7.47)!(n=78)! 7.05!(6.92-7.18)!(n=583)! 7.08!(7.01-7.15)!(n=2081)! 0.315!
PLCE% !! !! !! !! !! !! !! !!
Serotype! A/A!! A/C!! C/C!! P-value!
!
!!
! ! ! ! ! ! ! !
DENV1! 7.38!(7.24-7.53)!(n=578)! 7.39!(7.22-7.56)!(n=397)! 7.47!(7.03-7.91)!(n=67)! 0.972!
!
!!
! ! ! ! ! ! ! !
DENV2! 6.83!(6.67-7)!(n=334)! 6.99!(6.79-7.19)!(n=215)! 6.83!(6.38-7.29)!(n=44)! 0.938!
!
!!
! ! ! ! ! ! ! !
DENV3! 7.08!(6.82-7.34)!(n=157)! 7.19!(6.87-7.5)!(n=87)! 7.32!(6.35-8.29)!(n=19)! 0.198!
!
!!
! ! ! ! ! ! ! !
DENV4! 6.87!(6.75-6.98)!(n=472)! 6.74!(6.99-7.19)!(n=306)! 6.51!(6.18-6.83)!(n=54)! 0.867!
!
!!
! ! ! ! ! ! ! !
Overall! 7.08!(7-7.15)!(n=1546)! 7.09!(6.99-7.19)!(n=1012)! 7.02!(6.78-7.26)!(n=184)! 0.7!
 
Table&4:&Laboratory&features&by&MICB%and%PLCE%genotype&for&DENV1&
! !MICB% !! !! !! !! !! !! !! !!
Laboratory/clinical!feature! C/C!(n=4)! C/T!(n=46)! T/T!(n=171)! P;value!
!
!!
! ! ! ! ! ! ! !Platelet!nadir!(median(IQR))! 60.5!(39.5;85)! 80.5!(44;128)! 80!(48;127)! 0.608!
!
!!
! ! ! ! ! ! ! !Minimum!white!cell!count!
(median(IQR))! 2.25!(1.75;2.65)! 2.65!(2;3.8)! 2.6!(2.1;3.5)! 0.442!
!
!!
! ! ! ! ! ! ! !Maximum!haematocrit!(median(IQR))! 44.8!(43;49.5)! 45.3!(42.1;48.8)! 44.2!(41.5;48.1)! 0.421!
!
!!
! ! ! ! ! ! ! !PLCE% !! !! !! !! !! !! !! !!
Laboratory/clinical!feature! A/A!(n=119)! A/C!(n=89)! C/C!(n=13)! P;value!
!
!!
! ! ! ! ! ! ! !Platelet!nadir!(median(IQR))! 72!(49;124)! 83!(41;128)! 61!(46;172)! 0.961!
!
!!
! ! ! ! ! ! ! !Minimum!white!cell!count!
(median(IQR))! 2.6!(2.1;3.3)! 2.7!(2;3.6)! 3!(2.2;4.1)! 0.802!
!
!!
! ! ! ! ! ! ! !Maximum!haematocrit!(median(IQR))! 44!(41.7;47.2)! 44.5!(41.9;48.8)! 49!(42.7;51)! 0.0719!
!
!!
! ! ! ! ! ! ! ! 
  
Table&5:&Laboratory&features&by&MICB%and%PLCE%genotype&for&DENV2&
! !MICB% !! !! !! !! !! !! !! !!
Laboratory/clinical!feature! C/C!(n=4)! C/T!(n=31)! T/T!(n=121)! P;value!
!
!!
! ! ! ! ! ! ! !Platelet!nadir!(median(IQR))! 85!(39;110.5)! 70!(33;107)! 57!(29;90)! 0.497!
!
!!
! ! ! ! ! ! ! !Minimum!white!cell!count!
(median(IQR))! 2.7!(2.6;2.95)! 3.3!(2.5;3.9)! 2.7!(2.2;3.4)! 0.115!
!
!!
! ! ! ! ! ! ! !Maximum!haematocrit!(median(IQR))! 47.2!(44.3;49.3)! 45!(43.3;47.6)! 45.2!(42.5;48.4)! 0.719!
!
!!
! ! ! ! ! ! ! !PLCE% !! !! !! !! !! !! !! !!
Laboratory/clinical!feature! A/A!(n=88)! A/C!(n=55)! C/C!(n=13)! P;value!
!
!!
! ! ! ! ! ! ! !Platelet!nadir!(median(IQR))! 62.5!(30;101.5)! 58!(31;91)! 66!(30;116)! 0.912!
!
!!
! ! ! ! ! ! ! !Minimum!white!cell!count!
(median(IQR))! 2.8!(2.2;3.6)! 2.6!(2.3;3.5)! 2.8!(2.3;3.4! 0.987!
!
!!
! ! ! ! ! ! ! !Maximum!haematocrit!(median(IQR))! 45.6!(43.4;48.4)! 44.9!(41.1;47.9)! 44.7!(42;50)! 0.44!
!
!!
! ! ! ! ! ! ! ! 
  
Table&6:&Laboratory&features&by&MICB%and%PLCE%genotype&for&DENV3&
! !MICB% !! !! !! !! !! !! !! !!
Laboratory/clinical!feature! C/C!(n=3)! C/T!(n=13)! T/T!(n=57)! P;value!
!
!!
! ! ! ! ! ! ! !Platelet!nadir!(median(IQR))! 92!(82;102)! 67!(51;95)! 77!(48;111)! 0.803!
!
!!
! ! ! ! ! ! ! !Minimum!white!cell!count!
(median(IQR))! 2.7!(1.9;3.7)! 2.7!(1.9;3.9)! 2.6!(2.1;3.2)! 0.987!
!
!!
! ! ! ! ! ! ! !Maximum!haematocrit!(median(IQR))! 48.6!(45.1;50.6)! 43.6!(40;47)! 44.1!(41.9;47.9)! 0.229!
!
!!
! ! ! ! ! ! ! !PLCE% !! !! !! !! !! !! !! !!
Laboratory/clinical!feature! A/A!(n=44)! A/C!(n=24)! C/C!(n=5)! P;value!
!
!!
! ! ! ! ! ! ! !Platelet!nadir!(median(IQR))! 83!(50;117.5)! 70.5!(49;105)! 83!(67;96)! 0.876!
!
!!
! ! ! ! ! ! ! !Minimum!white!cell!count!
(median(IQR))! 2.4!(2;3.1)! 2.85!(2.1;3.8)! 2.6!(2.4;3.2)! 0.349!
!
!!
! ! ! ! ! ! ! !Maximum!haematocrit!(median(IQR))! 43.4!(41.1;46.7)! 45.1!(42.2;48.5)! 45.7!(45;50.4)! 0.12!
!
!!
! ! ! ! ! ! ! ! 
  
Table&7:&Laboratory&features&by&MICB%and%PLCE%genotype&for&DENV4&
! !MICB% !! !! !! !! !! !! !! !!
Laboratory/clinical!feature! C/C!(n=7)! C/T!(n=59)! T/T!(n=194)! P;value!
!
!!
! ! ! ! ! ! ! !Platelet!nadir!(median(IQR))! 83!(19;107)! 86!(51;113)! 72!(40;109)! 0.698!
!
!!
! ! ! ! ! ! ! !Minimum!white!cell!count!
(median(IQR))! 2.5!(2.3;4)! 2.9!(2.2;3.5)! 2.8!(2.1;3.5)! 0.747!
!
!!
! ! ! ! ! ! ! !Maximum!haematocrit!(median(IQR))! 44.7!(43;49.2)! 45!(41.9;48.6)! 45.1!(41.9;48.6)! 0.88!
!
!!
! ! ! ! ! ! ! !PLCE% !! !! !! !! !! !! !! !!
Laboratory/clinical!feature! A/A!(n=153)! A/C!(n=91)! C/C!(n=16)! P;value!
!
!!
! ! ! ! ! ! ! !Platelet!nadir!(median(IQR))! 72!(36;101)! 84!(54;121)! 61!(44.5;111.5)! 0.132!
!
!!
! ! ! ! ! ! ! !Minimum!white!cell!count!
(median(IQR))! 2.7!(2.1;3.4)! 3!(2.4;3.8)! 2.9!(2.15;3.5)! 0.342!
!
!!
! ! ! ! ! ! ! !Maximum!haematocrit!(median(IQR))! 44.4!(41.8;48.6)! 45.7!(42.3;48.6)! 43.5!(42;46.1)! 0.342!
!
!!
! ! ! ! ! ! ! ! 
  
Table&8:&Laboratory&features&by&MICB%and%PLCE%genotype&for&all&serotypes&
! !MICB% !! !! !! !! !! !! !! !!
Laboratory/clinical!feature! C/C!(n=18)! C/T!(n=150)! T/T!(n=554)! P;value!
!
!!
! ! ! ! ! ! ! !Platelet!nadir!(median(IQR))! 82.5!(47;101)! 80!(48;115)! 70!(41;113)! 0.494!
!
!!
! ! ! ! ! ! ! !Minimum!white!cell!count!
(median(IQR))! 2.6!(2.3;3.1)! 2.9!(2.3;3.8)! 2.7!(2.1;3.4)! 0.214!
!
!!
! ! ! ! ! ! ! !Maximum!haematocrit!(median(IQR))! 45.4!(44;49.2)! 45!(42;48.3)! 44.7!(41.8;48.4)! 0.244!
!
!!
! ! ! ! ! ! ! !PLCE% !! !! !! !! !! !! !! !!
Laboratory/clinical!feature! A/A!(n=409)! A/C!(n=266)! C/C!(n=47)! P;value!
!
!!
! ! ! ! ! ! ! !Platelet!nadir!(median(IQR))! 71!(41;109)! 76.5!(45;118)! 66!(37;114)! 0.675!
!
!!
! ! ! ! ! ! ! !Minimum!white!cell!count!
(median(IQR))! 2.7!(2.1;3.4)! 2.8!(2.2;3.6)! 2.9!(2.2;3.6)! 0.268!
!
!!
! ! ! ! ! ! ! !Maximum!haematocrit!(median(IQR))! 44.6!(41.9;48.1)! 45.1!(42;48.3)! 45!(42.4;50.3)! 0.336!
!
!!
! ! ! ! ! ! ! ! 
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3. PATHOGENESIS OF DENGUE TRANSMISSION 
Background 
The principle vectors of DENV are the mosquitoes Aedes aegypti and Aedes albopictus of the 
subgenus Stegomyia.16 Both have adapted to live in urban and peri-urban areas, and their 
larvae can be found in water containers around and inside houses.16 Ae. aegypti is the more 
domesticated of the two, and thus more closely implicated in DENV transmission. The global 
spread of dengue is, in part, linked to changes in human behaviour, notably the expansion of 
large urban centres that support the breeding of Ae. aegypti.17 However Ae. albopictus also 
has an important role in dengue transmission and has been implicated in various outbreaks. 
For example, outbreaks of dengue in the Seychelles in 1976-77, Ningbo, China in 2004, 
Gabon in 2007, Mauritius in 2009, Dongguan, China in 2010, Guandong, China and Japan in 
2014 were all associated with Ae. albopictus.18-25 Numerous features have supported the 
expansion of the geographic footprint of Ae. albopictus, including the ability of the eggs to 
undergo diapause thus aiding their survival through unfavourable conditions, relative 
refractoriness of adults to cold, and speculation around their ability to out-compete 
established species of mosquitoes.26-28 This global expansion and the potential competitive 
displacement of Ae. aegypti may prove to have an important role in the changing 
epidemiology of dengue.29,30  
Recent work has defined the infectious dose of DENV to Ae. aegypti mosquitoes by 
conducting biting experiments on viraemic dengue patients.31 This component of the thesis 
used similar methodology to directly compare the vector competence of Ae. aegypti and Ae. 
albopictus by assessing the susceptibility to both initial and disseminated DENV infection. 
This research has the potential to improve our understanding of transmission dynamics 
particularly in areas of dengue emergence where the contribution of Ae. albopictus is thought 
to be greatest. In addition, understanding the levels of virus that are infectious to mosquitoes 
have the potential to inform the design of therapeutic and chemoprophylactic candidates thus 
potentially improving the clinical management of the disease. 
Outline of paper 
Comparative susceptibility of Ae. aegypti and Ae. albopictus to 
dengue  
This manuscript describes the results of experiments that directly compared the susceptibility 
of Ae. aegypti and Ae. albopictus to both initial and disseminated DENV infection after blood 
feeding on viraemic dengue patients. Ae. albopictus is generally regarded as a secondary 
dengue vector – the aim of this work was to establish whether there are intrinsic differences in 
DENV susceptibility between the two mosquito species. We demonstrated that both mosquito 
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types were equally susceptible to acquiring an initial abdominal infection but that Ae. 
albopictus was less likely to acquire an infectious phenotype as defined by the presence of 
DENV in the mosquito saliva (OR=0.70; 95%CI:0.52-0.93).  
Previous vector competence studies have been based on laboratory experiments using 
artificial blood meals and laboratory-passaged viruses. This is the first comparative vector 
competence study using “field” conditions and the results have the potential to inform 
accurate transmission models which may be of particular use where the contribution of Ae. 
albopictus to dengue transmission is the greatest. 
Interestingly, our study showed that once infected Ae. albopictus had higher DENV RNA 
concentrations in their abdomens as compared to Ae. aegypti. We explored the possibility 
that this difference could result in greater virus sequence diversity by determining the 
consensus nucleotide sequence of the DENV-1 Env gene in the plasma of 10 patients and 
the corresponding abdominal tissue of 20 Ae. aegypti and 20 Ae. albopictus. We showed that 
the median number of nucleotide differences from the consensus sequence in plasma to the 
consensus sequence in the abdominal tissue of Ae. aegypti was 9 (IQR: 4-15), and for Ae. 
albopictus was 17 (IQR: 11-18) (P=0.02, Wilcoxon test (stratified by patient)). This difference 
raises the possibility that Ae. albopictus disproportionately contributes to the genetic diversity 
that exists within DENV populations. 
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RESEARCH PAPER 2: COMPARATIVE SUSCEPTIBILITY OF 
AEDES AEGYPTI AND AEDES ALBOPICTUS TO DENGUE 
VIRUS INFECTION AFTER FEEDING ON BLOOD OF VIREMIC 
HUMANS: IMPLICATIONS FOR PUBLIC HEALTH 
 
  


M A J O R A R T I C L E
Comparative Susceptibility of Aedes albopictus
and Aedes aegypti to Dengue Virus Infection
After Feeding on Blood of Viremic Humans:
Implications for Public Health
James Whitehorn,1,3 Duong Thi Hue Kien,3 Nguyet Minh Nguyen,3 Hoa L. Nguyen,3 Peter P. Kyrylos,5
Lauren B. Carrington,3,5 Chau Nguyen Bich Tran,3 Nguyen Thanh Ha Quyen,3 Long Vo Thi,3 Dui Le Thi,3
Nguyen Thanh Truong,4 Tai Thi Hue Luong,4 Chau Van Vinh Nguyen,4 Bridget Wills,2,3 Marcel Wolbers,2,3 and
Cameron P. Simmons2,3,5
1London School of Hygiene and Tropical Medicine, and 2Oxford University, United Kingdom; 3Oxford University Clinical Research Unit, and 4Hospital for
Tropical Diseases, Ho Chi Minh City, Vietnam; and 5University of Melbourne, Australia
Aedes albopictus is secondary to Aedes aegypti as a vector of dengue viruses (DENVs) in settings of endemicity,
but it plays an important role in areas of dengue emergence. This study compared the susceptibility of these 2
species to DENV infection by performing 232 direct blood-feeding experiments on 118 viremic patients with
dengue in Vietnam. Field-derived A. albopictus acquired DENV infections as readily as A. aegypti after blood
feeding. Once infected, A. albopictus permitted higher concentrations of DENV RNA to accumulate in abdom-
inal tissues, compared with A. aegypti. However, the odds of A. albopictus having infectious saliva were lower
than the odds observed for A. aegypti (odds ratio, 0.70; 95% conﬁdence interval, .52–.93). These results quan-
titate the susceptibility of A. albopictus to DENV infection and will assist parameterization of models for pre-
dicting disease risk in settings where A. albopictus is present.
Keywords. Dengue; Aedes aegypti; Aedes albopictus; susceptibility; transmission.
Dengue is the most important arboviral infection of hu-
mans, with an estimated 00 million clinically apparent
infections annually [1, 2]. In dengue-endemic countries,
Aedes aegypti (Linnaeus) is widely accepted to be the
primary vectors of dengue viruses (DENVs), with Aedes
albopictus (Skuse) regarded as a secondary vector. Yet
A. albopictus can clearly transmit DENV at scales that
are important to public health. For example, outbreaks
of dengue during 1976–1977 (in the Seychelles), 2004
(in Ningbo, China), 2007 (in Gabon), 2009 (inMauritius),
2010 (in Dongguan, China), and 2014 (in Guangdong,
China, and Japan) were associated with A. albopictus
[3–10]. These outbreaks demonstrate that, although A. al-
bopictus can be a competent vector of DENV, there must
be biological features that render A. albopictus generally
less well equipped to transmit DENV, compared with A.
aegypti.
Aedes albopictus originated in Asia but has geographi-
cally spread through global trade, particularly via used
car tires infested with A. albopictus eggs and larvae
[11]. It is now distributed throughout the United States,
Central America, and South America and in temperate
African and European countries [12–14].Numerous fea-
tures have supported the expansion of A. albopictus, in-
cluding the ability of the eggs to undergo diapause [15].
There is also speculation around their ability to outcom-
pete established species of mosquitoes [16, 17].
The expansion of A. albopictus has led to concern of
an associated increase in the range of dengue transmis-
sion. Lambrechts et al reviewed vector competence
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literature and reported that, although A. albopictus were more
susceptible to DENVmidgut infection, rates of virus dissemina-
tion to other tissues were signiﬁcantly lower in A. albopictus
than in A. aegypti [18]. Additionally, laboratory-reared A. albo-
pictus became increasingly susceptibility to DENV, which may
have been a confounding variable in the literature. Furthermore,
the comparative vector competence literature has been derived
entirely from laboratory experiments using artiﬁcial blood
meals and laboratory-passaged viruses. How well these labora-
tory conditions replicate the pathogenesis of DENV trans-
mission from viremic humans to mosquitoes in the ﬁeld is
uncertain.
The beneﬁts of understanding why A. albopictus is largely a
secondary vector of DENV in settings of endemicity are numer-
ous. First, existing risk-analysis models of the likelihood of
dengue outbreaks in southern Europe and the United States
could be improved with quantitative estimates of A. albopictus
vector competence [19, 20]. Second, probability maps of den-
gue occurrence could be reﬁned with better estimates of the
relative vector competence of A. albopictus versus A. aegypti.
Third, if the historical literature is correct and A. albopictus is
more resistant than A. aegypti to disseminated DENV infec-
tion, then this provides an opportunity to identify species-
speciﬁc antiviral defense mechanisms. Last, novel dengue
control efforts using Wolbachia-infected A. aegypti will be
better informed with an understanding of the vector compe-
tence of A. albopictus in candidate intervention settings [21].
To these ends, the current study compared the susceptibility of
A. aegypti and A. albopictus to initial and disseminated DENV
infection after direct blood-feeding episodes on viremic pa-
tients with dengue.
METHODS
Ethics Statement
All participants provided written informed consent to partici-
pate in the study. The study protocols were reviewed and
approved by the Scientiﬁc and Ethical Committee of the Hos-
pital for Tropical Diseases (CS/ND/12/15) and the Oxford
Tropical Research Ethical Committee (OxTREC 29–12). All in-
vestigations were conducted in accordance with the principles
expressed in the Declaration of Helsinki.
Patient Cohorts
The study was performed at the Hospital for Tropical Diseases
in Ho Chi Minh City, Vietnam, between September 2012 and
November 2013. The inclusion criteria were age of ≥15 years,
fever duration of ≤96 hours, and clinical suspicion of dengue;
positive result of an NS1 rapid test; and provision of written in-
formed consent. The exclusion criteria were current pregnancy,
determined by clinical examination or a urine dipstick test for
β-human chorionic gonadotropin; current intensive care unit
stay; intellectual disability; a history of severe reactions to mos-
quito bites; and severe dermatological conditions. Demographic
and clinical information were recorded prospectively in a stan-
dard case report form.
Mosquitoes for Blood-Feeding Experiments
All of the mosquitoes (A. aegypti and A. albopictus) that fed on
patients with dengue were F3 generation and derived from 2 in-
dependent pooled larval collections, each sampled from 3 loca-
tions within 5 km of each other in Ho Chi Minh City. The A.
aegypti used were distinct from those in our previous study [22].
Brieﬂy, ﬁeld-caught larvae were pooled and fed commercial dry
ﬁsh and dog food. Mosquitoes were housed as described previ-
ously [22]. Brieﬂy, adults (F1 generation) were kept in cages
containing males and females in an environmental chamber
with 12-hour cycles of light and dark at 27°C and 70% relative
humidity. F1 females were provided blood meals by direct feed-
ing on afebrile healthy human volunteers for multiple gonotro-
phic cycles over 45 days, with 15% sucrose provided freely in
addition. Eggs from F1 females were hatched and reared and
the subsequent F2 females provided with human blood meals
as described above. When female F2 mosquitoes were 12 days
old, they were killed and pooled into groups of 10 mosquitoes.
Each pool was homogenized and tested, along with appropriate
controls, by reverse transcription–polymerase chain reaction
(RT-PCR) to conﬁrm the absence of DENV, Japanese enceph-
alitis virus, and chikungunya virus. Eggs collected and stored
from F2 females were the source of F3 females that were used
for direct feeding on patients with dengue.
Experimental Exposure of Patients to Mosquitoes
Each patient was assigned a schedule of 2 exposures to mosqui-
toes on 2 different study days during the ﬁrst 4 days after enroll-
ment. The patient’s forearm was exposed to 30–40 A. aegypti
and A. albopictus aged 3–7 days (using a 2:3 ratio of A. aegypti
to A. albopictus because preliminary experiments indicated that
a higher fraction of A. aegypti took a blood meal) contained in a
mesh-covered plastic cup that was held against the patient’s
forearm for 5 minutes. After 5 minutes, mosquitoes were re-
turned to the insectary and subjected to cold anesthesia at 4°
C for 45 seconds. Engorged mosquitoes were transferred to
500-mL plastic cups, separated by species, and maintained in
an environmental chamber with 12-hour cycles of light and
dark at 27°C and 70% relative humidity for 14 days. The num-
ber of dead mosquitoes was recorded daily.
Clinical Adverse Events
Postexposure severe adverse events were deﬁned as any event
that was clinically signiﬁcant (ie, requiring clinical intervention,
prolonged hospitalization, or admission to an intensive care
unit) and possibly, probably, or deﬁnitely related to experimen-
tal exposure to mosquitoes.
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Detection of DENV in Mosquito Tissues and Saliva
Technicians blinded to clinical and virological details of the par-
ticipants performed laboratory assays of the mosquitoes. Mosqui-
toes were killed by cold exposure. The abdomen was dissected
from the rest of the mosquito body and suspended in 0.5 mL
of mosquito diluent (2% [v/v] heat-inactivated fetal calf serum
[FCS] in Roswell Park Memorial Institute 1640 medium, antibi-
otics, and antimycotics). Individual mosquito abdomens were
homogenized with 1-mm zirconia/silica beads for 15 minutes
at 30 Hz by using a TissueLyser II system (Qiagen), as described
previously [22]. Mosquitoes were scored as being infected with
DENV, using a previously described quantitative RT-PCR anal-
ysis of homogenized tissue, with the results expressed as copies
per abdomen [23]. Infectious virus in the saliva of individual
mosquitoes was detected as described previously [22]. Brieﬂy,
the proboscis of dewinged and delegged mosquitoes was inserted
into the end of a micropipette tip containing 6 µL of ﬁltered sal-
iva medium (a 1:1 solution of 15% [v/v] sucrose in normal saline
and inactivated FCS). After 30 minutes, the 6 µL of saliva medi-
umwas ejected and then drawn into a pointed glass capillary tube
(tip diameter, <0.3 µm), after which the volume of saliva medium
derived from 1 mosquito was injected into the thorax of 4–6 A.
aegypti (age, 4–7 days; volume injected, approximately 1 µL per
mosquito). These injected mosquitoes were maintained for 7
days in an environmental chamber as described above. After 7
days, the mosquitoes were killed and the bodies pooled, homog-
enized, and tested by quantitative RT-PCR for DENV infection,
with saliva samples scored as positive or negative depending on
this result.
Sequence Ampliﬁcation and Sequencing of the Gene Encoding
DENV Envelope Protein
Viral RNA was extracted as previously described from plasma
and mosquito abdomen tissues [22]. Complementary DNA
(cDNA) was synthesized from 8 µL of viral RNA by using the
Superscript III First-Strand Synthesis System for RT-PCR ac-
cording to manufacturers’ instructions. The genomic region
spanning the genes encoding premembrane and envelope pro-
teins was ampliﬁed from the cDNA in 16 amplimers. Subse-
quent steps were performed according to the manufacturers
instructions for 454 GS-Junior Next Generation Sequencing
method (Roche). Brieﬂy, the primers in this ﬁrst PCR round
contained universal tails at the 5′ end to allow the addition of
454 sequencing-speciﬁc nucleotides and isolate-speciﬁc multi-
plex identiﬁers (also known as “barcodes”) in a second PCR
round. The ﬁrst-round and second-round PCR analyses used
FastStart High Fidelity polymerase (Roche). The long-read se-
quencing performance of the 454 GS-Junior (between 400
and 500 bases), in combination with a sample pooling strategy
that uses barcoded amplicons, was used for parallel analysis of
pooled samples. GS Mapping software was used for primer
trimming and alignment of reads against a reference sequence
DENV-1/VN/BID-V2732/2007 (GenBank accession number
GQ199773.1). Sequence quality was measured using Phred
(Q) scores with a minimum acceptable threshold of 95% of se-
quencing reads having Q scores of >20 (1/100 errors per base).
Dengue Diagnostic Tests
Serological responses were detected using immunoglobulin M
(IgM) and immunoglobulin G (IgG) antibody-capture en-
zyme-linked immunosorbent assays in accordance with the
manufacturer’s instructions (Panbio, Australia). In accordance
with the manufacturer’s instructions, we classiﬁed serological
proﬁles as “probable secondary” when >22 U of IgG were de-
tected in either acute or early convalescent samples. If acute
or early convalescent samples were IgM positive but IgG nega-
tive, serological proﬁles were classiﬁed as “probable primary.”
When IgM or IgG tests result were equivocal, we classiﬁed the
serological proﬁle as “indeterminate.”
DENV plasma viremia levels were measured by a validated
quantitative RT-PCR assay that has been described previously
[23].
Statistical Analysis
The probability of successful human-to-mosquito transmission
was compared between A. aegypti and A. albopictus, using mar-
ginal logistic regression models. Models for assessment of abdo-
men samples were adjusted for the patient’s log10-transformed
viremia level, and models for assessment of saliva samples were
further adjusted for the abdominal tissue viremia level. Analyses
were performed for all patients and stratiﬁed by serotype. To ac-
count for potential within-patient correlation, model-robust sand-
wich standard error estimates were used throughout to construct
conﬁdence intervals (CIs) and P values. We derived 50% mosqui-
to infectious doses (MID50 values; deﬁned as plasma viremia lev-
els corresponding to a 50% probability of infection) for abdomen
infection on the basis of marginal logistic regression coefﬁcients
for each mosquito type, and corresponding 95% CIs were calcu-
lated using the delta rule. Since the proportion of mosquitoes with
infectious saliva was <50%, MID50 values were not estimated. In
the initial analysis of the transmission of DENV to saliva, mosqui-
toes with uninfected abdomens were assigned a log value of
0. This analysis was also run with exclusion of mosquitoes with
uninfected abdomen’s. The relationship between various covari-
ates and the probability of successful human-to-mosquito trans-
mission was assessed for each mosquito type, using a similar
multivariable marginal regression model. The covariates assessed
were day of illness, plasma viremia level, serotype, serological re-
sult, and abdominal viral burden. The number of mutations in the
DENV-1 consensus sequence was compared between mosquito
types, using a stratiﬁed version of the Wilcoxon test with stratiﬁ-
cation by patient [24]. All the analyses were performed using the
R statistical software package, version 2.13.2 (R Foundation for
Statistical Computing; Vienna, Austria).
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RESULTS
Study Population Characteristics
Between September 2012 and November 2013, 120 patients
with dengue were enrolled and experimentally exposed to
ﬁeld-derived A. aegypti and A. albopictus on 2 randomly allo-
cated days within the ﬁrst 4 study days. The patient enrollment
ﬂowchart is shown in Supplementary Figure 1. The ﬁnal cohort
for analysis comprised 118 DENV viremic patients with 232 in-
dependent mosquito exposure events. The baseline characteris-
tics of the patients enrolled are shown in Table 1. Experimental
exposure to mosquitoes was well tolerated, and no patient expe-
rienced a severe adverse event or required withdrawal from the
study. DENV serotype 1 (DENV-1) and DENV-4 were respon-
sible for 26% and 44% of cases, respectively, with DENV-2
(13%) and DENV-3 (16%) also represented.
Susceptibility of A. aegypti and A. albopictus to Acquisition of
DENV Infection After Direct Feeding
There was a dose-response relationship between plasma viremia
levels at the time of mosquito feeding and the proportion of
mosquitoes of either species with DENV-infected abdomens 14
days later (Figure 1). The overall DENV MID50 for A. aegypti
was lower than that observed for A. albopictus, but this difference
was not statistically signiﬁcant (7.0 log10 copies/mL [95% CI,
6.77–7.23] vs 7.1 log10 copies/mL [95% CI, 6.9–7.3]; Table 2).
Viral RNA concentrations of all 4 DENV serotypes were signiﬁ-
cantly higher in abdomen tissues from infected A. albopictus than
in those from A. aegypti (Supplementary Table 1). Given that A.
albopictus accommodated higher DENV RNA concentrations
once infected, we examined whether this could result in greater
virus sequence diversity. As a test case, the consensus nucleotide
sequence of the gene encoding DENV-1 envelope protein was
determined directly by analysis of plasma specimens from 10 pa-
tients and abdominal tissues from 20 A. aegypti and 20 A. albo-
pictus that had taken blood meals from these cases (ie, 2 A. aegypti
and 2 A. albopictus per patient). The median number of nucleo-
tide differences between the consensus sequences of the gene
recovered from plasma specimens and the gene recovered from
abdominal tissue was 9 (interquartile range [IQR], 4–15) for
A. aegypti and 17 (IQR, 11–18) for A. albopictus (P = .02, by the
Wilcoxon test [stratiﬁed by patient]; Supplementary Figure 2).
Table 1. Characteristics of 118 Patients With Dengue Virus (DENV) Infection, by DENV Serotype
Characteristic DENV-1 (n = 31) DENV-2 (n = 15) DENV-3 (n = 19) DENV-4 (n = 52) Overall (n = 118)a
Age, y 23 (19–31) 23 (21–32) 25 (20–27) 27.5 (22–34) 26 (20–32)
Sex
Male 12 (38.7) 7 (46.7) 5 (26.3) 17 (32.7) 41 (34.8)
Female 19 (61.3) 8 (53.3) 14 (73.7) 35 (67.3) 77 (65.3)
Illness duration at enrollment, db
1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
2 7 (22.3) 5 (33.3) 0 (0) 7 (13.4) 19 (16.2)
3 11 (36.7) 3 (20.0) 7 (36.8) 20 (38.4) 42 (35.9)
4 12 (40.0) 7 (46.7) 11 (57.9) 24 (46.2) 54 (46.2)
5 0 (0) 0 (0) 1 (5.3) 1 (2.0) 2 (1.7)
Viremia level, log10 copies/mL 8.1 (6.9–8.7) 7.6 (7.1–8.9) 6.6 (5.5–7.1) 7.2 (6.5–7.8) 7.2 (6.6–8.1)
Serological profilec
Primary 10 (32.3) 0 (0) 1 (5.3) 1 (2.0) 12 (10.3)
Secondary 17 (54.8) 12 (80.0) 16 (84.2) 48 (94.1) 94 (80.3)
Indeterminate 4 (12.9) 3 (20.0) 2 (10.5) 2 (3.9) 11 (9.4)
Clinical classification
Dengue 26 (83.9) 14 (93.3) 16 (84.2) 47 (90.4) 104 (88.1)
Dengue with warning signs 5 (16.1) 1 (6.7) 2 (10.5) 4 (7.7) 12 (10.2)
Severe dengue 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Others 0 (0) 0 (0) 1 (5.3)d 1 (1.9)e 2 (1.7)
Transferred to ICU 1 (3.2) 0 (0) 0 (0) 0 (0) 1 (0.9)
Data are no. (%) of patients or median value (interquartile range).
Abbreviation: ICU, intensive care unit.
a The viremia level for 1 patient was below the limit of detection.
b Data for 1 patient were missing.
c Data for 1 patient with DENV-4 infection were missing.
d One patient was categorized as having a “viral infection” but was actually infected with DENV-3.
e One patient was categorized as having a “viral infection” but was actually infected with DENV-4.
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Acquisition of Infectiousness Among A. aegypti and
A. albopictus
As was observed in abdomen tissues, there was a dose-response
relationship between the plasma viremia level and the propor-
tion of mosquitoes with infectious saliva 14 days after blood
feeding (Figure 2). However, the likelihood of detecting infec-
tious saliva differed by mosquito species and DENV serotype.
Table 3 summarizes the odds of abdomen and saliva infection
and demonstrates that the detection of infectious saliva was less
likely in blood-fed A. albopictus, compared with blood-fed A.
aegypti, in both unadjusted analysis and analysis that adjusted
for plasma viremia level (adjusted odds ratio [OR], 0.70; 95%
CI, .52–.93). By serotype, the odds of A. albopictus having infec-
tious saliva were signiﬁcantly lower for blood meals involving
uptake of DENV-2 and DENV-4, compared with those involv-
ing uptake of DENV-1 or DENV-3 (Table 3). These data
identiﬁed the odds of A. albopictus becoming infectious as
lower than the odds of A. aegypti becoming infectious after
feeding on the blood of viremic patients. This analysis used
all engorged mosquitoes as the denominator. Supplementary
Table 2 shows the odds of having infectious saliva, using mos-
quitoes with DENV-positive abdomens as the denominator.
This analysis conﬁrms that the odds of A. albopictus becoming
infectious were lower than those for A. aegypti after viremic
blood feeding (OR, 0.69; 95% CI, .49–.96).
Covariates and Their Association With Successful Human-to-
Mosquito Transmission
In multivariable regression analysis, a higher plasma viremia
level at the time of exposure was independently associated
with a greater likelihood of DENV transmission to abdominal
tissue for both mosquito types. Each 1-log increase in the
Figure 1. Dose-response scatterplot and curve (derived from logistic regression models) of plasma viremia versus the proportion of mosquitoes with
dengue virus (DENV)–infected abdomens after feeding on 118 DENV-infected patients, showing curves for Aedes aegypti and Aedes albopictus. Each dot
represents the proportion of mosquitoes that took a blood meal during an exposure event and had DENV-infected abdomens 14 days later and the corre-
sponding plasma viremia level in the patient at the time of mosquito exposure, stratiﬁed by DENV serotype.
Table 2. 50% Mosquito Infectious Doses (MID50 Values) for Aedes albopictus and Aedes aegypti Abdomen Infection, by Dengue Virus
(DENV) Serotype
Serotype A. aegypti A. albopictus Absolute Difference P Value
DENV-1 6.62 (6.10–7.13) 6.74 (6.27–7.21) 0.12 (−.11 to .35) .29
DENV-2 6.96 (6.54–7.38) 7.03 (6.62–7.43) 0.07 (−.17 to .30) .59
DENV-3 6.49 (5.69–7.30) 6.70 (5.86–7.56) 0.21 (−.39 to .82) .49
DENV-4 7.37 (7.04–7.70) 7.38 (7.07–7.69) 0.01 (−.21 to .24) .89
Overall 7.00 (6.77–7.23) 7.10 (6.90–7.30) 0.10 (−.04 to .24) .15
MID50 values (defined as plasma viremia levels corresponding to a 50% probability of infection) were derived on the basis of marginal logistic regression coefficients
for each mosquito type, and corresponding 95% confidence intervals were calculated using the delta rule.
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log10 plasma viremia level was associated with a 4.65-fold in-
crease in the odds of abdominal tissue infection in A. aegypti
(95% CI, 3.34–6.48) and a 5.3-fold increase in the odds of ab-
dominal tissue infection in A. albopictus (95% CI, 3.80–7.43;
Table 4). Each 1-log increase in the log10 plasma viremia level
was associated with 2.16-fold increase in the odds of saliva
infection in A. aegypti (95% CI, 1.68–2.78) and a 2.79-fold
increase in the odds of saliva infection in A. albopictus (95%
CI, 2.17–3.60; Table 4). These data highlight plasma viremia
level as a risk factor for infectiousness among A. aegypti and
A. albopictus. Supplementary Table 3 shows the association be-
tween these covariates and successful transmission, with mos-
quitoes with DENV-negative abdomens excluded from the
model.
Figure 2. Dose response scatterplot and curve (derived from logistic regression models) of plasma viremia versus the proportion of mosquitoes with
infectious saliva after feeding on 118 dengue virus (DENV)–infected patients, showing curves for Aedes aegypti and Aedes albopictus. Each dot point
represents the proportion of mosquitoes that took a blood meal during an exposure event and had saliva containing infectious DENV 14 days later and
the corresponding plasma viremia level in the patient at the time of mosquito exposure, stratiﬁed by DENV serotype.
Table 3. Comparison of the Odds of Abdomen and Saliva Infection Among Aedes albopictus Versus the Odds Among Aedes aegypti, by
Dengue Virus (DENV) Serotype
Specimen,
Serotype
Patients,
No.
A. albopictus A. aegypti
Unadjusted
OR (95% CI)
P
Value
Adjusted
OR (95% CI)a
P
Value
Infected/Tested,
No. (%)
Infected/Tested,
No. (%)
Abdomen
DENV-1 27 291/411 (70.8) 278/379 (73.4) 0.88 (.62–1.25) .48 0.79 (.52–1.20) .28
DENV-2 13 108/185 (58.4) 143/220 (65.0) 0.76 (.52–1.09) .13 0.97 (.52–1.82) .93
DENV-3 16 67/173 (38.7) 83/208 (39.9) 0.95 (.55–1.66) .86 0.76 (.39–1.48) .42
DENV-4 49 229/777 (29.5) 232/751 (30.9) 0.93 (.70–1.24) .64 0.95 (.69–1.31) .77
Overall 105 695/1546 (45.0) 736/1558 (47.2) 0.91 (.78–1.07) .27 0.85 (.69–1.06) .16
Saliva
DENV-1 27 177/411 (43.1) 142/379 (37.5) 1.26 (.89–1.80) .20 1.31 (.90–1.93) .16
DENV-2 13 22/185 (11.9) 91/220 (41.4) 0.19 (.11–.33) <.001 0.17 (.09–.31) <.001
DENV-3 16 17/173 (9.8) 35/208 (16.8) 0.54 (.21–1.37) .19 0.44 (.19–1.00) .051
DENV-4 49 60/777 (7.7) 92/751 (12.3) 0.60 (.36–.99) .044 0.60 (.37–.98) .041
Overall 105 276/1546 (17.9) 360/1558 (23.1) 0.72 (.55–.95) .022 0.70 (.52–.93) .014
Abbreviations: CI, confidence interval; OR, odds ratio.
a Marginal logistic regression models adjusted for plasma viremia.
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DISCUSSION
There is speculation on the arboviral disease risks posed by the in-
vasion of A. albopictus into southern Europe and the United
States [25]. Central to calibrating these risk assessments is an un-
derstanding ofA. albopictus vector competence. There is conﬂict-
ing literature on whether A. albopictus is less susceptible than
A. aegypti to disseminated DENV infection [26–32]. Further-
more, all of the previous work in this area has used laboratory
methods that do not mimic natural infection. Here, in experi-
ments involving direct feeding on viremic patients with dengue,
we provide evidence that A. albopictus had a susceptibility to ac-
quiring DENV infection that was similar to that of A. aegypti.
However, blood-fed A. albopictus was signiﬁcantly less likely to
become infectious with DENV-2 and DENV-4, suggesting an in-
terspecies difference of epidemiological importance.
A ﬁrst step in the establishment of DENV infection in mos-
quitoes is attachment of virus particles to luminal receptors on
the midgut epithelium, followed by virus entry via endocytic
pathways. There are few insights into the nature of these recep-
tors for DENV, although it has been proposed that the R67 and
R80 proteins may act as midgut receptors leading to subsequent
systemic infection [33]. Our ﬁnding that the plasma viremia
MID50 values for A. aegypti and A. albopictus were broadly sim-
ilar suggests that DENV uses common mechanisms to attach
and initially infect the midgut epithelium in these specimens.
The MID50 values for DENV-1 and DENV-4 measured in
this study were concordant with those observed previously,
whereas the MID50 values differed for DENV-2 and DENV-3
[22]. We speculate that this reﬂects the smaller numbers of pa-
tients with DENV-2 and DENV-3 in this current study and
hence decreased accuracy.
Our results identiﬁed that A. albopictus and A. aegypti were
equally likely to develop infectious saliva containing DENV-1
and DENV-3. However, DENV-2 and DENV-4 were detected
in saliva from A. albopictus less frequently than in saliva from
A. aegypti. This might simply reﬂect intrinsic differences between
the virus types in their virulence for A. albopictus, with DENV-1
and DENV-3 being ﬁtter in this instance. However, it is interest-
ing to note that, while DENV-1 was the dominant serotype in the
Key West outbreak of dengue with A. aegypti as the vector,
DENV-1 has not become further established in the southern
United States, where A. albopictus is prevalent [34].
We explored the relationship between various covariates and
the likelihood of successful human-to-mosquito transmission.
We conﬁrmed the importance of the plasma viremia level in suc-
cessful human-mosquito transmission: each 1-log increase
in plasma viremia level was associated with an approximately
5-fold increase in the odds of successful human-to-mosquito
transmission for bothA. aegypti andA. albopictus [22].This ﬁnd-
ing again suggests that interventions that reduce DENV viremia
during natural infection could have both an individual beneﬁt
and a public health beneﬁt through reducing human infectious-
ness and thus reducing the risk of further transmission [19].
DENV RNA concentrations were signiﬁcantly higher in ab-
dominal tissues of A. albopictus than A. aegypti for all serotypes.
Table 4. Covariates and Their Association With Successful Dengue Virus (DENV) Transmission Among Aedes albopictus and Aedes
aegypti
Variable
Abdomen Saliva (Among All Mosquitoes )
A. aegypti A. albopictus A. aegypti A. albopictus
Adjusted OR
(95% CI)
P
Value
Adjusted OR
(95% CI)
P
Value
Adjusted OR
(95% CI)
P
Value
Adjusted OR
(95% CI)
P
Value
Illness duration at enrollment
(per 1-d increase)
0.58 (.36–.93) .025 0.60 (.39–.92) .018 0.87 (.61–1.24) .45 0.91 (.62–1.34) .63
Viremia level (per 1-log10
copies/mL increase)
4.65 (3.34–6.48) <.001 5.32 (3.80–7.43) <.001 2.16 (1.68–2.78) <.001 2.79 (2.17–3.60) <.001
DENV serotype
DENV-1 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
DENV-2 0.57 (.18–1.78) .34 0.74 (.24–2.34) .59 1.43 (.69–2.95) .34 0.18 (.08–.39) <.001
DENV-3 1.29 (.30–5.49) .73 1.31 (.31–5.47) .71 1.08 (.41–2.86) .88 0.40 (.12–1.38) .15
DENV-4 0.27 (.10–.71) .008 0.36 (.15–.88) .026 0.48 (.24–.99) .046 0.23 (.12–.44) <.001
Serological profile
Primary 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Secondary 0.84 (.18–3.86) .83 0.73 (.18–2.96) .66 0.76 (.29–1.99) .58 1.01 (.45.2.26) .99
Indeterminate 0.27 (.06–1.16) .08 0.51 (.11–2.43) .40 0.37 (.13–1.09) .07 0.31 (.09–1.02) .054
Data are from marginal models.
Abbreviations: CI, confidence interval; OR, odds ratio.
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When examined for DENV-1, this was also associated with high-
er levels of sequence drift away from the consensus sequence of
the gene encoding envelope protein in the patient’s plasma sam-
ple. Plausibly, by being more permissive to DENV replication in
its abdominal tissues,A. albopictusmight contribute to the genet-
ic diversity that exists within DENV populations. Despite A. al-
bopictus harboring higher viral burdens in abdominal tissues,
signiﬁcantly fewer A. albopictus had infectious saliva resulting
from DENV-2 or DENV-4 infections. These data are broadly
consistent with previous observations demonstrating that A. al-
bopictus was more susceptible to fulminant DENV infection of
the mosquito body but that viral dissemination to saliva was
less than in A. aegypti [18]. That such nuanced interspecies dif-
ferences can exist is perhaps not surprising, given the literature
reporting variation in the susceptibility of A. aegypti populations
to DENV infection, albeit under laboratory conditions [35–39].
Future studies to understand the basis for these phenotypes, par-
ticularly when using ﬁeld-derived mosquitoes and direct feeding
on human viremic hosts, will require large sample sizes to over-
come the intrinsic variance in this system.
While our ﬁndings have identiﬁed interspecies differences in
susceptibility to DENV infection, the absolute differences be-
tween the mosquito types are nonetheless small. This points
to factors other than outright susceptibility to DENV infection
as important reasons why A. albopictus is a marginal contribu-
tor to dengue transmission in urban and peri-urban settings
in dengue-endemic countries. Behavioral attributes are also
important for vector competence, and thus we speculate that
the tendency of A. aegypti to live proximate to humans is the
major reason why it is the primary DENV vector.
Our study has limitations [18]. First, for practical reasons we
measured the phenotype of blood-fed, ﬁeld-derived mosquitoes
at 14 days after feeding; data acquisition at other time points
might have led to additional insights. Second, the results were
limited in scope to the virus serotypes and genotypes in circu-
lation during the study period, and consequently we acquired
sparse data on DENV-2 and DENV-3. Additionally, there
may be speciﬁc interactions between DENV types and mosquito
genotypes that inﬂuence infection outcome [40]. Studies in
other settings should be encouraged to understand the general-
izability of this work.
In summary, we are the ﬁrst to demonstrate that A. albopictus
are less likely than A. aegypti to develop an infectious phenotype
14 days after direct blood feeding on viremic patients with
dengue due to DENV-2 or DENV-4 infection. These results
will enable more-accurate parameterization of DENV transmis-
sion models in regions where dengue is endemic and those that
are at risk for endemicity. In addition, we have conﬁrmed the
central importance of plasma viremia in determining the likeli-
hood of mosquito tissue infection, suggesting that interventions
that attenuate viremia will have both individual and community
beneﬁts.
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Figure S1: Flow chart of patient enrolment and exposure to mosquitoes. IQR, 
interquartile range ! !!Clinically!suspected!dengue!cases:!306!
NS1!positive:!153!(50%)!
Enrolled:!120!(78%)!
Withdrew:!6!(5%)!!2!withdrew!before!exposure!
118!patients!exposed!to!a!median!number!(IQR)!of!15!(14M16)!
Aedes%aegypti%and!19!(17M20)!Aedes%albopictus%on!232!occasions!(114!exposed!twice!and!4!exposed!once)!
Median!number!(IQR)!engorged!Ae.%aegypti%per!event:!11!(8M13)!Median!number!engorged!Ae.%albopictus%per!event:!11!(8M14)!Total!engorged!Ae.%aegypti:!2559!Total!engorged!Ae.%albopictus:!2635!
670!Ae.%aegypti%died!!647!Ae.%albopictus%died!!
Final!cohort!for!analysis:!118!patients!with!232!exposure!events!for!1889!bloodMfed!Ae.%aegypti!and!1988!Ae.%albopictus%
 Figure S2: Box plot showing the number of mutations by mosquito type stratified by patient 
 
 
 
 Supplementary Table 1: Abdomen viral burden (log10 RNA copies per abdomen) according to mosquito 
type *!
 
 
Serotype 
Number of Ae. 
aegypti 
Ae. aegypti 
(median, IQR) 
Number of Ae. 
albopictus 
Ae. albopictus 
(median, IQR) p value 
All 1472 7.3(6.9-7.6) 1390 7.7(7.4-8.0) <0.0001 
DENV 1 556 7.0(6.7-7.3) 582 7.6(7.4-7.9) <0.0001 
DENV 2 286 7.5(7.2-7.8) 216 7.8(7.4-7.9) <0.0001 
DENV 3 166 7.1(6.6-7.5) 134 7.4(7.1-7.7) <0.0001 
DENV 4 464 7.4(7.2-7.7) 458 7.8(7.6-8.1) <0.0001 
 *Among infected abdomen tissues only.  
 IQR: Interquartile range; p value from Wilcoxon rank-sum tests 
Supplementary,Table,2.,Saliva,infection,among,positive,abdomen,!
!! No of patients Ae. albopictus   Ae. aegypti   Unadjusted OR (95CIs) p-values Adjusted OR (95CIs)*  p-values # infected/ N abdomen 
positive 
% 
# infected/ N 
abdomen 
positive 
% 
DENV1 27 177/291 60.8 142/278 51.1 1.49(1.01-2.19) 0.045 1.49(1.01-2.19) 0.046 
DENV2 13 22/108 20.4 91/143 63.6 0.15(0.08-0.27) <0.001 0.15(0.08-0.28) <0.001 
DENV3 16 17/67 25.4 35/83 42.2 0.49(0.23-1.06) 0.07 0.45(0.24-0.85) 0.014 
DENV4 49 60/229 26.2 92/232 39.7 0.54(0.30-0.96) 0.037 0.55(0.31-0.97) 0.040 
All 105 276/695 39.7 360/736 48.8 0.69(0.49-0.98) 0.035 0.69(0.49-0.96) 0.030 
*Marginal logistic regression models for adjusted for plasma viremia  !
Supplementary Table 3. Covariates and their association with successful DENV transmission among positive abdomen 
 
Saliva (among positive abdomen) 
Variable 
Aegypti Albopictus 
Adjusted OR(95%CI) p value Adjusted OR(95%CI) p value 
Day of illness at enrolment (+1 day) 0.99(0.73-1.34) 0.95 1.07(0.78-1.46) 0.70 
Viremia (+1 log -copies/ml) 1.01(0.78-1.31) 0.95 1.57(1.20-2.05) <0.001 
Serotype 
    DENV1 1.00(reference) 
 
1.00(reference) 
 DENV2 1.68(0.93-3.01) 0.08 0.17(0.08-0.35) <0.001 
DENV3 0.65(0.31-1.36) 0.26 0.31(0.11-0.91) 0.032 
DENV4 0.62(0.34-1.11) 0.10 0.29(0.16-0.51) <0.001 
Serology 
    Primary 1.00(reference) 
 
1.00(reference) 
 Secondary 0.91(0.49-1.71) 0.77 1.11(0.63-1.95) 0.72 
Indeterminate 0.74(0.32-1.73) 0.49 0.42(0.17-0.99) 0.049 
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4. CLINICAL MANAGEMENT 
Background 
There is an unmet need for an effective dengue therapeutic. An intervention that shortens the 
duration of illness and prevents or attenuates severe manifestations of disease would 
represent a major public health advance. In addition, there remain many questions about the 
optimal way to manage those patients with severe disease in terms of fluid management and 
the use of blood products. Dengue drug development is hampered by the lack of a suitable 
animal model of disease – it is possible that novel approaches such as the use of a dengue 
human infection model (DHIM) may assist this effort. 
Outline of papers 
Dengue therapeutics review  
This monograph aims to explain the rationale for a dengue therapeutic and to consider the 
current state of dengue therapeutics research. 
Lovastatin for dengue trial protocol  
HMG-CoA reductase inhibitors, or statins, were originally developed for lipid lowering and 
mortality reduction in cardiovascular disease.32 More recent research has demonstrated that 
statins have effects beyond their lipid-lowering properties, and it is thought that part of the 
mortality benefit seen with statins in cardiovascular disease is mediated through these anti-
inflammatory pleiotropic effects.33 These pleiotropic effects include the restoration or 
improvement of endothelial cell function, increasing production of nitric oxide, reducing the 
release of cytokines and acute phase proteins and reducing inflammatory responses within the 
vessel wall.34,35 As protein isoprenylation is involved in various intracellular signalling processes, 
it is thought that these beneficial effects are, in part, mediated through statin inhibition of the 
mevalonate pathway and thus inhibition of isoprenoid formation.33 These isoprenoid 
intermediates serve as attachment sites for proteins such as Rho, which is involved in the 
expression of pro-inflammatory cytokines. Furthermore, statins result in increased nitric oxide 
bioavailability and thus improved endothelial function as a result of their effect on the production 
of reactive oxygen species and on the activity of the enzyme nitric oxygen synthase.36 Statins 
have been shown to reduce the expression of pro-inflammatory cytokines in patients with 
hypercholesterolaemia, therefore controlling the migration of leucocytes to areas of endothelial 
inflammation.37 There is thought to be some overlap between the inflammatory processes seen 
in atherosclerosis and sepsis, and it has been proposed that chronic exposure to 
lipopolysaccharide is important in the pathogenesis of atherosclerosis.38 Various observational 
studies have suggested that a prior history of statin therapy is associated with improved 
outcomes for a diverse range of conditions including sepsis and pneumonia.39-47 A study in 
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healthy volunteers showed that the inflammatory response to endotoxin was suppressed in those 
receiving a statin at a high dose, perhaps explaining its beneficial effect observed in sepsis.35,48 
One of the major features of both dengue and sepsis is endothelial dysfunction resulting, in part, 
from exposure to inflammatory mediators.49-51 This suggests that in view of their pleiotropic 
effects, it is plausible that statins may favourably augment the pathophysiological mechanisms of 
these two conditions. However prospective clinical trials investigating their role as an adjunctive 
therapy in severe conditions have recently reported and the results have been disappointing. For 
example, a trial investigating the role of simvastatin as an adjunctive therapeutic for ventilator-
associated pneumonia was stopped early for futility.52 A trial investigating the role of atorvastatin 
as an adjunctive therapy in patients with severe sepsis showed no benefit of commencing de 
novo statin therapy in this group but suggested that prior statin use was associated with more 
favourable cytokine concentrations and better survival results.53 Furthermore, trials investigating 
the potential role of statins as adjuncts in acute respiratory distress syndrome (ARDS) and 
chronic obstructive pulmonary disease (COPD) showed no benefit.54,55 All of these trials reported 
after the date of commencement of patient recruitment into the trial of lovastatin in adult dengue 
cases reported in this thesis. 
Flavivirus replication is lipid-dependent and in vitro work has demonstrated that lovastatin may 
have some antiviral properties by reducing DENV virion assembly.56-58 This is postulated to occur 
through the blocking of viral transport from the endoplasmic reticulum to the Golgi apparatus in 
infected cells. It is therefore possible that statins may have a useful adjunctive role in dengue in 
view of both their endothelial stabilising effects and their potential antiviral activity. In addition, the 
low cost and safety profile of statins make them attractive therapeutic candidates. However the 
rare but recognised adverse events associated with statin therapy such as hepatitis and muscle 
inflammation, overlap with the clinical features of dengue making the safety of such a therapeutic 
approach a key question to address. To this end we designed and conducted a randomised, 
double-blind, placebo-controlled trial investigating the effects of short course lovastatin in adult 
patients with dengue. The primary endpoint of this trial was safety but it was also sufficiently 
large to address a priori defined secondary endpoints related to clinical and virological features of 
dengue. 
Lovastatin for dengue trial results 
The results of a randomised double-blind, placebo-controlled trial of five days lovastatin are 
presented. The trial was conducted in two phases. The first phase investigated 40mg 
lovastatin versus placebo in 30 patients, and the second phase investigated 80mg of 
lovastatin versus placebo in 300 patients. There was no difference in adverse event rates 
between treatment arms and no evidence of a beneficial effect on the a priori clinical and 
virological endpoints. These results showed that lovastatin was safe and well tolerated in 
dengue but that there was no evidence of a beneficial therapeutic effect.    
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Platelets in dengue survey 
As discussed above thrombocytopenia is a very common feature of dengue. In some settings 
the concern about bleeding leads clinicians to administer platelet transfusions as prophylaxis 
against haemorrhage. This approach lacks an evidence base and is potentially dangerous as 
it exposes patients to blood products and may represent an unnecessary fluid challenge at a 
time when fluid management is critical. To establish a clearer idea about clinical practice 
related to this area we designed a survey with different clinical scenarios and distributed it to 
clinicians involved with dengue management in 20 countries. The survey responses showed 
a wide variety in approaches to the use of platelets in dengue. The survey findings 
underscore the need to conduct clinical trials to better establish an evidence base to guide 
management in this area. It is possible that the on-going ADEPT trial currently recruiting in 
Singapore will better clarify the evidence in this area (ClinicalTrials.gov identifier 
NCT01030211).  
Dengue human infection model 
This monograph considers how a DHIM has the potential to be a game changer in the 
development of dengue therapeutics. It was written in light of a recently performed DENV 
challenge given to human recipients of a live dengue vaccine candidate.59 We consider how 
the controlled approach inherent to a DHIM would further dengue therapeutic research by 
allowing the study of pre-selected susceptible volunteers thus potentially reducing the sample 
size required to conduct an efficacy study. In addition, the approach would facilitate the study 
of pharmacokinetics and aid the choice of the optimal dosing strategy and potentially answer 
the question as to whether chemoprophylaxis is feasible in dengue. 
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Abstract: Dengue is the most common arboviral disease
of humans. There is an unmet need for a therapeutic
intervention that reduces the duration and severity of
dengue symptoms and diminishes the likelihood of severe
complications. To this end, there are active discovery
efforts in industry and academia to develop interventions,
with a focus on small molecule inhibitors of dengue virus
replication that are suitable for therapy or chemoprophy-
laxis. Advancements in animal models of dengue virus
infection together with the possibility of a dengue human
infection model have further enhanced the platform for
dengue drug discovery. Whilst drug discovery efforts
gestate, there are ongoing clinical research designed to
benefit today’s patients, including trials of supportive care
interventions, and descriptive studies that should improve
the ability of clinicians to make an accurate diagnosis early
in the illness course and to identify patients most at risk of
progression to severe disease. This review provides a state
of the art summary of dengue drug discovery, clinical
trials, and supportive allied research and reflects discus-
sions at the 2nd International Dengue Therapeutics
Workshop held in Ho Chi Minh City, Vietnam, in December
2013.
Introduction
The global dengue pandemic represents a major 21st-century
public health challenge, with approximately 3,000,000,000 people
living in areas at risk of transmission [1,2]. Dengue causes
individual suffering to those affected but also significant economic
costs to endemic countries, as hospitals are frequently over-
whelmed by dengue patients and those affected are unable to
attend school or go to work [1].
Dengue is a systemic viral infection caused by any of the dengue
viruses (DENV), of which there are four types, DENV-1–4. DENV
are members of the Flaviviridae family and possess a single-
stranded positive-sense RNA genome that encodes three structural
proteins and seven nonstructural proteins. Infection of susceptible
human hosts occurs after the bite of an infectious mosquito,
usually Aedes aegypti. In susceptible human hosts, DENV
replication likely occurs predominantly in cells of the reticuloen-
dothelial system [3,4]. Virus produced from infected tissues results
in a viremia that can allow for onward transmission of DENV to
naı¨ve mosquitoes that take a blood meal [5]. Dengue is a self-
limiting febrile illness, which, although often debilitating, typically
resolves after 4–7 days of symptoms without major complications.
Common symptoms include lethargy, headache, myalgia, nausea,
vomiting, and rash. Viremia is apparent 1–2 days prior to the
onset of symptoms, peaks during the first 1–2 days of fever, and
then declines over the next 3–5 days until resolution.
A small proportion of people who develop dengue do
experience severe complications during the illness. The most
common complication identified is a significant increase in
vascular permeability secondary to a transient vasculopathy;
typically, this becomes apparent between the fourth and sixth
day of illness, at a time when viremia is in steep decline or has
resolved and the patient is afebrile [6]. In some patients,
predominantly but not exclusively older children and young
adults, significant vascular leakage occurs and can result in life-
threatening hypovolaemic shock, with or without haemorrhage
[1]. Various host and viral factors influence the eventual clinical
phenotype of a DENV infection [7]. Current treatment is limited
to fluid resuscitation and supportive care [8]. To prevent the
complications that are typically observed between the fourth and
sixth day of illness would require the administration of a
therapeutic earlier in the course of illness. This raises a number
of challenges—patients may not present to healthcare settings
early in their illness, differentiating dengue from other febrile
illnesses (OFI) is not easy, rapid diagnostic tests are relatively costly
and not always available, and identifying patients at risk of severe
disease and thus most likely to benefit from a therapeutic remains
difficult. In addition, despite considerable research efforts, the
pathogenesis of dengue remains incompletely understood [7].
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These factors are challenges to the programmatic use of a dengue
therapeutic in routine clinical practice.
To date, few trials of new specific therapeutic interventions have
been conducted. However, this landscape is rapidly evolving,
driven by a growing awareness of the scale of the disease burden
[2], economic changes in endemic countries that are creating
viable markets, and strong basic science that is supporting rational
drug discovery and testing in small animal models. This article
reflects discussions held at the 2nd International Dengue
Therapeutics Workshop held in Ho Chi Minh City in December
2013 and attended by delegates from academia, industry, and
funding agencies. It aims to illustrate the ‘‘state of the art’’ in
dengue therapeutics discovery, clinical intervention trials, and
enabling allied research.
Target product profile for a dengue therapeutic
There remains an unmet need for an effective dengue
therapeutic that can shorten the duration of illness, reduce the
severity of common symptoms, and prevent the development of
severe complications such as dengue shock syndrome (DSS). An
example of a target product profile for an antiviral dengue drug is
shown in Table 1. Desirable properties of a therapeutic candidate
include low cost, ease of administration, and an excellent risk-
benefit profile. While preliminary studies will typically be
conducted in adults, it is important that children also be taken
into consideration when developing the target product profile, as
the disease burden of dengue falls most heavily on this age group.
State of the Art in Small Molecule Therapeutic
Trials in Dengue
Between 2007 and 2013, ten therapeutic trials in dengue
patients were reported [9–18]. These have varied in size, quality,
and design. Studies that have adopted a conventional randomised
controlled approach have included trials of chloroquine, prednis-
olone, lovastatin, celgosivir, and balapiravir [16–20]. Chloroquine
was investigated for both its antiviral properties and its potential
ability to modulate the immune response to infection; however, the
trial (n = 307 adult patients) did not demonstrate any clear
antiviral or clinical benefits [16]. Prednisolone was investigated
for its immunomodulatory properties with the hope that early
initiation of therapy would prevent or attenuate severe manifes-
tations of disease. The trial (n = 225 paediatric patients) was
powered for safety but yielded no evidence of therapeutic benefit
[18] and very limited evidence of attenuation of the host immune
response [21]. Balapiravir, a prodrug of a nucleoside analogue,
was clinically investigated as a candidate dengue antiviral on the
basis of in vitro findings. However, the absence of a strong
antiviral signal in 69 adult dengue patients led to cessation of the
trial [17]. Subsequent work has indicated balapiravir is poorly
metabolised to its active moiety in immune-activated cells,
suggesting a possible explanation for the clinical trial outcome
[22]. Another antiviral candidate, celgosivir, is a cellular glucosi-
dase inhibitor. In vitro studies suggested celgosivir had antiviral
activity against all four serotypes of DENV, and further in vivo
work using a lethal mouse model showed celgosivir had antiviral
activity against DENV-2 [23]. A clinical trial of celgosivir in 50
adult dengue cases suggested celgosivir was safe and well tolerated,
but there was no evidence of an antiviral effect at the doses used
[20,24]. Inhibitors of HMG-CoA reductase, known as statins,
were originally developed as lipid-lowering agents and have an
established role in cardiovascular risk modification [25]. More
recent research has shown that they have anti-inflammatory and
endothelial-stabilising properties, and this has prompted the
investigation of these drugs as adjunctive therapeutics for a range
of conditions such as sepsis, pneumonia, and acute lung injury
[26–28]. Based on the potential benefit of the properties of statins
on the endothelium and as an immunomodulatory agent, it is
plausible that they may have a beneficial effect in dengue. A trial
of early lovastatin therapy in adult dengue cases is ongoing [19].
State of the Art in Supportive Care Trials
Judicious fluid resuscitation is critical to the successful manage-
ment of patients with severe dengue [8]. Isotonic crystalloid fluids
(e.g., 0.9% normal saline and Ringer’s lactate) are recommended
for initial resuscitation of those with shock [1,29,30]. Colloid
solutions (e.g., hydroxyethyl starch and Gelofusine) are suggested
for patients with profound shock or for those who do not respond
to initial resuscitation with crystalloids [8,29]. There remain
questions surrounding the optimal fluid management of the
critically ill dengue patient, particularly for the estimated 30% of
DSS cases who suffer recurrent episodes of shock [31,32]. The
safety of starch solutions, currently integral to resuscitation of
severe dengue patients in many endemic countries, has also been
called into question [33,34]. While these safety concerns have
generally arisen in elderly patients, often with comorbidities, and
thus may not be relevant to the management of previously healthy
children and young adults, they make the establishment of a clear
evidence base for the optimal fluid resuscitation of patients with
Table 1. Target product profile for a dengue therapeutic.
Profile Ideal
Target population Adults and children (including infants and pregnant women)
Dosing frequency Once daily
Formulation Water-soluble tablet that can be dissolved in a small amount of liquid
Pill burden One tablet daily
Pharmacokinetic Half-life that enables once daily dosing
Bioavailability Fast acting, high volume of distribution
Interactions Minimal interactions with commonly used supportive care drugs
Safety Well tolerated; no need for lab monitoring
Stability No need for cold chain; 1–2-year shelf life at room temperature
Cost To be investigated; needs to be affordable in dengue-endemic countries
doi:10.1371/journal.pntd.0003025.t001
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single or recurrent episodes of shock ever more pressing. In
addition, the previous fluid intervention studies in dengue were all
conducted in children; given the diverse epidemiology of dengue,
with adults representing the majority of cases in some countries, it
is important that future fluid trials include adult patients [35,36].
Thrombocytopenia is almost universally observed in patients
with dengue [1]. Despite a lack of evidence, prophylactic platelets
are commonly administered in the belief that they can prevent
haemorrhage [37]. This practice is both costly and potentially
dangerous, as it constitutes administration of a blood product and
a fluid challenge at the point of infection when fluid balance is
critical [38–41]. A recently completed trial (n = 87 patients)
suggested that administration of prophylactic platelets has no
therapeutic benefit and is associated with an increased risk of
harm—three patients who received platelets developed severe
transfusion reactions [42]. The Adult Dengue Platelet Study
(ADEPT) trial aims to further clarify the evidence for the use of
prophylactic platelets in dengue (ClinicalTrials.gov identifier
NCT01030211).
State of the Art in Discovery of Antiviral Therapies
Encouragingly, a number of institutions, both academic and
pharmaceutical, are actively engaged in dengue therapeutic
discovery and development.
Novartis Institute of Tropical Diseases (NITD)
NITD has made a concerted effort to search for dengue
antiviral candidates. NITD has investigated host and virus protein
targets using both a cell-based infection approach and a target-
based rational approach [43]. Although several interesting
inhibitors with various modes of action have been identified,
some of which have demonstrated in vivo efficacy in mouse
models, as yet none have advanced to the point of a clinical trial
[44,45]. However, the knowledge gained from these efforts has
provided a better rationale for ongoing dengue drug discovery.
Unither Virology
Unither Virology is attempting to develop a broad-spectrum,
host-enzyme-targeted antiviral drug using an iminosugar platform.
Iminosugars inhibit host alpha-glucosidases that are required for
viral glycoprotein modifications. Inhibition of cellular glucosidase
suppresses viral replication by disruption of productive folding
pathways of the envelope glycoproteins prM (the intracellular
glycosylated precursor of M [membrane protein]) and E (envelope
protein). Encouraging results were seen with the leading candi-
date, UV-4, in a mouse model of DENV infection [46].
Monoclonal antibodies for dengue
Therapeutic antibodies are also being explored to block dengue
virus infection. Several potent monoclonal antibodies have been
developed, including one that selectively neutralises DENV-1 [47].
Two challenges were perceived for the antibody approach: (1) it is
likely that a panel of antibodies will be needed to inhibit all four
serotypes of virus, and (2) the relatively high cost and requirement
for parenteral administration may limit deployment in many
endemic countries. It remains to be determined whether a single
antibody that can potently neutralize all four serotypes can be
developed.
University of Leuven
Drug discovery at the University of Leuven has focused
primarily on viral proteins using a cell-based screening approach
and a wealth of experience gained from their research on hepatitis
C and HIV therapeutics [48]. Currently, the lead dengue antiviral
candidate is an inhibitor of nonstructural protein 4B (NS4B),
which shows antiviral activity across all four serotypes and in a
variety of cell lines.
University of Marseilles
Work at the University of Marseilles is mainly focused on the
screening of potential inhibitors of viral RNA-dependent RNA
polymerase activity. A panel of polymerase inhibitors with both
enzymatic and cellular activities has been identified. Efforts are
ongoing to improve the potency of these inhibitors, as well as to
identify their binding sites through biophysical and structural
studies.
University of Queensland
Investigators at the University of Queensland have been using
cell electrical impedance measurements as a correlate of cell fusion
mediated by enveloped viruses. This novel approach provides a
high-throughput screening platform for the investigation of
potential inhibitors of viral fusion. Besides flaviviruses, the
approach could be applied to screen for fusion inhibitors of other
enveloped viruses.
Monash University
Researchers at Monash University are exploring the possibility
of using inhibitors of nuclear transport as anti-DENV compounds
[49]. In DENV infection, nonstructural protein 5 (NS5) localises in
the nucleus through an interaction with importin-a1/b1 (IMPa1/
b1). Intriguingly, the antiparasitic agent, ivermectin, has been
shown to inhibit this interaction and reduce viral production [50].
Interestingly, ivermectin was also reported to inhibit flavivirus
helicase activity [51]. Furthermore, the well-established safety
profile of ivermectin demonstrated through its use in mass drug
administration programmes makes this an attractive therapeutic
candidate to investigate further.
State of the Art in Research Tools Supporting
Dengue Drug Development
Funding resources for developing dengue therapeutics
Several government funding agencies and research charities
around the world are currently supporting research on dengue,
including the United States National Institutes of Health (NIH),
the European Framework Programme, the Wellcome Trust
(United Kingdom), and the Agency for Science, Technology,
and Research (Singapore). The NIH, mostly through the National
Institute of Allergy and Infectious Diseases (NIAID), is currently
supporting several research projects to elucidate the basic biology
of dengue virus and the mechanisms of disease development and
to develop and evaluate therapeutics, diagnostics, and vaccines. A
list of NIH-supported projects on dengue can be found on NIH
Research Portfolio Online Reporting Tools (RePORT) (http://
report.nih.gov/index.aspx). There are different funding mecha-
nisms at the NIH to obtain support for dengue research. These
include the following: (1) grant mechanisms, some of which focus
on international research or product development partnerships
(http://www.niaid.nih.gov/researchfunding/ann/pages/opps.aspx),
and (2) preclinical and clinical research resources. These research
resources include dengue reagents, bioinformatic databases, in
vitro antiviral screening, evaluation of therapeutics in animal
models, therapeutic preclinical development services, and clinical
evaluation. Information about NIAID research services and
contact information can be found at http://www.niaid.nih.gov/
labsandresources/resources/Pages/default.aspx.
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A list of additional funding sources can be found at http://www.
niaid.nih.gov/researchfunding/ann/pages/found.aspx.
Mouse models of DENV infection
Mice deficient in interferon-a/b and interferon-c receptor
(AG129) are susceptible to DENV infection and can experience a
fulminant and fatal infection under certain experimental condi-
tions using DENV2 strains [52,53]. Ongoing work aims to develop
mouse models of disseminated disease with other DENV serotypes
and to replicate the severe disease that occurs in primary infections
in some infants born to immune mothers [54]. As such, mouse
models like the AG129 system provide a valuable mechanism to
evaluate inhibitors of DENV infection and replication under in
vivo conditions. One limitation of mouse models, however, is that
they do not replicate the temporal sequence of the virological and
common clinical events seen in humans with severe dengue, in
particular the occurrence of hypovolemic shock relatively late in
the illness course at a time when DENV infection of tissues has
very nearly or already resolved. It may be that the vasculopathy
seen in some DENV-infected patients is a phenomenon unique to
humans. Thus, dengue mouse models may have limited utility in
assessing interventions that target the cascade of host-mediated
responses that are believed to partly underlie the syndrome of
severe dengue in humans.
Nonhuman primates and dengue
Nonhuman primates (NHPs), such as rhesus macaques (Macaca
mulatta), are naturally susceptible to DENV infection and develop
a viremia of similar duration to humans, yet they rarely manifest
clinical signs or symptoms [55]. A trial of nonpegylated interferon
in rhesus monkeys yielded a delay to peak viremia but with no
change in the overall area under the curve. In another trial of
recombinant pegylated interferon therapy versus placebo, a log
decrease in viremia was observed over several days with a trend
towards improved viral clearance, but the magnitude of the
response was not deemed to be clinically useful [56]. NHPs have
rarely been used in dengue drug development, perhaps because of
the cost and the scarcity of laboratories capable of performing such
studies. However, several NHP models have been developed that
address different dengue manifestations [56–58]. These models
could be utilized as part of a rational drug development plan,
particularly for the advancement of novel drug entities, including
direct-acting antiviral agents. In these scenarios, NHPs could
provide the opportunity to conduct prophylactic and therapeutic
trials in an animal model in which the virological and immuno-
logical features of disease are likely more ‘‘human-like’’ than in
mice.
Dengue human infection models (DHIM)
US Army researchers are developing a DHIM, whereby
flavivirus-naı¨ve adults are experimentally challenged with a
DENV-1 virus strain that previously proved insufficiently atten-
uated to be used as a vaccine candidate for the purposes of vaccine
development [59]. This is not a novel concept. Over 700 subjects
have participated in such trials spanning from 1902 until the
present time [60]. Rederivation of the challenge strain is in
process, and an initial small-scale human trial to demonstrate the
safety of the strain is currently being planned.
The administration of a dengue human infection will be
conducted with all the current safeguards to protect human
volunteers. The study would be done under a Food and Drug
Administration (FDA) Investigational New Drug (IND) appli-
cation, with independent review by both scientists and
ethicists. The human volunteers would be informed of the
study design, why the study was being done, and of the risks
and the benefits of being in the trial. One challenge for the
DHIM is that it should replicate the features of naturally
acquired DENV infection, and early studies suggest this is
possible [60]. A DHIM would also support the fast-track
development of potential therapeutics, as it would allow for
experimentally controlled trials of chemoprophylaxis and
therapy and for detailed pharmacokinetic and basic research
studies in preselected individuals.
Physiological endpoints in therapeutic studies
As early phase research of novel therapeutic candidates is often
exploratory and focused on safety, it is necessary to investigate
surrogate markers of clinical impact rather than the major clinical
complications themselves, e.g., DSS. Sensitively measuring the
endothelial response to specific interventions in early-phase clinical
trials would be ideal. Various noninvasive techniques have been
developed that assess functional properties of the endothelium
[61]. Peripheral artery tonometry is a user-independent method of
measuring endothelium-dependent microvascular reactivity.
Changes in microvascular reactivity have been shown to
correlate with disease severity and outcome in sepsis and
malaria [62,63]. Alternatively, techniques such as videomicro-
scopy can be used to directly evaluate microcirculatory networks
and perfusion status; studies using this method have demon-
strated altered microcirculation in severe sepsis, again with
correlations with the severity of organ dysfunction and outcome
[64,65]. These techniques have been used to monitor responses
to particular therapies in other infectious diseases and may have
a role as proxy endpoints for clinical trials in dengue [66–68]. It
is possible that using noninvasive techniques that assess
endothelial function and microcirculation may provide useful
correlates of the capillary leak that is characteristic of severe
dengue—ongoing observational research aims to evaluate this
potential role [63,69].
Clinical descriptive studies and diagnostic/prognostic
signs and symptoms
A number of important issues complicate the management of
potential dengue cases in endemic areas. First, given the
nonspecific nature of the symptoms and signs during the early
febrile phase, establishing a firm clinical diagnosis without reliance
on expensive diagnostics is difficult. Second, prediction of risk for
the development of complications such as shock due to systemic
vascular leakage is currently poor. A prospective multicentre
observational study, aiming to enrol 10,000–12,000 outpatients
presenting with a febrile illness consistent with possible dengue,
is currently underway in seven countries across Southeast Asia
and Latin America and is expected to report in 2016 (www.
idams.eu). The availability of improved strategies for early
diagnosis and risk prediction, ideally using a simple laboratory
or a laboratory and clinical algorithm, would not only greatly
facilitate patient triage but likely also enhance the productivity
of clinical trials of early therapeutic interventions by focusing
enrolment towards patients at greatest risk of complications. In
high-risk patients, it may be easier to differentiate the treatment
effect between the existing standard of care versus the standard
of care plus the clinical intervention. From a practical
perspective, a clinical trial enrolling patients at the highest risk
of developing complications could reduce the size, duration, and
cost of dengue randomised controlled trials, since the patient
population would be enriched for the main endpoints of clinical
relevance and interest.
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State of the Art in Prospects for Dengue
Chemoprophylaxis
The concept of chemoprophylaxis for dengue has not been
widely discussed as yet. Nonetheless, there are plausible scenarios
and population groups that might benefit from an orally available
chemoprophylactic agent. For example, aid workers, missionaries,
and military travellers to dengue epidemic settings or ‘‘at risk’’
individuals living in areas of focal transmission in an endemic
setting might benefit from chemoprophylaxis. Prophylactic deliv-
ery of a dengue antiviral compound has the theoretical advantage
of interrupting the course of infection earlier than a therapeutic
drug, i.e., prior to the development of peak viremia. However, a
chemoprophylactic agent would need to be orally available, have
an extremely good safety profile, and possess pharmacokinetic
characteristics that allow for relatively infrequent dosing. Addi-
tional issues requiring further consideration, particularly for
endemic settings, concern the identification of suitable target
groups, the duration of dosing, and the risk-benefit ratio.
Conclusions
There remains an unmet need for an effective dengue
therapeutic or prophylactic, particularly in light of the continuing
geographic expansion of dengue and the lack of an effective
vaccine [2,70]. This article has summarised the state of the art in
the field of dengue therapeutics and the potential future land-
scape of therapeutic research. Increased collaboration between
academia and industry, perhaps through public-private partner-
ships, is likely to be necessary for the successful development of an
effective dengue therapeutic [43]. There remain many questions,
foremost of which is whether an antiviral intervention can have a
positive clinical impact when peak viremia typically occurs in the
first 48 hours of illness and before most patients seek medical care.
The dengue drug development field will benefit from a consensus
on methodological approach in the conduct of early phase trials,
common case report forms, and data sharing; efforts to provide
these to the research community are underway [71]. In the long
run, it is likely that a dengue therapeutic (or prophylactic) small
molecule would fit into a ‘‘package’’ of dengue control measures
comprising immunisation, vector control, and individual therapy.
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Abstract
Background: Dengue is the most important vector-borne viral infection of man, with approximately 2 billion
people living in areas at risk. Infection results in a range of manifestations from asymptomatic infection through to
life-threatening shock and haemorrhage. One of the hallmarks of severe dengue is vascular endothelial disruption.
There is currently no specific therapy and clinical management is limited to supportive care. Statins are a class of
drug initially developed for lipid lowering. There has been considerable recent interest in their effects beyond lipid
lowering. These include anti-inflammatory effects at the endothelium. In addition, it is possible that lovastatin may
have an anti-viral effect against dengue. Observational data suggest that the use of statins may improve outcomes
for such conditions as sepsis and pneumonia. This paper describes the protocol for a randomised controlled trial
investigating a short course of lovastatin therapy in adult patients with dengue.
Methods/design: A randomised, double-blind, placebo-controlled trial will investigate the effects of lovastatin
therapy in the treatment of dengue. The trial will be conducted in two phases with an escalation of dose between
phases if an interim safety review is satisfactory. This is an exploratory study focusing on safety and there are no
data on which to base a sample size calculation. A target sample size of 300 patients in the second phase, enrolled
over two dengue seasons, was chosen based on clinical judgement and feasibility considerations. In a previous
randomised trial in dengue, about 10% and 30% of patients experienced at least one serious adverse event or
adverse event, respectively. With 300 patients, we will have 80% power to detect an increase of 12% (from 10% to
22%) or 16% (from 30% to 46%) in the frequency of adverse events. Furthermore, this sample size ensures some
power to explore the efficacy of statins.
Discussion: The development of a dengue therapeutic that can attenuate disease would be an enormous advance
in global health. The favourable effects of statins on the endothelium, their good safety profile and their low cost
make lovastatin an attractive therapeutic candidate.
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Background
Dengue is the most common and important vector-
borne viral infection of man, with at least 2 billion
people living in areas of risk [1]. Clinical dengue varies
from asymptomatic infection to severe disease charac-
terised by shock and haemorrhage. There are currently
no specific therapeutic agents and disease management
is limited to careful fluid management [2,3].
Statins
Statins are inhibitors of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase. They were first
used clinically in the late 1980s and quickly became
established as an effective drug for both lipid lowering
and mortality reduction in cardiovascular disease [4].
They are currently one of the most prescribed classes of
drugs globally. Statins have an excellent safety profile
[5]. The most common adverse effects are rises in the
level of liver transaminases and myopathy. These effects
are rare and appear to be dose-related [5,6]. More recent
research has demonstrated that statins have additional
beneficial effects. These pleiotropic effects include the
restoration or improvement of endothelial cell function,
an increased production of nitric oxide, and a reduction
in the release of cytokines and acute phase proteins.
These effects lead to a reduction of inflammation within
the vessel wall [7,8]. Observational studies suggest that
statin therapy may result in improved outcomes for a di-
verse range of conditions, including sepsis and pneumo-
nia [9-13]. In addition, there are a number of on-going
randomised clinical trials to assess the therapeutic effi-
cacy of statins in sepsis and acute lung injury
(NCT00528580, NCT00676897, NCT00979121).
Statins and dengue
One of the major features of both dengue and sepsis is
widespread vascular endothelial disruption resulting, in
part, from exposure to inflammatory mediators [14-16].
This suggests that in view of their pleiotropic effects, it
is plausible that statins may favourably augment the
pathophysiological mechanisms of these two conditions.
A study in healthy volunteers showed that the
endotoxin-induced inflammatory response was sup-
pressed in those receiving a statin at a high dose (sim-
vastatin 80 mg), perhaps explaining the beneficial effect
observed in sepsis [8,17]. Furthermore, in vitro work has
demonstrated that lovastatin may have an anti-viral ef-
fect in dengue by reducing virion assembly [18,19].
Choice of study drug
We have chosen lovastatin as the study drug for both
scientific and pragmatic reasons. In light of the US Food
and Drug Administration’s safety recommendations
about the risks of muscle toxicity with simvastatin, there
were concerns from the regulatory authorities in Vietnam
about the safety of using this agent in dengue. An additional
reason for our choice was the dengue anti-viral effect
observed with lovastatin in in vitro experiments [18]. As
this effect may also be observed in vitro, we believe it is
rational to test the drug used in the original work. Further-
more, lovastatin is commonly prescribed and available in
Vietnam as a generic and will therefore be immediately
available to patients if there is a positive result from the
trial.
Aims of the trial
Typically, severe vascular leakage and shock occur
around the fifth day of illness in patients with dengue
[20]. It is possible that initiation of statin therapy early
in the course of the illness may prevent or favourably
modulate these effects. As the proportion of patients
who develop shock or other complications after presen-
tation to hospital is low (approximately 5%), a large trial
would be required to demonstrate a clinical benefit
[2,21]. However, this study presents an opportunity to
assess formally the safety of using statins in the treat-
ment of this disease. In addition, such a study will also
provide an opportunity to investigate the effect of statin
usage on the immune response during dengue infection
and to generate preliminary data for planning a Phase III
trial in the future.
Although there is extensive experience of using statins
as a lipid-lowering agent, and an increase in the amount
of observational data from their use in critically ill
patients, this will be the first study looking at the use of
statins in dengue. We propose to investigate the effect of
lovastatin for 5 days in adult dengue patients presenting
in the first 72 hours of illness. The rational of a 5-day
treatment course is to cover the transient ‘critical’ phase
of infection when complications arise, which typically
occurs around the fifth day of illness [3]. Our proposed
treatment course will start on the second or third day of
illness and continue to the seventh or eighth day of
illness, which is into the recovery phase. As this is the
first study investigating statin therapy in dengue with a
particular focus on safety, we propose a dose-escalation
study, investigating 40 mg lovastatin versus placebo with
a safety review after recruitment of the first 30 patients.
If this review is satisfactory, we will increase the lovasta-
tin dose to 80 mg and conduct a further safety review
after the next 30 patients.
Methods/design
Design
This study is a randomised, placebo-controlled, double-
blind trial investigating lovastatin therapy in Vietnamese
adults with dengue infection. The trial will be conducted
in two phases, with an escalation of dose between phases
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if the results of an interim data review show no safety
concerns within the first cohort of patients treated with
the lower dose.
Patients will be followed for clinical and laboratory
endpoints in hospital until study day 6 (or daily as out-
patients from discharge to day 6) and reviewed at an
outpatient visit on day 28.
Inclusion and exclusion criteria
All patients aged 18 or more presenting to the Hospital
of Tropical Diseases, Ho Chi Minh City with a clinical
suspicion of dengue, less than 72 hours of fever and a
positive rapid test for dengue non-structural protein 1
(NS1) will be eligible for recruitment into the study. Ex-
clusion criteria are: signs or symptoms suggestive of an-
other acute infectious disease, alanine transaminase
levels greater than 150 U/l, creatine kinase levels greater
than 1000 U/l, liver cirrhosis, myopathy, current or use
within past week of statins, pregnancy and lactation. In
addition, patients taking medications contraindicated for
use with statins, for example, isoniazid for treatment of
tuberculosis, will be excluded.
Primary endpoint
The primary endpoint of this study is an evaluation of
the safety and tolerability of lovastatin therapy in adult
patients with dengue. Comparing the rates of adverse
events between randomised treatment arms will assess
this.
Secondary endpoints
The secondary endpoints of this study are fever clear-
ance time (see definition), plasma viraemia (area under
the log-transformed viraemia curve from enrolment
until study day 6), platelet nadir between day 3 and 8 of
illness, maximum haematocrit between day 3 and 8 of
illness, percentage increase in haematocrit between day
3 and 8 of illness from baseline, maximum alanine trans-
aminase (ALT) and creatine kinase (CK) recorded be-
tween day 3 and 8 of illness, lowest oxygen saturation
recorded between day 3 and 8 of illness, number of
patients in each group requiring colloid, and disease
progression as defined by one or more of the following:
(a) admission to the ICU, (b) diagnosis of shock (see
definition), (c) diagnosis of severe bleeding (see defin-
ition), (d) development of encephalitis, (e) death. In
addition, quality of life scores obtained using a visual
analogue scale will be compared between treatment
groups. The times from enrolment to the first sample
with viraemia less than 1000 copies/ml and the first
negative NS1 antigenaemia sample will be compared be-
tween treatment groups.
Definitions
1. Fever clearance time is the time from enrolment to
the first time the temperature falls to <37.5°C and
remains below this level for 48 hours.
2. Shock: cardiovascular decompensation requiring fluid
resuscitation and considered to be due to plasma
leakage.
3. Severe bleeding is clinically severe if it results in
haemodynamic instability or requires fluid
resuscitation or a blood transfusion. Any bleeding
resulting in death and any intracranial bleed are
considered severe.
4. Baseline haematocrit: the haematocrit value obtained
at the day 28 follow-up visit, or (if the day 28 value is
missing) the expected age- and sex-matched
population value.
Randomization procedure
Randomization to either treatment arm will be in a 1:1
ratio. Randomization will be stratified according to the
ward of recruitment. A randomization list will be pre-
pared and maintained confidentially from study staff by
the clinical trials pharmacist. Block randomization using
variable block sizes will be used.
A chronological log of all enrolled patients will be
maintained. Each enrolled patient will be assigned the
next available sequential study code. The assigned num-
ber will correspond to a coded, sealed, pre-packaged bot-
tle containing six doses of either lovastatin or visually
matched placebo. Blinding will be maintained amongst
the attending physicians and nurses by ensuring that the
study drug and the placebo have an identical appearance.
In addition the administration schedule will be identical.
Enrolment
Patients presenting to the out-patients department or
in-patient wards with a clinical suspicion of dengue and
less than 72 hours of fever will be identified to study
staff. Study staff will approach these patients, check eli-
gibility criteria and confirm dengue by NS1 rapid test.
Eligible and consenting patients will have screening
blood tests sent and provided these are satisfactory will
be allotted the next consecutive study number and en-
rolled to the study.
Safety reviews
This trial will be conducted in two phases with an escal-
ation of dose if the results of an interim data review
show no safety concerns within the first cohort treated
with the lower dose. The dose will begin at 40 mg per
day in cohort 1 and may continue at 80 mg per day in
cohort 2. A DSMB (data and safety monitoring board)
review will take place when day 6 study data are
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available from the 30th patient enrolled in cohort 1. If
this review is satisfactory, the dose will be increased to
80 mg per day and recruitment into cohort 2 will com-
mence. Further DSMB reviews will take place when day
6 study data are available from the 30th and 100th
patients enrolled in cohort 2.
Treatment and drug dispensation
Patients will be assigned to one of two treatment arms:
! Active medicinal product: 40 mg (stage 1) or 80 mg
(stage 2) lovastatin once daily for 5 days.
! Placebo: visually matched placebo once daily for 5
days.
The first dose will be given as soon as practically pos-
sible after enrolment.
An unblinded study pharmacist will prepare study
drug bottles centrally and will distribute the bottles as
required. Drugs will be stored in accordance with the
manufacturers’ recommendations in a secure area.
Lovastatin and the placebo must be maintained below
25°C. All movements of study medication will be
recorded. Both individual subject and overall drug ac-
countability records will be kept up to date by the study
staff.
Data collection
Clinical evaluation
Patients will be followed by a study physician daily until
discharge, and all signs and symptoms recorded in the
case report form. An ultrasound scan will be performed
on day 6 of illness to detect signs of plasma leakage.
Clinical management decisions will remain in the hands
of the attending ward doctors. In the event that shock or
any other serious complication develops, the patient will
be transferred to the appropriate ICU. Details of all ad-
verse events will be recorded on specific forms, together
with an assessment as to whether the event is likely to
be related to any treatment received, and all serious
events will be reported promptly to the DSMB.
Quality of life will be measured by questionnaire and
visual analogue scale daily.
Patients who are fit to discharge on or after study day
3 may be followed as an outpatient until study day 6. All
patients will be asked for attend a follow-up visit for re-
view after 4 weeks.
Laboratory evaluation
Haematocrit, platelet and total cholesterol measure-
ments will be carried out daily or more frequently if
clinically indicated. These tests will be repeated at the
follow-up visit.
Renal and liver function tests, electrolytes and coagu-
lation profiles, will be carried out at enrolment, 48 hours
later, day 5 or 6 of illness and at the follow-up visit. If
the ALT measured 48 hours after enrolment is greater
than 250 U/l, the study drug will be discontinued. It
should, however, be noted that hepatic dysfunction
might be secondary to dengue infection and could be
positively affected by statin therapy.
Conventional serological and virological tests will be
used to confirm dengue infection and identify the infect-
ing serotype. Plasma samples collected at daily intervals
until discharge (and daily until day 6 if discharged before
day 6) will be assessed for viraemia levels, NS1 levels,
and concentrations of various pro- and anti-
inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-10).
DNA will be extracted from residual blood samples
and genotyped for genetic variants known to be asso-
ciated with severe dengue, for example, MICB and
PLCE1 [22].
Statistical considerations
Sample size
This is an exploratory study focusing primarily on safety
and there are no preliminary data regarding the effects
of statins in dengue on which to base a sample size cal-
culation. A target sample size of 300 patients in cohort
2, enrolled over two dengue seasons, was chosen based
on clinical judgement and feasibility considerations. In a
previous randomised trial in dengue, about 10% and 30%
of patients experienced at least one serious adverse event
or adverse event, respectively [23]. With 300 patients,
we will have 80% power to detect an increase of 12%
(from 10% to 22%) or 16% (from 30% to 46%) in the fre-
quency of adverse events. In addition, this sample size
ensures some power to explore the efficacy of statins.
Specifically, this study will have 80% power to detect an
increase in the rate of fever clearance by 40% due to sta-
tins. Based on simulations, we previously found that 30
patients give approximately 80% power to detect a 0.5
log10-copies/ml per day higher viraemia clearance, a
reasonable estimate of what an effective anti-viral might
achieve [24]. Thus, with 300 patients (a ten-fold higher
sample size), we expect to be able to detect a (hypothet-
ical) 0.16 log10-copies/ml per day higher viraemia clear-
ance due to statins.
Statistical analysis
The primary analysis population will include all patients
randomised to placebo from cohort 1 and all patients
(regardless of treatment assignment) from cohort 2
according to the intention-to-treat principle. Owing to
their low number, patients randomised to low-dose sta-
tins from cohort 1 will only be descriptively analysed.
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The proportion of patients with any adverse events,
any serious adverse events, or specific adverse events
will be summarised and compared between the treat-
ment arms based on Fisher’s exact test.
Pre-defined secondary endpoints will be compared be-
tween the two treatment arms based on linear regression
for continuous endpoints, logistic regression for binary
endpoints, and Cox regression for time-to-event end-
points. For laboratory markers, comparisons will be
adjusted for the pre-dose value of the respective marker
and the day of illness at enrolment; plasma viraemia and
NS1-endpoints will additionally be adjusted for dengue
serotype.
The clinical, virological and immunological findings
will also be correlated with MICB and PLCE1 genotype
using descriptive statistical methods.
A detailed statistical analysis plan will be finalised
prior to unblinding the study data base.
Ethical considerations
Ethical approval
This protocol and both the patient information sheet
and the consent form have been reviewed and approved
by the Institutional Review Board of the Hospital for
Tropical Diseases in Ho Chi Minh City, the Oxford
Tropical Research Ethics Committee and the Ethics Com-
mittee of the London School of Hygiene and Tropical
Medicine.
Informed consent and information sheet
All patients entering the study must give informed
consent.
Withdrawal from the trial
Each participant has the right to withdraw from the
study at any time. The reason for withdrawal will be
recorded in the case report form.
Confidentiality
Patients who enter the trial will be given a unique identi-
fication number. This number will be used on both la-
boratory specimens and case report forms. The study
wards and the research unit have the facilities to store
study information securely.
The role of the data and safety monitoring board (DSMB)
An independent DSMB will be set up consisting of a
biostatistician and senior clinical researchers with ex-
pertise in dengue and clinical trials. The DSMB will re-
view the protocol and agree to a data review schedule
and reporting requirements before the study com-
mences. All data reviewed by the DSMB will be in the
strictest confidence. A DSMB charter will outline its re-
sponsibilities and operation.
The DSMB will perform a safety review after day 6
data are available for the first 30 patients enrolled (Co-
hort 1: 40 mg lovastatin daily). This review will be based
on a report created by the DSMB statistician containing
unblinded summary tables of baseline demographics,
serious adverse effects, adverse effects and disease pro-
gressions, as well as viraemia curves. If no safety con-
cerns are identified, the lovastatin dose will be increased
to 80 mg daily and recruitment will commence in cohort
2. Enrolment will continue in cohort 1 while awaiting
the outcome of the DSMB review. Additional safety
reviews will take place after the day 6 data are available
for the 30th and 100th patients in cohort 2.
Discussion
Dengue remains a significant global public health chal-
lenge with costs to both the infected individual and the
struggling health systems of dengue-endemic countries.
At present, treatment is limited to supportive care. A
therapeutic that can attenuate disease and prevent pro-
gression to severe disease would represent a highly sig-
nificant advance with enormous benefits for both
patients and health systems. There is growing observa-
tional evidence from the critical care field to suggest that
statins may have a beneficial role in a number of condi-
tions, such as sepsis, acute lung injury and pneumonia.
Statins have beneficial pleiotropic effects, including sta-
bilizing and anti-inflammatory effects on the endothe-
lium. As endothelial dysfunction is so important in
dengue pathogenesis, stabilizing effects at this site may
prove to be clinically beneficial. In addition, statins have
an excellent safety profile and a low cost. In view of this,
we are optimistic about the potential benefit of lovasta-
tin in dengue.
Trial status
We expect that patients will start being recruited to this
trial in November 2012.
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Summary  
Background: Dengue endangers billions of people in the tropical world. There is 
currently no available therapeutic. The severe manifestations reflect, in part, 
inflammatory processes affecting the vascular endothelium. In addition to lipid 
lowering, statins have pleiotropic effects that improve endothelial function. 
Epidemiological studies suggest outcomes from a range of acute inflammatory 
syndromes are improved in patients taking statins at presentation. 
Methods: We performed a randomised, double-blind, placebo-controlled trial of five 
days of lovastatin in dengue. The trial was conducted in two phases – the first phase 
investigated 40mg lovastatin versus visually matched placebo in 30 patients, and the 
second phase investigated 80mg lovastatin versus visually matched placebo in 300 
patients. Adult patients with less than 72 hours fever and a positive dengue NS1 rapid 
test were eligible for recruitment. The primary outcome was safety. The secondary 
outcomes were disease progression, fever clearance time, effect on plasma viremia, 
and quality of life. 
Findings: The rates of adverse events were similar in both treatment arms. There was 
no difference in disease progression, fever clearance time, effect on plasma viremia, 
and quality of life scores between the treatment arms. 
Interpretation: Our findings show that lovastatin was safe and well tolerated in adult 
patients with dengue. Although not powered to address efficacy, there was no 
evidence of a beneficial effect on dengue viremia or clinical manifestations of the 
disease. Our study suggests that continuing statin therapy in patients with dengue is 
safe.  
Funding: Wellcome Trust of the United Kingdom (grant: 097430/Z/11/Z). 
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Introduction 
Dengue exerts an enormous toll on countries of the tropical world, with an estimated 
390 million infections annually.1 While the majority of symptomatic patients recover 
after a short but often debilitating illness, a small proportion progress to severe 
disease, in particular development of an unusual vasculopathy characterized by 
endothelial dysfunction and a plasma leakage syndrome that may result in 
hypovolaemic shock.2 Other less common complications include severe bleeding and 
severe liver/organ involvement.3 Myalgia and arthralgia are prominent constitutional 
symptoms associated with dengue, and rhabdomyolysis resulting in renal failure is 
also occasionally reported.4 Currently there is no licensed vaccine or therapeutic,5 and 
health systems in endemic areas are frequently overwhelmed with patients during the 
dengue season.2 It is clear there is a major unmet need for a therapeutic agent that can 
shorten the duration and severity of symptoms and/or prevent the development of 
complications. 
Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, also 
known as statins, have beneficial effects beyond their lipid-lowering properties, 
including specific effects on endothelial function.6-10 These beneficial effects are thought 
to be partly mediated through statin inhibition of the mevalonate pathway, resulting in 
inhibition of isoprenoid formation and reduced expression of pro-inflammatory 
cytokines, thereby controlling migration of leucocytes to areas of endothelial 
inflammation.11,12 Statins also result in increased nitric oxide bioavailability and thus 
may improve endothelial function by modulating the production of reactive oxygen 
species.13 Endothelial dysfunction is increasingly being recognised as an important 
factor in the pathogenesis of atherosclerosis,14,15 and these pleiotropic effects, together 
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with the lipid-lowering properties, likely explain the prognostic benefits of statin use in 
cardiovascular disease. There is thought to be some overlap between the inflammatory 
processes seen in atherosclerosis and sepsis, and several observational studies have 
suggested that prior statin therapy may be associated with improved outcomes in 
conditions such as sepsis and pneumonia.16-20 As a result statins are now being 
investigated as potential adjunctive therapy for a variety of conditions in which 
endothelial dysfunction is thought to play a role, including sepsis and acute respiratory 
distress syndrome although, to date, their adjunctive role has not been substantiated in 
prospective trials.21,22 
Although the detailed mechanisms underlying the microvascular endothelial dysfunction 
seen in severe dengue remain incompletely understood, we hypothesised that the 
endothelial stabilising effects of statins could favourably modulate the severity of the 
vasculopathy, especially if used early in the disease course. In addition, in vitro work has 
shown that lovastatin reduces dengue virion assembly, raising the possibility that statins 
may have some antiviral properties.23,24 Furthermore, the low cost and ready 
availability of statins are attractive properties of this class of drug. However, although 
statins have a generally good safety profile, given the recognised association between 
statin use and hepatic and muscle dysfunction,25-27 which are both common features of 
dengue, our primary objective was to assess the safety of a five-day course of 
lovastatin administered to adult patients early in the course of dengue illness. In 
addition, we investigated the potential effects of lovastatin on a variety of clinical and 
virological parameters. 
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Methods 
Study design and participants 
We performed a randomised, placebo-controlled, double-blind, dose escalating trial of 
lovastatin for adult patients with dengue.28 In the first phase we assessed 40mg 
lovastatin versus placebo (30 patients), and in the second phase, conducted after an 
interim safety review, we assessed 80mg lovastatin versus placebo (300 patients). The 
study was conducted at two centres in Vietnam: the Hospital for Tropical Diseases in 
Ho Chi Minh City, and Tien Giang Hospital, My Tho City.  
Ethical approval was obtained from the institutional review boards of the Hospital for 
Tropical Diseases and the Ministry of Health of Vietnam, the London School of 
Hygiene and Tropical Medicine, and the Oxford University Tropical Research Ethics 
Committee. The trial was registered with the ISRCTN registry (number: 
ISRCTN03147572). 
The trial protocol has been published,28 but briefly patients aged 18 or over, 
presenting within 72 hours of fever onset with an illness consistent with dengue, in 
whom a rapid test for dengue non-structural protein 1 (NS1) was positive (NS1 Ag-
STRIP, Bio-Rad) were eligible for inclusion providing they gave written informed 
consent. Exclusions included signs or symptoms suggestive of another acute 
infectious disease, an alanine transaminase (ALT) level > 150 U/L, a creatine kinase 
(CK) level > 1000 U/L, a platelet count < 50 x 109/L, pregnancy or lactation, or a 
history of cirrhosis or myopathy. Patients were also excluded if they were currently 
taking statins or had taken them within the week prior to presentation, or were taking 
any medication contraindicated with statins. 
 
6 
Randomisation and masking 
We randomly assigned enrolled patients in a 1:1 ratio to receive lovastatin (40mg 
(phase one), 80mg (phase two)) or placebo once daily for five days. Randomisation 
was stratified according to the ward of recruitment, using block randomisation with 
variable block sizes of four or six. The Vietnamese pharmaceutical company, 
DOMESCO, provided lovastatin and visually matched placebo without charge. The 
clinical trials pharmacist was the only person who had access to the computer-
generated randomisation list; she pre-packaged bottles containing six doses of either 
lovastatin or visually matched placebo, including an extra emergency dose in case of 
vomiting. All other study staff were blinded to treatment allocation until after 
completion of the study and locking of the database. Each enrolled patient was 
assigned the next available study code that corresponded to a pre-packaged bottle of 
study drug. Clinical data were captured on structured case report forms that were then 
entered into a secure web-based database. 
Study Procedures 
Potential participants were identified either on the dengue wards or among patients 
attending the emergency department. Screening took place on the dengue ward and 
was streamlined to ensure completion within four hours. Upon enrolment history and 
detailed examination findings were documented by attending physicians specifically 
trained in all study procedures. Participants received the first dose of study drug as 
soon as possible after randomisation, with subsequent doses given once daily in the 
morning; all doses of study drug were directly observed. Standardized clinical 
information was recorded daily throughout the disease course by the trained 
physicians. These physicians were also responsible for all clinical management 
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decisions, but with the following caveats relating to worsening hepatitis, myositis or 
thrombocytopenia; if the ALT exceeded 250 U/L, the CK exceeded 1000 U/L, or the 
platelet count fell below 5 x 109/L the study drug was stopped. Adverse events and 
details of their severity and likely relatedness to the study drug were recorded in the 
case report form and on standardized forms. Serious adverse events were reported to 
the relevant institutional review boards and to an independent data and safety 
monitoring committee (DSMB).  
Haematocrit, platelet and total cholesterol measurements were performed at 
enrolment (study day one), then daily to study day six, and thereafter as clinically 
indicated and at the follow-up visit four weeks after enrolment. Renal and liver 
function tests, electrolytes, and coagulation profiles were carried out on study days 
one, three, and five, then as clinically indicated and at the follow-up visit. An 
ultrasound scan was performed on illness day six to assess plasma leakage. Quality of 
life was measured using a visual analogue scale daily.  
Serological and virological tests were used to confirm the dengue diagnosis and 
identify the infecting serotype, as outlined in Supplementary Text 1. Plasma samples 
obtained daily were assessed for viremia levels using an internally controlled, 
serotype-specific, real-time RT-PCR assay.29 Serial samples from each patient were 
assayed at the same time. 
The independent DSMB provided study oversight. Interim safety reviews were 
performed at the end of the first phase, and after the 30th and 100th patients were 
recruited in phase two.  
Outcomes 
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This was an exploratory study focusing on safety, with the primary outcome defined 
as a comparison of the proportion of patients with any adverse events, and with any 
serious adverse events, between the treatment arms. The cut-offs described above for 
worsening hepatitis (ALT > 250U/L) and myositis (CK > 1000 U/L), and marked 
thrombocytopenia (platelet count < 5 x 109/L), defined certain prespecified adverse 
events, but in addition we graded all laboratory abnormalities as Grade 1-4 following 
the established CTCAE system. The secondary outcomes were: (1) disease 
progression as defined by admission to ICU, development of severe dengue (shock, 
severe bleeding or neurological involvement), or death; (2) fever clearance time; (3) 
the area under the log10-transformed curve (AUC) for plasma viraemia between days 
three and six of illness; and (4) the lowest value of the quality of life score captured 
on a visual analogue scale.  All definitions used in the trial are detailed in 
Supplementary Text 1. 
Additional exploratory outcomes, intended primarily to evaluate vascular leakage 
severity and other characteristic features of dengue, are described in Supplementary 
Text 1.  
Statistical analysis 
The planned sample size of 300 patients in phase two was based on medical and 
feasibility considerations as well as on power considerations for key endpoints. In a 
previous randomised trial in dengue, about 10% and 30% of participants experienced 
at least one serious adverse event (SAE) or adverse event (AE) respectively.30 The 
planned sample size guaranteed a power of 80% to detect an increase of 12% in the 
SAE frequency or 16% in the AE frequency. More extensive power considerations are 
discussed in the published protocol.28  
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The two study cohorts were analysed separately. Cohort one was analysed 
descriptively. The main analysis included all patients in cohort two, following the 
intention-to-treat principle. The proportion of patients with adverse events were 
summarised and compared between the treatment arms using Fisher’s exact test. The 
pre-defined secondary endpoints were compared between the treatment arms based on 
linear regression for continuous endpoints, logistic regression for binary endpoints 
and Cox regression for time-to-event endpoints. The main explanatory variable in the 
regression models was the treatment assignment, and all analyses were adjusted for 
day of illness at recruitment. Comparisons of laboratory markers were additionally 
adjusted for the pre-dose enrolment value, and also for serotype and immune status 
for plasma viraemia comparisons.  
All analyses were performed with the statistical software R v3·1·3 (R Foundation for 
Statistical Computing, Vienna, Austria).32 
Role of the funding source 
The funder of the study and the drug manufacturer had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The 
corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.  
 
Results 
Patients were recruited into phase one in November and December 2012. 
Supplementary Figure 1 shows the trial profile with respect to screening, enrolment 
and withdrawals. The baseline characteristics at randomisation were similar in the two 
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study groups. Illness duration and adverse event rates were also similar in the two 
groups. These data are summarised in Supplementary Tables 1 and 2. All adverse 
events resolved fully.  
Following the initial safety review by the DSMB, phase two commenced in April 
2013 and completed recruitment in January 2015. Figure 1 shows the trial profile. Of 
the 515 subjects with a positive NS1 test who were assessed for eligibility, 339 
underwent formal screening and 300 patients were enrolled and randomised. Elevated 
ALT and/or CK levels were the most common reasons for potential participants to fail 
screening. 
The baseline characteristics were similar in the two study groups and are summarised 
in Table 1. Treatment was stopped prematurely in 17 patients in the placebo arm and 
19 patients in the lovastatin arm. 11 patients in the placebo arm developed laboratory 
abnormalities on study day 3 where the protocol required the study drug to be stopped 
– ten with ALT elevations above 250 U/L and one with a CK elevation above 1000 
U/L. 12 patients in the lovastatin arm had ALT elevations above 250 U/L that 
required the study drug to be stopped. However, in neither treatment arm were these 
laboratory derangements associated with clinical deterioration. The clinical reasons 
for stopping the study drug were concerns about AST elevations when the ALT level 
did not meet the stopping criteria. 
Treatment allocation was unblinded in only one case (placebo arm, after completion 
of study drug), where a pregnancy test requested by the patient on study day six was 
positive; the pregnancy test at enrolment had been negative. Two patients in the 
lovastatin arm withdrew from the study within 24 hours (one self-discharged and one 
withdrew consent after the first dose of study drug); no adverse events were 
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documented and these participants were excluded from all analyses as no data were 
available. Data from other participants who withdrew from the study later are 
included in the analyses up to the time of withdrawal. 
The number of adverse events did not differ significantly between the groups. 97/151 
(64%) of patients in the placebo group and 82/149 (55%) of patients in the lovastatin 
group had a clinical and/or pre-specified laboratory adverse event (p=0·13). Eight 
patients in the placebo group and four patients in the lovastatin group experienced a 
serious adverse event (p=0·38). In addition 112/151 (74%) of patients in the placebo 
group and 110/149 (75%) of patients in the lovastatin group had at least one grade 
three or four laboratory adverse event identified (p=1) Details of these adverse events 
are summarised in Table 2. As expected, biochemical evidence for hepatic 
dysfunction was common, with a total of 14/151 (9%) and 16/149 (11%) in the 
placebo and lovastatin groups respectively exceeding the prespecified ALT cutoff of 
250 U/L during the acute illness, including those participants in whom the study drug 
had been stopped early due to worsening hepatitis. In one patient in each group the 
CK level exceeded 1000 U/L at some time, but less marked CK elevations were 
common in both groups. No patient developed renal compromise at any time. There 
was no significant change in the coagulation profile during the study.  
Of note, the serious adverse events in this study were all in the category of “prolonged 
hospitalisation”. In 11 patients these prolonged hospital stays were for monitoring of 
abnormal laboratory tests (nine patients had hepatitis and two had thrombocytopenia) 
without clinical symptoms, and in one patient (in the placebo arm) the prolonged stay 
was for diarrhoea and persistent fever. All patients with serious adverse events 
recovered fully. 
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Very few patients progressed to severe dengue. Two patients in the placebo group 
developed hypovolemic shock and one patient in the lovastatin group was admitted to 
intensive care for close monitoring (OR: 0·51; 95%CI: 0·02-5·38; p=0·57). The fever 
clearance time did not differ significantly between the study groups (median time to 
fever clearance four days in both groups; HR: 0·93; 95%CI: 0·72-1·21; p=0·60)) 
(Table 3 and Supplementary Figure 2). Lovastatin had no observable effect on the 
dengue viremia kinetics or on the quality of life scores (Figure 2A and 2B).  
There were no significant differences between the treatment arms in the various 
predefined exploratory endpoints (see Table 4), except in the peak percentage change 
in total cholesterol levels relative to enrolment values; a greater relative reduction was 
observed in the lovastatin group (30%) compared to the placebo group (23%) 
(p<0·0001)). Of note, markers for plasma leakage, including percentage 
haemoconcentration and presence of serosal effusions on ultrasound, were similar 
between the treatment arms. 
 
Discussion 
We hypothesized that the reported benefits associated with statin use in several 
observational studies of acute inflammatory syndromes might be relevant to dengue, a 
condition in which endothelial dysfunction is central to pathogenesis. In this 
randomised, double-blind, placebo-controlled trial in Vietnamese adults with dengue, 
we found that lovastatin was safe and well tolerated. In particular we found no 
evidence of adverse effects on hepatic or muscle dysfunction, both characteristic 
features of acute dengue as well as recognised, albeit rare, complications of statin 
therapy. However, we also found no evidence of a beneficial effect on any clinical or 
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virological endpoints. 
While our study did not include pharmacokinetic analysis, we used 80 mg lovastatin 
daily, the upper end of the dose range for adults, and it is reasonable to assume that 
therapeutic concentrations were achieved as evidenced by the significantly greater 
reduction in cholesterol in the lovastatin group. The rates of clinical and laboratory 
adverse events were similar between the treatment arms. Rates of serious adverse 
events were also similar, and in all cases these events were classified as serious due to 
prolonged hospitalization for laboratory monitoring rather than on the basis of clinical 
deterioration. Of note, both liver and muscle abnormalities were observed frequently 
in both treatment arms, and were no more prevalent in the lovastatin arm; similar 
abnormalities identified during screening for the study indicate that these are common 
features of dengue, likely highlighted here by our particular focus on identifying 
safety issues related to statins.  
Progression to severe dengue occurred infrequently in the study population (1%) and 
there was no difference in the rate of disease progression between the study groups. In 
view of the small number of events, it is possible that the study missed a small 
beneficial effect. The frequency of dengue shock syndrome is higher in children and 
hence children are the preferred patient population for investigation of drugs with 
immunomodulatory or endothelial stabilising properties.34 However since we 
observed no differences in the magnitude of haemoconcentration or in the presence of 
serosal effusions on ultrasound between the study groups in this adult trial, we do not 
consider there to be a compelling case for a trial of statin therapy in children at 
present. We also found no other evidence of the anti-inflammatory properties of 
statins, in particular fever clearance times were unaffected by statin therapy. 
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However, more sensitive methods of assessing endothelial function are needed, and 
could prove useful for future trials of dengue therapeutics. Various noninvasive 
techniques have been developed and ongoing observational research is assessing the 
correlation between measurements derived from these techniques and more 
conventional methods for identifying plasma leakage in dengue.35,36  
Another limitation of our study is that we obtained relatively sparse data on DENV-2 
and DENV-3 due to the dominance of DENV-1 and DENV-4 during the study. While 
in vitro laboratory studies have suggested that statins may reduce dengue virion 
assembly, potentially through blocking of viral transport from the endoplasmic 
reticulum to the Golgi apparatus in infected cells, we found no evidence of an 
antiviral effect.23,24 It is possible that the effects of statins may differ between the 
serotypes and it is interesting to note that the in vitro work that suggested a potential 
antiviral effect used DENV-2. 
As in other recent trials of antiviral and immunomodulatory agents for dengue,30,37-39 
we administered the study drug within 72 hours of illness onset. However, it is 
possible that even initiating a therapeutic within this timeframe is already too late to 
modulate the disease pathways. Peak viraemia typically occurs earlier in the illness 
and is already waning by 72 hours.40 In addition, there is evidence that endothelial 
dysfunction is established by 72 hours.41,42 Thus to favourably modulate the outcome 
of infection even earlier intervention may be necessary, a significant practical hurdle 
in many dengue-endemic regions as patients rarely present to health services so early. 
It also raises the question of whether dengue therapeutic development should focus 
more on identifying chemoprophylactic agents that could be used in those at most risk 
of severe disease, and also on optimising supportive care for those who do develop 
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severe disease. The ability to distinguish patients at risk of severe disease early in the 
course of their infection could lead to a more targeted approach to the conduct of 
clinical trials, by focusing on the subset of patients most likely to benefit. The use of 
dengue human infection models may also allow streamlining of potential therapeutic 
candidates through the early rejection of agents that do not demonstrate pre-identified 
efficacy signals.43,44 
Following the initial hope raised by the observational studies suggesting that prior statin 
therapy was associated with improved outcomes in a number of inflammatory 
conditions, several prospective trials investigating statins as adjunctive therapy have 
recently been published;21,22,45 similar to our study findings, none of these trials 
showed a beneficial role for de novo statin therapy. Despite these negative results, this 
“discovery-in-practice” approach remains important given the high pre-clinical failure 
rate observed with traditional drug discovery. A dengue therapeutic or 
chemopropylactic agent remains a desirable component of a dengue control package 
and, given the ongoing expansion of dengue’s geographic footprint, both drug 
development approaches need to be considered. 
In conclusion we have shown that lovastatin therapy is safe in adult patients with 
dengue although we did not demonstrate any clinical or virological benefit. While the 
study findings do not endorse adjunctive statin therapy for dengue, the data provide 
reassurance to clinicians about the safety of continuing established statin therapy in 
patients who develop dengue. This is a situation that is likely to become increasingly 
common as the epidemiology of dengue changes, especially in contexts where older 
age-groups with associated co-morbidities are more likely to be affected, for example 
in Singapore.33 Our study further underlines the importance of identifying risk factors 
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for dengue progression, thus potentially allowing a more personalised approach to 
dengue clinical trials. Early diagnosis and recognition of severe features together with 
good supportive care remain central to clinical management.  
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Figure legends 
Figure 1: Study enrolment and follow-up for phase two of the study.  
Figure 2: Viraemia levels in lovastatin and placebo-treated patients. Figure 2A shows 
the viraemia levels by serotype, and Figure 2B shows the viraemia by immune status. 
The coloured lines in each graph correspond to loess scatterplot smoothers derived 
from local polynomial regression fitting to data from each treatment arm. The grey 
background lines represent individual patient data. There was no significant 
difference in viremia kinetics between the treatment groups. 
Supplementary Figure 1: Study enrolment and follow-up for phase one of the study. 
Supplementary Figure 2: Kaplan-Meier of fever clearance time in lovastatin and 
placebo-treated patients. The proportions of patients who remained febrile during 
inpatient monitoring (study days one to five) are shown. There was no significant 
difference in fever clearance time between the treatment groups 
!!
! !
1388 febrile patients assessed and NS1 rapid tests 
performed 
515 patients NS1 positive 
339 patients screened 
300 patients randomized 
(298 laboratory-confirmed dengue; 2 with 
inconclusive diagnostics) 
39 patients failed screening: 
High ALT (>150U/L): 17 
High CK (>1000U/L): 11 
High ALT and CK: 1 
Low platelets (<50x109/L): 7 
Medical decision: 2 
Patient refusal: 1 
176 patients not screened: 
Illness duration > 72 hours: 53 
Patient refusal: 123 
151 assigned placebo 
 
149 assigned 80mg 
lovastatin 
151 included in intention-to-
treat analysis 
149 included in intention-to-
treat analysis 
130 completed 5 days 
treatment 
134 completed 5 days 
treatment 
19 discontinued 
treatment 
Adverse event: 121 
Attending doctor 
decision: 22 
Withdrawal of 
consent: 4 
Self-discharge: 1 
 
17 discontinued 
treatment 
Adverse event: 111 
Attending doctor 
decision: 12 
Withdrawal of 
consent: 3 
Self-discharge: 1 
Patient refused to 
take study drug on 
day 5: 1 
 
!1. Exceeded protocol-defined laboratory thresholds for ALT and CK 
2. Doctors’ decision based on AST elevations (when ALT threshold remained below the 
stopping threshold) 
!!


 
 
Table 1: Baseline characteristics of the patients in phase two of the study  
 
The summary statistic is the absolute count (%) for categorical variables and median 
(inter-quartile range) for continuous variables. There were 9 patients with negative 
plasma viraemia at baseline; however, DENV serotype could be determined in one of 
them based on subsequent plasma viraemia measurements. DENV = dengue virus, 
WBC = white blood cell count, AST = aspartate transaminase, ALT = alanine 
transaminase, CK = Creatine kinase 
Day of illness was calculated based on the actual date of fever onset (Supplementary 
Text 1) meaning some patients who were within 72 hours of fever onset were 
classified as being on day four of illness 
 Placebo (n=151) 80mg Lovastatin (n=149) 
Age (years) 27 (21-33) 25 (21-34) 
Sex       
Male 66 (44%) 65 (44%) 
Female 85 (56%) 84 (56%) 
Temperature (°C) 38·2 (37·7, 38·5) 38·2 (37·7, 38·5) 
Day of illness at enrolment       
1 1 (1%) 2 (1%) 
2 28 (19%) 20 (13%) 
3 65 (43%) 64 (43%) 
4 57 (38%) 63 (42%) 
DENV serotype       
1 63 (42%) 53 (36%) 
2 16 (11%) 15 (10%) 
3 13 (9%) 15 (10%) 
4 53 (35%) 64 (43%) 
Negative 6 (4%) 2 (1%) 
Immune status       
Probable primary 35 (23%) 43 (29%) 
Probable secondary 111 (74%) 96 (64%) 
Inconclusive 5 (3%) 10 (7%) 
Plasma viraemia (log10 
copies/mL) 
7·9 (7·1, 8·9) 7·8 (6·9, 8·6) 
Haematocrit (%) 41·8 (39·2, 44·8) 41·0 (38·7, 44·2) 
Platelet count (x109/L) 111 (90, 140) 112 (89, 149) 
WBC (x106/dL) 3·2 (2·3, 4·0) 3·1 (2·3, 3·9) 
AST (U/L) 51 (36, 79) 45 (32, 72) 
ALT (U/L) 38 (25, 67) 31 (23, 60) 
CK (U/L) 95 (67, 153) 92 (67, 123) 
Cholesterol (mmol/L) 3·8 (3·3, 4·3) 3·8 (3·2, 4·3) 
Table 2: Primary Outcomes - Adverse Event Details 
 
P-values derived from Fisher’s exact test. 
    Placebo (n=151) 80mg Lovastatin (n=149)4 P-value 
Adverse events (clinical and/or prespecified laboratory events)  
Any 97 (64%) 82 (55%) 0·13 
Abdominal pain 4 (3%) 5 (3%) 0·75 
Diarrhoea 39 (26%) 29 (19%) 0·22 
Vomiting 27 (18%) 22 (15%) 0·53 
Bleeding 51 (34%) 38 (26%) 0·13 
Muscle pain 7 (5%) 7 (5%) 1 
Worsening hepatitis1  14 (9%) 16 (11%) 0·70 
Worsening myositis2  1 (1%) 1 (1%) 1 
Marked thrombocytopenia3 1 (1%) 1 (1%) 1 
Serious adverse events                   
Any 8 (5%) 4 (3%) 0·38 
Diarrhoea 1 (1%) 0 1 
Hepatitis 6 (4%) 3 (2%) 0·50 
Thrombocytopenia 1 (1%) 1 (1%) 1 
Grade 3 & 4 laboratory adverse events          
Any 112 (74%) 110 (74%) 1 
High ALT (> 200 (M) or 185 (F) U/L) 65 (43%) 65 (44%) 1 
High AST (> 200 (M) or 185 (F) U/L) 65 (43%) 65 (44%) 1 
High creatine kinase (> 570 U/L) 9 (6%) 6 (4%) 0·60 
Low platelet count (< 50 X 109 /L) 89 (59%) 84 (56%) 0·73 
Low sodium (< 120 mmol/L) 1 (1%) 0 1 
Low white cell count (< 1 X 109 /L) 1 (1%) 3 (2%) 0·37 
1. Worsening hepatitis defined as ALT > 250 U/L  
2. Worsening myositis defined as CK > 1000 U/L 
3. Marked thrombocytopenia defined as a platelet count that led to clinical concern. In the cases here it represented a low platelet count that 
required a prolonged hospital stay for observation. Conventionally in Vietnam patients are kept in hospital until the platelet count is 
above 50 x 109/L.  
4. Two patients withdrew on day one in the lovastatin arm meaning the outcome data was not available 
 
 
 
 
 
 
Table 3: Secondary Outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary statistic is events (%) for categorical variables and median (IQR) for continuous data. Median (IQR) for time to fever clearance was based on 
Kaplan-Meier estimation. 
Outcomes of two patients in the lovastatin arm were not available due to early withdrawal. In addition, 3 patients (1 in the lovastatin arm) were excluded from 
the analysis of fever clearance due to having already defervesced at baseline, 9 patients (2 in the lovastatin arm) were excluded from the analysis of viremia as 
the initial DENV RT-PCR was negative, 4 patients (2 in the lovastatin arm) were excluded from the analysis of quality of life due to missing data. 
The p-value and CI for disease progression were derived from logistic regression and the effect is the odds ratio. The p-value and CI for the AUC of viraemia 
and minimum quality of life score were derived from linear regression and the effect is the absolute mean difference. The p-value and CI for fever clearance 
were derived from Cox regression and the effect is the hazard ratio. 
All analyses were adjusted for day of illness at baseline. In addition, analysis for fever clearance was adjusted for baseline temperature, analysis for minimum 
quality of life was adjusted for baseline quality of life, and analysis for AUC of viremia was adjusted for baseline log10 viremia, dengue serotype and 
immune status. 
1. Two patients in the lovastatin arm withdrew on day one of the study meaning the outcome data were not available 
Outcome Placebo (n=151) 80mg Lovastatin 
(n=149)1 
Effect (95%CI); p-
value 
Disease progression 2 (1·3%) 1 (0·7%) 0·53 (0·02, 5·57); 
p=0·592 
Time to fever clearance (days) 4 (3, 5) 4 (3, 5) 0·93 (0·72, 1·21); 
p=0·604 
AUC of viremia between days 3 & 6 of illness 
(log10 copies/mL x days) 
16·8 (12·5, 21·6) 16·1 (11·5, 20·2) -0·17 (-0·88, 0·54); 
p=0·639 
Minimum quality of life score  50 (40, 60) 50 (50, 60) 1·07 (-1·33, 3·46); 
p=0·381 
Table 4: Exploratory Outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome Placebo  
(n=151) 
80mg Lovastatin 
(n=149)1 
Effect (95%CI); p-value 
Platelet nadir (between day 3 & 8 of illness) (x109/L) 43 (24, 64) 44 (25·5, 71) 2·47 (-3·98, 8·91); p=0·45 
Peak haematocrit (between day 3 & 8 of illness) (%) 46 (42·8, 49·3) 44·3 (42, 49) -0·55 (-1·21, 0·11); p=0·10 
Peak percentage change in haematocrit from baseline (between 
day 3 & 8 of illness) (%) 
9·72 (4·46, 15·2) 8·93 (5·01, 12·7) -1·29 (-2·87, 0·29); p=0·11 
Ascites on ultrasound between day 5 & 7 of illness 23 (16%) 17 (12%) 0·69 (0·35, 1·37); P=0.29 
Pleural effusion on ultrasound between day 5 & 7 of illness 14 (10%) 11 (8%) 0·79 (0·34, 1·81); P=0.58 
Peak ALT (between day 3 & 8 of illness) (U/L) 110 (63·5, 183·8) 88·5 (46, 184·8) 6·02 (-27·56, 39·60); p=0·72 
Peak CK (between day 3 & 8 of illness) (U/L) 125 (79·5, 199) 108 (70, 200) 55·76 (-84·48, 196·01); 
p=0·44 
Peak ALT (during study) (U/L) 140 (81·8, 221·8) 133 (67·3, 269) 16·74 (-19·99, 53·47); 
p=0·37 
Peak CK (during study) (U/L) 125 (79·5, 199) 116 (72, 200) 56·81 (-83·43, 197·04); 
p=0·43 
Colloid requirement 1 (0·66%) 0 (0%) NA 
Peak viremia (during study) (log10 copies/mL) 8·04 (7·15, 9·16) 8·04 (7·12, 8·78) 0·03 (-0·09, 0·14); p=0·63 
Undetectable viremia achieved  70 (49·3%) 87 (60·8%) 1·36 (0·98, 1·89); p=0·07 
AUC of viremia during study (log10 copies/mL x days) 26·2 (18·2, 31·9) 22·7 (17·6, 30) -0·54 (-1·64, 0·57); p=0·34 
Total number of days in hospital 8 (7, 8) 8 (7, 8) 0·02 (-0·25, 0·28); p=0·89 
Peak percentage change in cholesterol from baseline (during 
study) (%) 
-23·1 (-29·4,-15·4) -30·4 (-38·4,-23·6) -8·49 (-11·34,-5·63); 
p=<0·0001 
Summary statistic is events (%) for categorical variables and median (IQR) for continuous data. 
Treatment effect for colloid requirement cannot be estimated as there was only 1 case in the placebo group who required colloid. 
The p-values and CIs for ascites and pleural effusion on ultrasound were derived from logistic regression with adjustment for day of illness at baseline, the 
effects are odds ratio.  
The p-values and CIs for all laboratory variables were derived from linear regression with adjustment for baseline value and the day of illness at baseline, and 
the effect is an absolute mean difference. Analyses for plasma viremia (peak viremia, AUC of viremia) were additionally adjusted for dengue serotype and 
immune status. 
The reported comparison for “undetectable viremia achieved” was based on a Cox regression of the time from enrolment to the first undetectable viremia with 
adjustment for baseline viremia, the day of illness at baseline, dengue serotype and immune status, and the effect is a hazard ratio. 
1. Two patients in the lovastatin arm withdrew on day one of the study meaning outcome data were not available for these patients 
Definitions used in Lovastatin for Dengue Trial 
Clinical Definitions 
SHOCK: cardiovascular decompensation (indicated by tachycardia, cool peripheries 
and narrowing of the pulse pressure to less than 20 mmHg) requiring fluid 
resuscitation and thought to be due to plasma leak. 
SEVERE BLEEDING: Bleeding was defined as clinically severe if it resulted in 
haemodynamic instability and required fluid resuscitation or a blood transfusion. In 
addition, any bleed that required an intervention to control the bleeding (e.g. nasal 
packing) was classified as severe. Any intracranial bleed or bleed that resulted in 
death were classified as severe. 
CNS INVOLVEMENT: This was defined as any alteration of consciousness 
(GCS<15), occurrence of convulsions or any focal neurological deficit even if 
transient. 
DISEASE PROGRESSION: This was present if any of the following occurred: (1) 
transfer to ICU, (2) shock, (3) severe bleeding, (4) CNS involvement, or (5) death. 
FEVER CLEARANCE TIME: This was defined as the time (days) from enrolment to 
the first time the temperature fell to < 37.5 oC and remained below this level for 24 
hours, or less than 24 hours if the patient was well enough to be discharged home. 
DAY OF ILLNESS: This was calculated using the actual date of illness onset and the 
date of enrolment. This definition meant that some patients who were within 72 hours 
of fever onset were classified as being on day four of illness at enrolment. 
 
Laboratory Definitions 
DENGUE DIAGNOSIS: Serological responses were detected using immunoglobulin 
M (IgM) and immunoglobulin G (IgG) antibody-capture enzyme-linked 
immunosorbent assays (Panbio, Australia). DENV plasma viremia levels were 
measured by a validated quantitative RT-PCR assay. A patient was deemed to have 
laboratory-confirmed dengue if DENV was detected using the RT-PCR assay or if 
there was evidence of IgG or IgM seroconversion in paired samples.  
All patients had a positive NS1 rapid test at screening. If a patient had a negative RT-
PCR result and inconclusive serology they were deemed to have an inconclusive 
laboratory diagnosis – this occurred in two patients (both in the placebo arm). Nine 
patients (two in the lovastatin arm) had negative RT-PCR results – these patients were 
excluded from the analysis of viremia kinetics. 
DENGUE IMMUNE STATUS: We classified serological profiles as "probable 
secondary" when >22 Units of IgG (Panbio’s recommended cut-off for a positive 
result) were detected in either acute or early convalescent samples. If acute and early 
convalescent samples were IgM positive but IgG negative then we classified as 
"probable primary". Where IgM or IgG tests results were equivocal or inconsistent we 
classified the serological profile as "indeterminate”. 
LABORATORY ADVERSE EVENTS: In additon to the prespecified cutoffs for 
particular parameters (ALT, CK and platelet count) laboratory adverse events were 
also graded according to the values in the following table, following the convention of 
the CTCAE guidelines.1   
 
 Grade 1 Grade 2 Grade 3 Grade 4 
Haematological     
Haemoglobin  10g/dl – 
12.5g/dl 
8 – 9.9 g/dl 6.5 –7.9g/dl <6.5 g/dl 
White cell count 2 – 2.94 K/µl 1.0 - 1.99 K/µl <1.0 K/µl  
Platelets  75 – 200 K/µl 50 – 74 K/µl 20 - 49 K/µl  <20 K/µl  
Biochemical     
Sodium (low) 130 – 135 
mmol/L 
120 - 129 
mmol/l 
<120 mmol/l - 
Sodium (high) 146 – 150 
mmol/L 
151 – 155 
mmol/L 
156 – 160 
mmol/l 
>160 
mmol/l 
Potassium (low) 3.0 – 3.5 
mmol/l 
2.5 – 2.9 
mmol/l 
<2.5 mmol/l  
Potassium (high) 5 – 5.5 mmol/l 5.6 – 6.0 
mmol/l 
6.1 – 7.0 
mmol/l 
>7.0 mmol/l 
Creatinine Male 121 – 180 
µmol/L 
Female 101 – 
150 µmol/L 
Male 181 – 360 
µmol/L 
Female 151 – 
300 µmol/L 
Male > 360 
µmol/L 
Female > 300 
µmol/L 
- 
Total Bilirubin 18 – 27 µmol/L 28 – 51 µmol/L 52 – 170 
µmol/L 
 
> 170 
µmol/L 
 
AST  Male 41 – 120 
U/L 
Female 38 – 
111 U/L 
Male 121 – 200 
U/L 
Female 112 – 
185 U/L 
Male 201 – 
400 U/L 
Female 186 – 
370 U/L 
Male > 400 
U/L 
Female 
>370 U/L 
ALT Male 41 – 120 
U/L 
Female 38 – 
111 U/L  
Male 121 – 200 
U/L 
Female 112 – 
185 U/L 
Male 201 – 
400 U/L 
Female 186 – 
370 U/L1 
Male > 400 
U/L 
Female > 
370 U/L 
Creatine kinase 191 – 285 U/L 286 – 570 U/L >570 U/L - 
Cholesterol 5.21 – 7.75 
mmol/L 
7.76 – 10.34 
mmol/L 
> 10.34 
mmol/L 
- 
Prothrombin 
time 
13.4 – 20 
seconds 
20.1 – 33 
seconds 
>33 seconds - 
 
Exploratory endpoints 
The exploratory outcomes included the following laboratory values observed between 
days three and eight of illness (i.e. during the time the study protocol required a 
specific schedule of investigations, when dengue complications typically occur): 
platelet nadir, maximum haematocrit, peak percentage increase in haematocrit from 
baseline, and maximum ALT and CK. We also assessed the maximum recorded ALT 
and CK observed during the whole illness episode, recognising that some laboratory 
derangements occur later in the evolution of dengue, and the peak percentage 
decrease in cholesterol during follow-up from baseline.  
The numbers of patients requiring colloid therapy, and the total number of days in 
hospital, were also compared between the groups.  
Additional pre-specified outcomes were the proportion of patients who developed an 
undetectable viremia, the peak viremia and the log10-transformed plasma viremia 
AUC for the whole study period. 
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! 107 febrile patients assessed and NS1 rapid tests 
performed 
61 patients NS1 positive 
41 patients screened 
30 patients randomized 
(30 laboratory-confirmed dengue) 
11 patients failed screening 
High ALT (>150U/L): 2 
High CK (>1000U/L): 2 
High ALT and CK: 1 
Patient refusal: 3 
Repeat NS1 negative: 1 
Reasons not clear: 2 
20 patients not screened: 
Illness duration > 72 hours: 1 
Patient refusal: 19 
16 assigned placebo 
 
14 assigned 40mg lovastatin 
 
15 completed 5 days 
treatment 
 13 completed 5 days 
treatment 
1 discontinued 
treatment 
Withdrawal of 
consent: 1 
 
1 discontinued 
treatment 
Withdrawal of 
consent: 1 
 

Supplementary Table 1: Baseline characteristics of patients in phase one of the 
study 
 
 
The summary statistic is the absolute count (%) for categorical variables and the 
median (inter-quartile range) for continuous variables 
Day of illness was calculated based on the actual date of fever onset (Supplementary 
Text 1) meaning some patients who were within 72 hours of fever onset were 
classified as being on day four of illness 
  Placebo (n=16) 40mg Lovastatin (n=14) 
Age (years) 23 (19-28) 26 (21-48) 
Sex       
Male 8 (50%) 5 (36%) 
Female 8 (50%) 9 (64%) 
Temperature (°C) 39 (38·2, 39·5) 39 (38·6, 39·6) 
Day of illness at enrolment       
1 0 0 
2 6 (38%) 5 (36%) 
3 8 (50%) 8 (57%) 
4 2 (12%) 1 (7%) 
DENV serotype       
1 7 (44%) 5 (36%) 
2 2 (12%) 2 (14%) 
3 4 (25%) 3 (21%) 
4 3 (19%) 4 (29%) 
Immune status       
Probable primary 3 (19%) 0 
Probable secondary 12 (75%) 12 (86%) 
Inconclusive 1 (6%) 2 (14%) 
Plasma viraemia (log10 
copies/mL) 
8·6 (7·6, 9·3) 8.4 (7·8, 9·1) 
Haematocrit (%) 40·4 (37·9, 42·7) 42·7 (40·0, 45·0) 
Platelet count (x109/L) 130 (108, 171) 106 (87, 147) 
WBC (x106/dL) 3·7 (3·4, 4·5) 3·2 (2·8, 4·1) 
AST (U/L) 35 (26, 61) 39 (35, 90) 
ALT (U/L) 23 (16, 47) 27 (22, 71) 
CK (U/L) 78 (66, 116) 120 (91, 156) 
 
Supplementary Table 2: Details of adverse events in phase one of the study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The summary statistic is the absolute count (%) for categorical variables and the median (inter-quartile range) for continuous variables.  
 
1. All five serious adverse events were “prolonged hospitalisation”. These included two patients with mucosal bleeding (one in each treatment 
arm), one patient with diarrhoea (in the lovastatin arm), one patient with hepatitis (in the placebo arm), and one patient who developed a urinary 
tract infection (in the placebo arm). 
Characteristic Placebo (n=16) 40mg Lovastatin (n=14) 
Any adverse event       
Yes 9 (56%) 6 (43%) 
No 7 (44%) 8 (57%) 
Any serious adverse event1       
Yes 3 (19%) 2 (14%) 
No 13 (81%) 12 (86%) 
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Abstract
Dengue is the most important arboviral infection of humans. Thrombocytopenia is frequently observed in the course of
infection and haemorrhage may occur in severe disease. The degree of thrombocytopenia correlates with the severity of
infection, and may contribute to the risk of haemorrhage. As a result of this prophylactic platelet transfusions are sometimes
advocated for the prevention of haemorrhage. There is currently no evidence to support this practice, and platelet
transfusions are costly and sometimes harmful. We conducted a global survey to assess the different approaches to the use
of platelets in dengue. Respondents were all physicians involved with the treatment of patients with dengue. Respondents
were asked that their answers reflected what they would do if they were the treating physician. We received responses from
306 physicians from 20 different countries. The heterogeneity of the responses highlights the variation in clinical practice
and lack of an evidence base in this area and underscores the importance of prospective clinical trials to address this key
question in the clinical management of patients with dengue.
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Introduction
Dengue is globally the most important arboviral infection and
threatens an estimated 2.5 billion people worldwide [1]. Throm-
bocytopenia is almost universally observed in dengue infection [2].
This results from both reduced production and increased
destruction of platelets [3–5]. It is thought that severe thrombo-
cytopenia correlates with disease severity and may contribute to
the risk of developing haemorrhage [6,7]. The 2009 WHO dengue
guidelines do not advocate the use of prophylactic platelet
transfusions, whereas the 2011 regional WHO guidelines for
South East Asia suggest prophylactic platelets may be considered
in those with a platelet count less than 106109/L [8,9]. Some
dengue-endemic countries support the use of prophylactic platelet
transfusions to prevent haemorrhage in patients with thrombocy-
topenia, for example India (,106109/L), whereas others, such as
Brazil, do not [10,11]. However platelet transfusions are costly,
potentially dangerous and their use in dengue lacks an evidence
base [12–15].
Methods
We conducted a survey among physicians directly involved in
the care of dengue patients in order to determine how platelets are
used in the clinical management of dengue. The majority of
respondents were practicing physicians in dengue-endemic areas.
The exceptions to this were respondents from Africa, where
dengue is emerging, and the UK where the respondents were
infectious disease physicians who regularly see patients who have
recently travelled to dengue-endemic areas. A questionnaire
containing nine case histories and an additional question about
prophylactic platelet transfusion thresholds was emailed to
physicians with experience in managing dengue patients and
known to us. Respondents were specifically asked that their
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responses reflect what they would do if they were the treating
physician. Email recipients were invited to further disseminate the
questionnaire within their own clinical networks. The complete list
of questions is available as a supplementary file (Questionnaire S1).
The case histories were based on real clinical cases seen at the
Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam.
Four case histories describe patients with clinically non-severe
dengue but varying levels of thrombocytopenia. Case 1 describes
an 18-year-old female with platelets of 236109/L and no bleeding.
Case 2 describes a 28-year-old male with platelets of 296109/L.
He had no bleeding but a past history of a perforated peptic ulcer.
Case 3 describes a 29-year-old female with a rapid fall in platelets
to 226109/L. She had no bleeding. Case 4 describes a 30-year-old
male with platelets of 36109/L and no bleeding. Five case
histories describe patients with different manifestations of severe
dengue associated with varying levels of thrombocytopenia. Case 5
describes a 19-year-old male with platelets of 186109/L. He had
dengue hepatitis but no bleeding. Case 6 describes a 20-year-old
female with platelets of 176109/L. She had suspected dengue
encephalitis but no bleeding. Case 7 describes a 24-year-old male
with platelets of 316109/L. He had hepatic failure thought to be
secondary to dengue but no bleeding. Case 8 describes a 23-year-
old female with platelets of 86109/L. She had shock, epistaxis and
vaginal bleeding. Case 9 describes a 23-year-old male with
platelets of 336109/L. He had shock and mucosal bleeding. The
final question aimed to determine thresholds at which a physician
would consider transfusing platelets as prophylaxis against
haemorrhage. Respondents were asked to select a single option.
Results
In total, 306 physicians from 20 different countries responded
within a specified time period. The responses from Asia were 52
from Indonesia, 7 from Bangladesh, 5 from the Philippines, 9 from
Singapore, 8 from Cambodia, 18 from Malaysia, 3 from Thailand,
20 from Vietnam and 12 from India. The responses from Latin
America and the Caribbean were 13 from Cuba, 10 from Brazil,
17 from Paraguay, 6 from Peru, 1 from Mexico, 1 from Bolivia, 1
from Martinique and 81 from Colombia. The responses from
Africa were 37 from Nigeria and 2 from South Africa. In addition
there were 3 responses from the UK.
Among the 4 case histories describing patients with clinically
non-severe dengue associated with varying levels of thrombocy-
topenia, 16–24% of respondents recommended platelet transfu-
sion at platelet concentrations of 22–296109/L., but approxi-
mately one-third of the respondents would transfuse platelets if the
count fell to 36109/L. (Table 1)
Among the 5 case histories describing patients with different
manifestations of severe dengue associated with varying levels of
thrombocytopenia, more respondents would transfuse platelets if
the patient was in shock and bleeding (case histories 8 and 9).
There were substantial differences in the responses from physicians
in Africa than those from Asia and America for all 9 cases
(Table 1).
The final question aimed to determine thresholds at which a
physician would consider transfusing platelets as prophylaxis
against haemorrhage. Respondents were asked to select a single
option. 31 (10%) respondents would consider a prophylactic
platelet transfusion if the platelet count was below 506109/L. 8
(2.6%) respondents would consider a prophylactic platelet
transfusion if the platelet count was below 406109. 10 (3.3%)
respondents would consider a prophylactic platelet transfusion if
the platelet count was below 306109. 17 (5.6%) respondents would
consider a prophylactic platelet transfusion if the platelet count
was below 206109. 46 (15%) respondents would consider a
prophylactic platelet transfusion if the platelet count was below
106109. 190 (62%) respondents would only consider transfusing
platelets in patients with signs of haemorrhage.
The responses categorised by global region are summarised in
Table 1.
Discussion
Our study has limitations. There is an element of selection bias
in the way the survey was conducted, as the physicians who
distributed the survey within their countries were known to have
an interest in dengue. The survey is subject to response bias
meaning that the answers may not accurately reflect clinical
practice in the respective countries. In addition, the country
representation is not balanced.
Despite these limitations the striking result of this survey is the
heterogeneity of approaches to the use of prophylactic platelet
transfusions in dengue. 112/306 respondents would consider
transfusing platelets prophylactically at various levels of thrombo-
cytopenia. When the responses are categorised by region (Table 1)
African respondents would advocate platelet transfusions more
frequently, perhaps reflecting more limited experience with
dengue and experience with other haemorrhagic fevers. The
choice to use prophylactic platelet transfusions may be influenced
by cost and availability of platelets, as well as individual experience
in managing dengue and other medical conditions that affect the
platelet count. There is considerable variability within countries
suggesting an individual’s practice may differ from recommenda-
tions in guidelines. For example 6/12 Indian respondents and 7/
10 Brazilian respondents would consider the use of prophylactic
platelets. The responses reflect wide variation in clinical practice
and are indicative of the paucity of clinical evidence to guide
practice in this area.
At present there is limited evidence to support the use of
prophylactic platelet transfusions in dengue despite their inclusion
in some national guidelines. As the global reach of dengue
continues to expand the need to conduct clinical trials to construct
Author Summary
A low platelet count is a common feature of dengue
infection. It is thought that the platelet count correlates
with the severity of the infection and may contribute to
the risk of developing haemorrhage, a well-recognised
complication of dengue. As a result of this platelet
transfusions are used in some settings to reduce the risk
of haemorrhage. There is currently no evidence to support
this practice, and platelet transfusions are costly and
sometimes harmful. We conducted a survey assessing the
use of platelets in dengue. Respondents were all physi-
cians involved with the treatment of patients with dengue.
Respondents were asked that their answers reflected what
they would do if they were the treating physician. We
received 306 responses from 20 different countries. The
striking feature of the survey responses was the hetero-
geneity of approaches to the use of platelets in dengue.
These findings highlight the variation in clinical practice
and lack of an evidence base in this area and underscore
the importance of conducting prospective clinical trials to
address this key question in dengue clinical management.
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an evidence base to guide the appropriate use of platelets in
dengue becomes ever more pressing.
Supporting Information
Questionnaire S1 Dengue clinical scenarios.
(DOC)
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Table 1. Proportion of respondents choosing to transfuse platelets stratified by geographic region (n, (%)); BP = blood pressure;
HR =heart rate; HCT=haematocrit.
Clinical case
Asia
(n =134)
Africa
(n =39)
S. America
& Caribbean
(n=130) UK (n =3)
Total
(n =306)
Case 1 18-year-old female; platelets 236109/L; no haemorrhage; BP 120/80; HR 105; HCT 39% 12 (9) 38 (97.4) 8 (6.2) 0 (0) 58 (19)
Case 2 28-year-old male; platelets 296109/L; no haemorrhage; past history of perforated
gastric ulcer; BP 100/75; HR 92; HCT 42%3
20 (14.9) 39 (100) 13 (10) 0 (0) 72 (23.5)
Case 3 29-year-old female; rapid fall in platelets to 226109/L; no haemorrhage;
haemodynamically stable
12 (9) 30 (76.9) 6 (4.6) 0 (0) 48 (15.7)
Case 4 30-year-old male; platelets 36109/L; no haemorrhage; haemodynamically stable 57 (42.5) 37 (94.9) 23 (17.7) 3 (100) 120 (39.2)
Case 5 19-year-old male; platelets 186109/L; dengue hepatitis; no haemorrhage; BP 90/60;
HR 120; HCT 47%
11 (8.2) 36 (92.3) 7 (5.4) 2 (66.7) 56 (18.3)
Case 6 20-year-old female; platelets 176109/L; dengue encephalitis; no haemorrhage;
BP 100/70; HR 100; HCT 40%
25 (18.7) 39 (100) 19 (14.6) 1 (33.3) 84 (27.5)
Case 7 24-year-old male; platelets 316109/L; hepatic failure secondary to dengue; no
haemorrhage; BP 125/70; HR 110; HCT 42%
5 (3.7) 39 (100) 9 (6.9) 0 (0) 53 (17.3)
Case 8 23-year-old female; platelets 86109/L; shock, epistaxis and vaginal bleeding; BP 75/50;
HR 110; HCT 42%
86 (64.2) 39 (100) 43 (33.1) 3 (100) 171 (55.9)
Case 9 23-year-old male; platelets 336109/L; shock and mucosal bleeding; BP 70/50; HR 120;
HCT 46%
57 (42.5) 39 (100) 26 (20) 1 (33.3) 123 (40.2)
Prophylactic platelet transfusion threshold:
,506109/L 8 (6) 23 (59) 0 (0) 0 (0) 31 (10.1)
,406109/L 1 (0.7) 7 (17.9) 0 (0) 0 (0) 8 (2.6)
,306109/L 1 (0.7) 7 (17.9) 2 (1.5) 0 (0) 10 (3.3)
,206109/L 12 (9) 1 (2.6) 2 (1.5) 2 (66.7) 17 (5.6)
,106109/L 33 (24.6) 0 (0) 12 (9.2) 1 (33.3) 46 (15)
Not in absence of bleeding 75 (56) 1 (2.6) 39 (30) 0 (0) 190 (62.1)
doi:10.1371/journal.pntd.0001716.t001
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Dengue clinical scenarios 
Case 1:  
A 18-year-old woman is seen in the emergency clinic. She has been unwell for 5 days with a 
high fever, headache and has developed a rash. On examination she is febrile (38.4), her 
pulse is 105 and her blood pressure is 120/80. Her rapid diagnostic test for dengue is 
positive. Her other investigations are as follows: 
HB = 14.2g/dL AST = 65 IU/L 
WCC = 3.4 x109/L ALT = 50 IU/L 
PLT = 23 x109/L Clotting profile normal 
Hematocrit = 39%  
 
Which of the following would be part of your management plan (tick all that apply)? 
• Discharge home with advice and anti-pyretics    ! 
• Admission for observation      ! 
• Platelet transfusion        ! 
• Parenteral fluids       ! 
Case 2: 
A 28-year-old man is admitted to the ward with dengue (confirmed serologically). He has had 
a fever for 7 days. 6 months ago he was admitted to hospital with a severe upper 
gastrointestinal haemorrhage secondary to a perforated peptic ulcer. Currently he is febrile 
(38.2), his BP is 100/75 and his pulse is 92. Investigations are as follows: 
HB = 15.2g/dL AST = 62 IU/L 
WCC = 5.1 x109/L ALT = 45 IU/L 
PLT = 29 x109/L APTT = 45 seconds PT = 12 seconds 
Hematocrit = 42%  
 
Which of the following would be part of your management plan (tick all that apply)? 
• Parenteral fluids       ! 
• Platelets to prevent haemorrhage (given history of peptic ulceration) ! 
• Upper GI endoscopy       ! 
• Chest x-ray and ultrasound      ! 
Case 3: 
A 29-year-old female with confirmed dengue (NS1 and PCR positive) has been admitted for 
observation on the 3rd day of illness. On the second day of admission she remains febrile 
(38.8) but is otherwise stable. However the laboratory calls you to inform you that her platelet 
count has fallen from 102 x109/L to 22 x109/L. You re-examine her with this result in mind but 
find no evidence of haemorrhage. Her other blood tests, including hematocrit and a clotting 
profile are normal. 
Which of the following would you do (tick all that apply)? 
• Discharge home with advice to return if complications develop   ! 
• Continue to observe        ! 
• Administer platelets and observe as an inpatient     ! 
• Arrange imaging to look for evidence of occult haemorrhage   ! 
Case 4: 
A 30-year-old man is seen in the clinic with suspected dengue. He has a 5-day history of 
fever, malaise and headache. On examination he is febrile (38.8) and has a rash that is 
suggestive of dengue. He is haemodynamically stable and has no evidence of haemorrhage. 
The haematology laboratory phone you to inform you that his platelet count is 3 x109/L. 
Would you consider arranging a platelet transfusion? 
• Yes          ! 
• No          ! 
Case 5: 
A 19-year-old man with suspected dengue is admitted on the 6th day of illness. He has a rash 
suggestive of dengue infection and significant bruising at venepuncture sites. He denies any 
bleeding. He is afebrile (36.2), his blood pressure is 90/60 and his pulse is 120. Investigations 
are as follows: 
HB = 15.2g/dL AST = 320 IU/L 
WCC = 2.1 x109/L ALT = 160 IU/L 
PLT = 18 x109/L APTT = 49 seconds PT = 13 seconds 
Hematocrit = 47%  
 
Which of the following would be part of your management plan (tick all that apply)? 
• Administer parenteral fluids      ! 
• Admit to a high dependency area for careful monitoring   ! 
• Ultrasound of liver       ! 
• Platelet transfusion to prevent haemorrhage    ! 
Case 6: 
A 20-year-old woman is admitted with fever and a reduced level of consciousness. According 
to her family she has been unwell for 4 days complaining of a headache in addition to her 
fever. The day prior to admission she had an episode of vomiting. On examination she has a 
reduced GCS (11/15), she is febrile (38.5), her pulse is 100 and her blood pressure is 100/70. 
She has scattered petechiae on her lower limbs but no other evidence of bleeding. She has a 
CT scan of her brain, which is normal, a blood film for malaria, which is negative and a lumbar 
puncture that shows 92 white cells (90% lymphocytes) with normal biochemistry. She has a 
positive NS1 rapid test for dengue and you suspect she may have dengue encephalitis. Her 
other investigations are as follows: 
HB = 12.9 g/dL AST = 165 IU/L 
WCC = 2.9 x109/L ALT = 135 IU/L 
PLT = 17 x109/L Clotting profile normal 
HCT = 40%  
 
Which of the following form part of your management plan (tick all that apply)? 
• Admit for neurological observation      ! 
• Treat with parenteral aciclovir while awaiting CSF PCR result   ! 
• Administer platelets as prophylaxis against haemorrhage   ! 
• Commence parenteral fluids       ! 
Case 7: 
A 24-year-old man with suspected dengue is admitted to hospital. He has had a fever for 5 
days. On examination he is febrile (38.6), his pulse is 110 and his blood pressure is 125/70. 
Physical examination reveals some mild bruising and mild hepatomegaly with tenderness on 
palpation of his right upper quadrant. Dengue is confirmed by PCR. Investigations are as 
follows: 
HB = 13.6 g/dL AST = 1845 IU/L 
WCC = 4.9 x109/L ALT = 1250 IU/L 
PLT = 31 x109/L APTT = 72 seconds PT = 19 seconds 
HCT = 42%  
 
Which of the following would be part of your management plan (tick all that apply)? 
• Admission for observation      ! 
• Parenteral fluids       ! 
• Institute supportive treatment for pending hepatic failure   ! 
• Platelets        ! 
• Vitamin K        ! 
Case 8: 
A 23-year-old woman is admitted on the 7th day of illness. She has dengue as confirmed by 
an NS1 assay. She reports some epistaxis and abnormal menstrual bleeding. On 
examination she has scattered petechiae and bruising at venepuncture sites. She has a 
temperature of 37.9, her blood pressure is 75/50 and her pulse is 110. Investigations are as 
follows: 
HB = 8.9g/dL AST = 125 IU/L 
WCC = 9.2 x109/L ALT = 107 IU/L 
PLT = 8 x x109/L APTT = 61 seconds PT = 17 seconds 
Hematocrit = 42%  
 
Which of the following would be part of your management plan (tick all that apply)? 
• Administer parenteral fluids      ! 
• Admit to HDU        ! 
• Administer packed red cells      ! 
• Administer platelets       ! 
• Start IV heparin        ! 
• Chest x-ray and ultrasound      ! 
• Nasal packing        ! 
Case 9: 
A 23-year-old man is referred to the hospital with confirmed dengue (NS1 positive). He has 
been unwell for a week. He had been treated with parenteral fluids at the referring health 
centre. On examination he is afebrile, his pulse is 120 and his blood pressure is 70/50. There 
is widespread bruising at the site of venepuncture as well as scattered petechiae elsewhere. 
On examination of his mouth there is evidence of some mucosal bleeding. While examining 
him he has haemetemesis. His investigations are as follows: 
HB = 10.1 g/dL AST = 324 IU/L 
WCC = 7.2 x109/L ALT = 127 IU/L 
PLT = 33 x109/L APTT = 68 seconds; PT = 16 seconds 
HCT = 46%  
 
Which of the following would form part of your management plan (tick all that apply)? 
• Parenteral fluids       ! 
• Packed red cells       ! 
• Platelets        ! 
• Insertion of CVP line       ! 
• Admission to intensive care facility     ! 
Question 10: 
At what level would you consider prescribing platelets as prophylaxis against haemorrhage 
(please chose 1 response)? 
• <50 x109/L         ! 
• <40 x109/L         ! 
• <30 x109/L         ! 
• <20 x109/L         ! 
• <10 x109/L         ! 
• In the absence of haemorrhage I would not prescribe platelets   ! 
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Dengue is a arboviral infection that represents a major global health burden. There is an unmet need for effective
dengue therapeutics to reduce symptoms, duration of illness and incidence of severe complications. Here, we con-
sider the merits of a dengue human infection model (DHIM) for drug development. A DHIM could allow exper-
imentally controlled studies of candidate therapeutics in preselected susceptible volunteers, potentially using
smaller sample sizes than trials that recruited patients with dengue in an endemic country. In addition, the
DHIM would assist the conduct of intensive pharmacokinetic and basic research investigations and aid in deter-
mining optimal drug dosage. Furthermore, a DHIM could help establish proof of concept that chemoprophylaxis
against dengue is feasible. The key challenge in developing the DHIM for drug development is to ensure the model
reliably replicates the typical clinical and laboratory features of naturally acquired, symptomatic dengue.
Keywords. dengue; human infection model; clinical trial; drug development.
The 4 serotypes of dengue virus (DENV-1 to DENV-4)
are the most important arboviral pathogens of humans.
The global burden of dengue, recently estimated at ap-
proximately 100 million cases per year, remains unchal-
lenged by licensed vaccines or sustainable vector control
strategies [1]. The scale of the dengue burden in the en-
demic countries of Asia and Latin America has a nega-
tive economic impact and places a signiﬁcant clinical
burden on often fragile health care systems [2–4].
Dengue is an acute systemic febrile illness that man-
ifests with abrupt onset as an undifferentiated fever that
is difﬁcult to distinguish from other infections without
laboratory diagnostic tests [1]. Headache, malaise, my-
algia, retro-orbital pain are common symptoms in
adults [5]. The clinical features differ by age group,
with symptoms such as cough, vomiting and abdominal
pain more common in children [6]. Leukopenia and
thrombocytopenia are common laboratory features.
In most cases, fever and symptoms resolve unevent-
fully after 3–7 days with no long-term sequelae [1]. In a
subset of cases, a transient vascular leakage syndrome
develops after 3–4 days of illness, which, when severe,
can lead to life-threatening hypovolemic shock (called
dengue shock syndrome) and/or hemorrhage [1, 5].
The vascular leak syndrome may be associated with
complement activation and a coagulopathy that can
contribute to the risk of hemorrhage [7, 8]. Signs of vas-
cular leakage include an increasing hematocrit, micro-
albuminuria, or the accumulation of ﬂuids at serosal
surfaces (eg, pleural effusions) [5].
Supportive care and the careful titration of mini-
mum volumes of parenteral crystalloid ﬂuids to main-
tain stable cardiac output during the 1–3-day period
of vascular permeability are critical elements in dengue
case management [5].Vasopressors are commonly used
in cases with prolonged shock. Clinically signiﬁcant
hemorrhage requiring use of blood products is more
common in adults than in children [9].
Improvements in the management of severe dengue
cases have seen the case mortality rate decline over the
last decade in many but not all endemic settings [10–
12]. At present there is no validated way of identifying
which patients will progress to more severe disease, mean-
ing that health facilities in endemic areas are often
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overwhelmed with patients with dengue who require ongoing ob-
servation as outpatients or are admitted for inpatient observation.
THE CASES FOR DENGUE THERAPEUTIC AND
PROPHYLACTIC AGENTS
Antivirals
A drug that can shorten the duration of illness and reduce the
risk of disease progression would be a signiﬁcant advance for
both patients and for overstretched health systems in dengue-
endemic countries. An obvious approach is to target virus rep-
lication with a small molecule antiviral drug that given early in
the course of illness has the potential to shorten the duration of
infection. Moreover, because high early DENV viremia levels
are a risk factor for the development of more severe disease,
an antiviral drug might also reduce the incidence of severe com-
plications [13, 14]. In addition, a drug that reduces the magni-
tude and duration of viremia has the potential to reduce onward
DENV transmission by reducing the length of time an individ-
ual patient is infectious to mosquitoes [15]. Alternatives to
small molecule antiviral drugs include therapeutic monoclonal
antibodies; however, high costs and requirement for parenteral
administration are currently barriers to their use.
Disease Modulators
Both host and virus factors are important in inﬂuencing the
outcome of DENV infection. A range of host factors, such as
age, sex, genotype, and ﬂavivirus infection history, inﬂuence
the disease outcome [10, 16, 17]. Because the manifestations
of severe dengue are typically observed in secondary DENV in-
fections and when innate and adaptive immune responses have
driven steep declines in viremia levels, it is widely held that the
immune system plays an important role in disease pathogenesis
[18]. This represents the rationale for use of an immunomodu-
latory drug that can favorably modulate the poorly deﬁned im-
munopathogenic mechanisms postulated to underlie severe
dengue. It is possible that the dichotomous approach of target-
ing either the virus or the immune response is an oversimpliﬁed
strategy to the development of dengue therapeutics. Other phys-
iological systems are involved in the control of endothelial in-
tegrity, but their role in dengue remains poorly understood [19].
Prophylaxis
Avaccine would be the most effective prophylactic public health
intervention for control of dengue, but the development of an
efﬁcacious tetravalent dengue vaccine is proving to be a chal-
lenge [20, 21]. An alternative or adjunctive approach is the
use of drug chemoprophylaxis in the community. Chemopro-
phylaxis using oseltamivir has been advocated for controlling
the spread of inﬂuenza within households and was commonly
used in some settings during the 2009 H1N1 inﬂuenza pandem-
ic, creating a precedent for such an approach for an acute viral
infection [22, 23]. The safety proﬁle of a prophylactic dengue
drug would have to be exemplary, and there are major questions
of whether this approach could be cost-effective and sustain-
able, given the temporally and spatially heterogenous patterns
of DENV transmission in endemic regions [24, 25]. Moreover,
in most dengue-endemic regions a signiﬁcant fraction of the
population is already immune and will not beneﬁt from chemo-
prophylaxis. Consequently, in endemic areas the number need-
ed to treat, and the duration they need to be treated for, may be
large for the prevention of a single symptomatic case and very
large for the prevention of severe cases. There is a marginally
stronger argument for chemoprophylaxis in populations with
no immunity to DENV. Examples of this include dengue-
naive travelers or military personnel who are transiently present
in areas of high DENV transmission. Similarly, chemopro-
phylaxis could be indicated for communities experiencing “vir-
gin soil” dengue outbreaks because of importation by viremic
travelers or infected mosquitoes.
PREVIOUS CLINICAL TRIALS OF
THERAPEUTICS FOR DENGUE AND
RELEVANCE TO THE DENGUE HUMAN
INFECTION MODEL
For a disease with an estimated global burden prevalence of 100
million cases per year, remarkably few clinical trials of treat-
ment approaches have been performed. Early trials tested
ﬂuid resuscitation approaches in patients with hypovolemic
shock [26–28]. More-recent trials have tested the candidate
antiviral agents chloroquine and balapiravir or have targeted
the immune response by use of oral corticosteroids [29–31]. Al-
though none of these trials have demonstrated therapeutic efﬁ-
cacy, they have provided a framework for the conduct of such
trials and has led to the publication of recommendations for a
standardized approach to dengue clinical trial design and con-
duct [15]. In addition, a trial of lovastatin in dengue is currently
underway and further trials are planned [15, 32]. The virological
ﬁndings in these trials, consistent with previous literature, have
underscored the need for antiviral therapy to commence early
in the course of illness, because illness resolves and patients are
no longer infectious to Aedes aegypti mosquitoes by 5–7 days
after illness onset [14, 15, 33–35].
POTENTIAL ROLES FOR A HUMAN INFECTION
MODEL IN DENGUE DRUG DEVELOPMENT
In principal, a dengue human infection model (DHIM) pro-
vides opportunities for fast-tracking dengue drug development,
particularly therapeutic and prophylactic antivirals. The overall
strength of the DHIM is that it allows for controlled prophy-
lactic or therapeutic studies of DENV infection in susceptible
participants who have been preselected for a set of desirable
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characteristics. In contrast, prophylactic or therapeutic studies
of DENV infection in an endemic country population are sub-
ject to the vagaries of ethnic diversity of the patient population,
ﬂuctuating serotype and genotype prevalence, variable viremia
levels, and prior ﬂavivirus infection histories. Collectively, these
sources of variation in an endemic country population probably
boost the required patient sample size required for detection of
therapeutic or clinical safety signals.
CRITICAL HURDLES FOR A DHIM
Central to the usefulness of a DHIM is whether it mimics the
main features of a symptomatic dengue case. This is a funda-
mental and critical hurdle in the development of a successful
DHIM for use in dengue therapeutic development. Thus, the
kinetics of clinical, virological, hematological, and biochemical
changes that are typically present in a naturally acquired and
clinically uncomplicated adult dengue case should also manifest
in the adult DHIM. In the beginning, at least, we assume that
the DHIM will involve participants who are ﬂavivirus naive,
and thus all experimental infections will be primary infections.
In the context of dengue drug development, the characteristics
of a symptomatic, naturally acquired DENV infection that a
DHIM would need to replicate include acquisition of infection
and certain clinical, virological, and laboratory features.
Acquisition of Infection
ADHIM could use DENV-infected mosquitoes to elicit infection
in human volunteers. Although this approach may be optimal in
replicating the natural history of DENV infection because, for
Table 1. Early-Phase Clinical Studies of Antiviral Drugs: Strengths and Weaknesses of the DHIM vs Trial Conducted in a Dengue-
Endemic Setting
Hurdle DHIM
Dengue-Endemic
Setting Notes
Dengue case burden At call Usually seasonal and
with yearly variation
in case numbers
In endemic settings dependent on the force of
infection
Clinical research capacity Available Variable In endemic settings dependent on local
expertise, experience and resources
Efficiency of regulatory system Variable Variable In endemic settings dependent on research
infrastructure and local regulatory
requirements
Accredited testing laboratories Available Variable In endemic settings dependent on research
infrastructure and local regulatory
requirements
Ability to ship research specimens
across international borders
Yes Variable In endemic settings dependent on research
infrastructure and local regulatory
requirements
Variance in viremia and serotypes Serotype controlled;
possibly less
variance in viremia
Variable In endemic settings dependent on local viral
epidemiology
Early therapy possible Yes Variable In endemic settings dependent on patients
presenting early
Pharmacokinetic studies Yes Yes/Variable May require international shipping of samples
from endemic countries
Intensive pathophysiological monitoring Yes Possibly Ability to conduct intensive monitoring is
dependent on the local resources available
Chemoprophylaxis studies Yes More difficult The controlled setting of the DHIM is ideally
suited to this kind of study
Provide proof of concept that therapy
reduces major clinical complications
Probably not, requires
large sample sizes
Yes Severe clinical events in healthy adults with
primary DENV infections are rare
Provide proof of concept that therapy
mitigates typical lab features
Probably not, requires
large sample sizes
Yes Demonstrating mitigation would require large
sample size
Serious adverse events; clinical
experience of managing severe
dengue
Variable Yes Extensive clinical experience and expertise in
endemic settings
Clinical studies of secondary heterotypic
DENV infections
Difficult Yes Ethical hurdles for the DHIM in view of known
risks associated with secondary heterotypic
infections
Clinical studies in participants who have
received dengue vaccine candidates
Yes Yes In the DHIM will depend on the balance of
perceived risks and benefits
Abbreviations: DENV, dengue virus; DHIM, dengue human infection model.
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example, the immunoregulatory effects of mosquito saliva would
be replicated, it may present additional regulatory and logistical
hurdles. Alternatively, a DHIM could use subcutaneous inocula-
tion of laboratory-cultured virus, as used in the challenge exper-
iments by Sun and colleagues [36]. This approach bypasses
issues surrounding use of mosquitoes, although it remains to
be determined if there are material differences between needle-
delivered and mosquito-delivered DENV infection.
Clinical Features
Typical signs and symptoms of dengue that a DHIM would need
to replicate in otherwise healthy adults include fever, headache,
myalgia, musculoskeletal pain, and nausea or vomiting [37].
Minor hemorrhagic features may occur between days 3 and 6
of illness (eg, petechiae) [37]. Prevention or rapid amelioration
of these self-limiting symptoms will be a target of dengue thera-
peutic drug development. Primary infections in otherwise healthy
adults are rarely associated with severe clinical complications, but
it would be prudent to exclude the elderly and those with comor-
bid conditions from the volunteer pool, because these groups are
at elevated risk of severe complications [38, 39].
Virological Features
The intrinsic incubation period of DENV infection has been es-
timated to be between 4–10 days [5].Work that reanalyzed his-
torical mosquito exposure experiments estimated that the
intrinsic incubation period in primary infection was approxi-
mately 6 days [40]. The duration of viremia varies by serotype
and DENV infection history. The peak viremia level is often not
observed in naturally occurring infections because it precedes
the time point when patients attend health care facilities, but
ﬁndings suggest that the peak level occurs later in primary in-
fections as compared to secondary [33]. Studies suggest that pri-
mary infections with DENV-1 are associated with a longer
viremic period and higher viremia levels [33, 41]. An optimal
DHIM would replicate the virological features of a naturally
acquired DENV infection to enable conﬁdent predictions of
therapeutic or prophylactic drug efﬁcacy in the ﬁeld.
Laboratory Features
A DHIM should elicit thrombocytopenia and leukopenia, both
typical features in patients with primary or secondary dengue.
In addition, many patients have minor elevations in transami-
nase and creatine kinase levels [9, 42]. Clotting abnormalities
are also often observed in severe cases with elevated activated
partial thromboplastin times and reduced levels of ﬁbrinogen;
however, these occur less frequently in primary infections [43].
STRENGTHS AND WEAKNESSES OF A DHIM
FOR DRUG DEVELOPMENT
The strengths and weaknesses of a DHIM for performing
early-phase clinical studies compared to performing such
studies in naturally acquired cases in an endemic country are
summarized in Table 1. In short, the great advantage of the
DHIM for early-phase drug development is the ability to per-
form controlled prophylactic or early therapeutic studies in a
setting amenable to intensive pharmacological and basic re-
search investigations.
FOCUS AREAS IN WHICH THE DHIM COULD
SUBSTANTIALLY ADVANCE CLINICAL DRUG
DEVELOPMENT
ADHIM that mimics natural infection would be particularly well
suited to early-phase studies of chemoprophylaxis and accompa-
nying pharmacokinetic studies, in which the timing of treatment
and infection can be controlled. In contrast, in a dengue-endemic
country, early-phase chemoprophylaxis trials would require large
and lengthy community-based cohort studies, as has been used
to derive evidence for oseltamivir in the chemoprophylaxis of in-
ﬂuenza [22]. The DHIM would thus be a more cost-effective and
time-efﬁcient route to acquiring proof of concept evidence that
chemoprophylaxis for dengue is possible. For a given antiviral
drug, a DHIMwould also be well-suited for studies that accurate-
ly deﬁne the therapeutic window in symptomatic cases, since the
time of infection, onset of symptoms and treatment will be pro-
spectively documented. In contrast, in endemic countries enroll-
ment of study participants is dependent on patients seeking
health care, who will have various durations of illness history at
the time of study enrollment. A DHIM can also aid the develop-
ment of alternative therapeutic approaches, such as immuno-
modulatory agents. In addition, a DHIM may aid the
development of noninvasive physiological monitoring tech-
niques within clinical trials, perhaps through the identiﬁcation
of appropriate physiological measurements that could be used
as end points [15].
In conclusion, the work of Sun and colleagues [36] has shown
that a DHIM is possible. This is a signiﬁcant advance in the ﬁeld
with the potential to contribute to the development of successful
dengue therapeutics and much else. The future use of the DHIM
in dengue clinical research will require a signiﬁcant investment
from multiple stakeholders. Its contribution in drug development
may aid in the selection of appropriate candidate drugs for further
development and assist pharmacokinetic studies. The potential
signiﬁcance of these contributions suggests that investing in a
DHIM is both appropriate and timely.
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5. DISCUSSION AND FUTURE DIRECTIONS 
The work presented in this thesis expands the knowledge base of dengue clinical 
management and dengue pathogenesis. I described studies that expand our knowledge of 
the MICB and PLCE genes in dengue susceptibility and advance our understanding of 
pathogenesis. I described experiments that directly compared the susceptibility of Ae. aegypti 
and Ae. albopictus to initial and disseminated dengue infection after blood feeding on viremia 
dengue patients. The insights from this work will allow greater understanding of dengue 
transmission dynamics, will inform mathematical models of transmission, as well as 
potentially inform endpoints of various therapeutic and chemoprophylactic interventions. In 
addition, I have described a randomised clinical trial of lovastatin in adult patients infected 
with dengue. While the trial did not show a clinical benefit it raised important further questions 
for future intervention studies. 
Discussion 
A deeper understanding of dengue susceptibility will provide insights into disease 
pathogenesis and has the potential to assist vaccine and therapeutic development. Since 
publication of a GWAS study that identified two susceptibility loci for DSS, a lot of attention 
has been directed at the genes in which the SNPs are located.7 The work described in this 
thesis has extended the finding of the GWAS by confirming the associations with DSS but 
also demonstrating that these SNPs are also associated with less severe forms of the 
disease. Given that MICB encodes a ligand involved in natural killer cell activation, we 
speculated that mutations in this gene might be associated with higher plasma viremia levels. 
Our work did not show this, meaning that the functional basis of these observed associations 
remains unclear. We analysed the relationship between the mutations and the initial 
(enrolment) viremia – it is possible that there were different patterns in viral clearance 
between the host genotypes that could not be explored in this study. While it may be argued 
that these insights into disease pathogenesis are “small print”, the whole-genome approach 
removes bias and has the potential to shed light on hitherto unexpected aspects of the host-
pathogen interaction process and, thus, to inform potentially novel therapeutic approaches.60 
The expansion of the geographic range of Ae. albopictus has led to concerns about an 
associated increased arboviral threat to North America and Europe.61,62 Being able to 
accurately quantitate the comparative susceptibility of Ae. albopictus to dengue infection will 
lead to the creation of more precise disease transmission models, which may be able to 
assist public health authorities in planning outbreak responses. In addition, clear data on the 
levels of viraemia in patients that are infectious to mosquitoes has the potential to influence 
the design and conduct of therapeutic trials assessing therapeutic and chemoprophylactic 
agents. The 50% mosquito infectious dose (MID50) estimates presented here could be further 
refined by pooling data from our team’s previous study, which could further enhance the 
contribution this work can make to transmission models.31 The work described in this thesis 
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has demonstrated that Ae. albopictus and Ae. aegypti are equally susceptible to the 
acquisition of an initial dengue infection but that Ae. albopictus is overall less susceptible to 
the acquisition of an infectious phenotype. This difference varied by serotype – Ae. albopictus 
was less likely to acquire an infectious phenotype with DENV-2 and DENV-4 but there was no 
difference observed between the mosquito types with DENV-1 and DENV-3. Previous vector 
competence studies were conducted using laboratory experiments – by using direct feeding 
experiments on viraemic dengue patients our study replicated field conditions and is thus 
better placed to inform transmission models. Interestingly, our work also showed that Ae. 
albopictus is able to accommodate a higher viral burden in its abdominal tissue. By analysing 
a subset of DENV-1-infected patients and their associated mosquitoes we showed that this 
higher viral burden potentially contributes to higher sequence diversity in DENV populations. 
It would be valuable to extend this work by using larger sample sizes and assessing different 
serotypes.  
Despite dengue’s enormous global impact there is still no licensed therapeutic to combat the 
toll of the disease on patients and overburdened health systems in the tropical world. There is 
a pressing need for a therapeutic that can shorten the duration of illness and reduce the risk 
of disease progression.63 Clinical trials have been conducted in dengue that have used 
different approaches to influence the disease outcome. These include attempts to reduce 
dengue viraemia or modulate the host response to dengue infection.63 Unfortunately, to date, 
these attempts have not demonstrated a clinical benefit.64-66 It is important to note that these 
studies were, in the main, powered for safety as opposed to efficacy. While a dramatic clinical 
benefit would likely to have been demonstrated, it is possible that a subtle benefit could have 
been overlooked. However even if this was the case then the number needed to treat would 
be very large implying that it would probably not reflect a viable treatment option. It was 
against this backdrop that the lovastatin dengue trial was designed. Statins have received a 
lot of attention as potential therapeutic adjuncts in a diverse range of conditions such as 
sepsis and ARDS. It was felt that the potential endothelial stabilising effects of statins could 
maintain the endothelial integrity thus reducing capillary permeability. Consequently, 
improvements in capillary permeability should translate to lower levels of 
haemoconcentration, and a reduced frequency of severe complications. In addition there was 
a suggestion from some laboratory work that lovastatin may have some antiviral effects in 
dengue. Furthermore, its low cost and good safety profile made lovastatin an attractive 
therapeutic candidate. Given interest in its use as an adjunctive agent in critical care 
medicine, we had hoped to assess whether it had a use in patients with severe dengue but 
due to concerns about the potential side effects of statins (e.g. hepatitis and muscle 
inflammation) and their overlap with expected clinical features of dengue, the regulatory 
authorities in Vietnam did not allow this. It is, however, sobering to note that despite huge 
initial interest the proposed beneficial role of statins has not been supported in prospective 
clinical trials in ventilator-associated pneumonia, sepsis and ARDS.52,53,67 While we were able 
to show that lovastatin was safe in dengue we did not show any evidence of a clinical or 
 188 
virological benefit that would support further larger studies. Given the endothelial stabilising 
effects of statins and the fact that dengue shock is more common in children it is possible that 
we may have observed more of a clinical benefit if we had targeted a younger age group.68,69 
The peak viraemia occurs very early in the course of clinical illness and there is already 
evidence of endothelial dysfunction after 72 hours of illness suggesting that the timing of our 
intervention may have been too late to influence the clinical and virological outcome.70-72 
Conducting intervention studies with patients recruited even earlier in their illness raises 
significant practical issues as patients rarely present to health facilities so early. While we 
have not yet tested an antiviral specifically designed for dengue, it is possible that the focus of 
intervention studies should shift to studying potential chemoprophylactic agents, and, in 
parallel, studies that aim to optimise supportive care of the critically ill. A chemoprophylactic 
agent would have to have an excellent safety profile and would probably appeal most to 
travellers or short-term visitors to high transmission settings. However it is possible that a 
chemoprophylactic could be used in endemic settings as a reactive ring-fencing approach 
around an index case or cluster of cases – work from Thailand suggests that dengue 
transmission is often highly focal.73 In addition, selectively targeting patients most at risk of 
severe disease could be an effective strategy in the rollout of a chemoprophylactic agent. 
Unfortunately we are not yet able to identify patients at risk of disease progression although it 
is hoped that on-going cohort studies (www.idams.eu) will aid with this. 
Future directions 
The host susceptibility work described above extends our understanding of the MICB and 
PLCE1 genes in dengue susceptibility but it raises as many questions as it answers. While 
the whole-genome approach is an unbiased way of addressing key questions in disease 
susceptibility, linking findings to functional mechanisms of pathogenesis is always a 
challenge. Given that MICB encodes a ligand involved in NK cell activation we had 
speculated that mutations in this gene would be associated with higher plasma viraemia. The 
additional work, also described above, suggests that this is not the case. Our study only 
looked at enrolment viraemia and not at viral kinetics over the course of dengue illness. It 
would be intriguing to see whether there are different patterns of viral clearance across the 
genotypes – prospective studies such as intervention trials are ideally suited to answer this. 
Defining the functional role of PLCE1 is more challenging. The fact that mutations in this gene 
appear to be associated with such a diverse range of conditions raises intriguing questions, 
but as yet no answers, as to this gene’s role in both health and disease. It is likely that further 
advances in our understanding of dengue pathogenesis will come from prospective studies 
with well-planned sampling approaches as opposed to the traditional descriptive study 
approach. 
I have presented the first direct comparison of Ae. aegypti and Ae. albopictus acquisition 
potentials through direct blood feeding experiments on viraemic dengue patients. This work 
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showed that overall Ae. albopictus was less susceptible to disseminated dengue infection and 
thus acquisition of an infectious phenotype but that this difference varied by serotype. In 
addition, the study showed that the abdominal viral burden was higher in Ae. albopictus, and 
in further analysis of a subset of DENV-1-infected mosquitoes was associated with more 
sequence diversity accumulation. Further questions related to this are important to address – 
are similar observations seen in other serotypes? How does this sequence variety contribute 
to viral persistence? What is the nature of the midgut barrier mechanism in Aedes 
mosquitoes? In addition, this work adds to the data confirming the central role of patient 
plasma viraemia in infecting mosquitoes and maintaining community dengue transmission. 
Can the administration of a suitable chemoprophylactic agent stop community transmission? 
It is possible that the use of a DHIM could aid in the identification of an appropriate candidate, 
and that this kind of approach to disease control could have a role in areas affected by 
sudden surges of cases. It is important to note that the overall difference in mosquito 
susceptibility to disseminated DENV infection between mosquito types is small suggesting 
that many other factors influence the secondary role of Ae. albopictus in dengue 
transmission. Understanding these factors and forming a clearer picture of vector 
competence would be an important advance.  
It is clear that there remain many unanswered challenges in understanding dengue 
pathogenesis and in the development of therapeutic interventions. One of the issues in 
designing therapeutic intervention trials in dengue is the relative rarity of severe disease. 
While this is obviously a good thing for public health it means that trials powered to an 
endpoint of shock would be large and costly. Perhaps an alternative approach is to design 
community-based intervention trials with hospital admission as an endpoint? While hospital 
admission is often a surrogate for the development of dengue with warning signs, the reasons 
for admission vary greatly between health centres and among different health providers. This 
kind of trial would require a very standardised approach to clinical management and hospital 
admission approaches. A move towards community studies would more realistically reflect 
the burden of dengue, would have potential cost advantages and would allow a larger sample 
size than is typically used in a hospital-based intervention study. As discussed above, there 
remain major questions about the optimal timing of administering a therapeutic. Two trials 
have been conducting with the therapeutic candidate being administered within 48 hours of 
fever onset.64,74 The trials of chloroquine, corticosteroids, and lovastatin administered the 
study drugs within 72 hours of fever onset.65,66,75 The fact that none of these trials showed an 
effect on viraemia kinetics or clinical outcome suggest that we may have “missed the boat”. 
We know that peak viraemia occurs early in illness and that there is already evidence of 
endothelial dysfunction by 72 hours after fever onset.70-72 It is possible that the eventual 
clinical phenotype has already been defined before the patient with dengue presents to health 
services. Perhaps only a subgroup of patients will benefit from an effective therapeutic? 
Perhaps the urban centres of the tropical world need to adopt the personalised medicine 
approach to contribute to the management of dengue cases? We do not yet have the ability 
 190 
to identify such a subgroup of patients but it is hoped that on-going cohort studies will aid in 
the identification of features that predict patients most at risk of disease progression. In 
addition, it is possible that insights into host susceptibility and pathogenesis will aid this 
process. 
As discussed above it is possible that the emphasis in therapeutic trials should be on 
optimising care of the critically ill. There remain many questions surrounding appropriate 
supportive care in dengue. Currently clinical management is limited to appropriate fluid 
resuscitation, which is effective and life-saving.12 However, what is less clear is how best to 
resuscitate patients who develop recurrent episodes of shock. Answering this important 
question would be challenging as it would require a trial involving very unstable patients, but 
would be an important advance for the field. Thrombocytopenia is a very common feature of 
dengue and in some settings patients are given prophylactic platelets to prevent 
haemorrhage. This practice lacks an evidence base – establishing this would assist clinical 
management. A recently completed trial in 87 patients suggests that platelet transfusions in 
dengue have no benefit and have an association with harm.76 It is hoped that the on-going 
ADEPT trial will better clarify the evidence in this area (ClinicalTrials.gov identifier 
NCT01030211).  
Sun and colleagues used an experimental dengue challenge to assess the efficacy of a live 
tetravalent vaccine.59 This approach has the potential to overcome the hurdles that the lack of 
an animal model that effectively replicates human dengue illness poses. The development 
and use of a dengue human infection model (DHIM) has the potential to greatly assist the 
development of therapeutics. This approach would allow the fast track of drug development 
by allowing controlled studies to be performed in participants pre-selected for a number of 
favourable characteristics. The controlled approach would also allow detailed 
pharmacokinetic studies to be performed, which is often not possible in the less controlled 
setting of a clinical trial in an endemic country. The use of a DHIM would allow the earlier and 
more efficient identification of therapeutic candidates that can be take on into further phases 
of clinical development.  
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